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Abstract 
The genetic heterogeneity of cancer creates patient-to-patient variability that makes it 
difficult to predict whether the patient will respond to a treatment. This is particularly true for 
VEGF-targeting therapies, for which, in some cancers, response rates have typically been low and 
overall survival has only been extended slightly if at all. Development of predictive biomarkers 
for VEGF-targeting therapies has traditionally focused either on measurement of VEGF family 
ligand concentrations in the plasma or on tumor-derived transcriptomic data. Here, we 
incorporate both of these types of information into a whole-body computational model of the 
kinetic interactions between VEGF ligands and receptors. Gene expression data from a 
population of cancer patients allows us to create a virtual population where the effects of multiple 
VEGF-targeting drugs can be tested. This approach allows us to limit our analysis to relevant 
genes instead of the entire genome and allows us to incorporate mechanistic information, both of 
which should lead to models with better reproducibility.  
We first examined patterns of expression of VEGF ligands and receptors as well as a related 
family, the Semaphorins. Several previously defined subtypes of cancer were associated with pro-
angiogenic alterations in the expression of these genes. Multivariate biomarkers based on VEGF 
and Semaphorin gene expression were, in some cases, able to provide better separation of patients 
according to prognosis. These results provide clinically relevant subtypes and highlight the role 
that Semaphorins may play in processes that drive tumor angiogenesis and progression. 
We then used gene expression data to create three virtual populations: patients with breast, 
kidney, or prostate cancers. Drug response metrics in these populations allowed us to determine 
characteristics of patients that make them more responsive to treatments. We found that the best 
biomarkers of response differed between cancer types. This approach can be applied to other 
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The genomic heterogeneity of cancer produces widely varying responses to therapies, not 
only between different types of cancer, but also from patient to patient with the same type of 
cancer. Therapies that target angiogenesis, the growth of new blood vessels from existing 
vasculature, in particular suffer from low response rates. Biomarkers are needed that can be used 
at the time of diagnosis to differentiate tumors likely to respond to a drug tumors likely to be 
resistant. At least two key types of information can aid in the development of predictive 
biomarkers: 1) molecular-level mechanistic knowledge of the pathway targeted by a therapy, and 
2) measurements of the level of expression of genes in that pathway, from a large set of tumor 
samples. Currently only the latter is typically used; we will integrate both together to improve the 
predictive power. 
1.1 Tumor Angiogenesis 
In order to support the rapidly expanding population of tumor cells that is characteristic 
of cancer, an adequate supply of oxygen and other nutrients must be maintained. To do this, 
tumors secrete proteins into the microenvironment that promote angiogenesis, the formation of 
new blood vessels from existing networks of capillaries. This blood vessel sprouting and 
remodeling, which is a normal part of organ growth and of adult physiology, can be co-opted to 
supply tumors by stimulating the growth of new branches from the host organ vasculature. Due to 
its importance in tumor progression, angiogenesis is considered a hallmark of cancer [1].  
Angiogenesis is a complex multicellular process. Endothelial cells are the major cell type 
comprising blood vessels. Sprout formation from existing blood vessels occurs due to 
proliferation and migration of endothelial cells. Chemical signals originating from tumor cells 
create gradients that guide the direction of endothelial cell migration. Other stromal cells in the 
tumor microenvironment contribute to angiogenesis as well. Pericytes associate with and stabilize 
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microvessels composed of endothelial cells. Cells from the immune system, such as 
macrophages, are recruited to the site of the tumor and secrete pro-angiogenic chemical signals 
[2,3].  
The wide array of chemical signals can influence angiogenesis, either by enhancing or 
inhibiting it. The shift in the net effect of these factors from anti-angiogenic to pro-angiogenic 
that occurs during tumor progression is referred to as the angiogenic switch [4]. A major pro-
angiogenic group of proteins is the vascular endothelial growth factor (VEGF) family (Section 
1.1.2). Other pro-angiogenic growth factors include the fibroblast growth factor (FGF) family, the 
platelet-derived growth factor (PDGF) family, the hepatocyte growth factor (HGF) family, the 
epidermal growth factor (EGF) family, and the angiopoietin family. Inhibitors of angiogenesis 
include thrombospondins [5] and peptides derived from CXC chemokines and type IV collagen 
[6]. Another family, the semaphorins (Section 1.1.3), have both pro- and anti-angiogenic effects, 
depending on the specific member of the family. 
1.2 Molecular Regulators of Angiogenesis in Cancer 
The complexity of the molecular regulatory network for angiogenesis – the number of 
competing ligands and receptors, the synergistic and antagonistic downstream effects – is 
exacerbated by the observation that all of the components can be dysregulated in cancer. It would 
be impossible to integrate all these changes and the underlying interaction network to predict 
outcomes without a detailed mathematical model. 
1.2.1 VEGF Family 
The VEGF family plays a large role in the regulation of angiogenesis. This family 
comprises five genes encoding ligands (VEGFA, VEGFB, VEGFC, VEGFD, and PlGF), three 
receptor tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3), and two neuropilin co-receptors 
(NRP1 and NRP2). The network of interactions between these families is complex. Some of the 
ligand genes encode multiple splice isoforms, with the VEGFA121, VEGFA165, VEGFA189, PlGF-
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1, PlGF-2, VEGFB167, and VEGFB186 proteins playing major roles in adult angiogenesis. 
Proteolytic processing of the ligands plays a role in modulating the receptor binding affinity of 
VEGFC and VEGFD. Alternative splicing also affects the genes encoding receptors: shortened 
soluble forms of VEGFR1 and VEGFR2 that retain ligand binding have been found. Some ligand 
isoforms are heparin-binding and thus reversibly bind to extracellular matrix, from which they 
can be released by proteases. The isoforms also have differing affinities for neuropilins, with 
some unable to bind them at all. Homodimers of all three RTKs occur, as well as VEGFR1-
VEGFR2 and VEGF2-VEGFR3 heterodimers. Complex formation between VEGF RTKs and 
neuropilins can occur in a ligand-dependent or -independent manner, depending on the ligand and 
receptor. The VEGF receptors can form complexes with neuropilin co-receptors, altering both 
ligand affinities and signaling output [7,8]. 
Ligand-activated VEGF receptors induce a cascade of intracellular signals that ultimately 
promote the proliferation and migration of endothelial cells. VEGF receptors are type V RTKs 
with seven extracellular immunoglobulin domains, a transmembrane domain, and intracellular 
tyrosine kinase domains. Ligand binding triggers receptor dimerization, which leads to receptor 
phosphorylation, recruitment of adapter proteins, and downstream signaling. Phosphorylation of 
specific tyrosine residues on the receptors leads to differences in phenotype due to activation of 
different pathways, with phosphorylation of VEGFR2 at Y951, Y1175, and Y1214 in particular 
having varying abilities to lead to proliferation, migration, survival, and permeability. The role of 
VEGFR1 phosphorylation and signaling is unclear; some studies indicate VEGFR1 may inhibit 
angiogenesis simply by serving as a VEGF sink, leading to reduced VEGFR2 binding. VEGFR2 
signaling tends to promote angiogenesis while VEGFR3 tends to promote lymphangiogenesis due 
to its expression on lymphatic endothelial cells [7,8]. 
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1.2.2 Semaphorin Family 
Semaphorins are a large family of 20 proteins with diverse roles in both neural and 
vascular development. They are organized into 5 subfamilies (classes 3 through 7) based on their 
structures. The class 3 semaphorins are unique in two ways: they are the only subfamily that can 
bind to the VEGF co-receptors neuropilin-1 and -2, and they are secreted in a soluble form. The 
other subfamilies are membrane-associated, although proteolytic cleavage can produce soluble 
forms. The receptors responsible for semaphorin signal transduction are the plexins. Whereas 
class 3 semaphorins must bind to a neuropilin co-receptor prior to forming a complex with 
plexins, semaphorins in the other classes bind plexins directly. Plexins themselves form a large 
family of proteins; there are 9 plexin receptors, divided into 4 subfamilies (classes A through D). 
Plexins have intracellular GAP domains that can inactivate R-Ras, leading to collapse of the 
cytoskeleton and reduced motility [9]. 
Semaphorins were originally studied to gain insight into their functions in neural 
development but more recently their effects on the tumor vasculature have been characterized [9]. 
Knockdown of Sema3A in mouse models increases angiogenesis, whereas addition of exogenous 
Sema3A reduced the vascular density [10]. Most class 3 semaphorins have the ability to repel 
endothelial cells in culture [11], with some dependence on the specific neuropilin and plexin 
receptors that are present [12]. Semaphorins outside of class 3 also play roles in angiogenesis. 
Sema4A inhibits angiogenesis in chick embryos and mouse corneas by binding to Plexin-D1 and 
inhibiting the formation of Rac-GTP [13]. Some semaphorins are able to enhance angiogenesis. 
Sema4D can increase endothelial cell motility by binding to Plexin-B1 and activating a variety of 
kinases including Src [14]. Sema5A can enhance angiogenesis through binding to Plexin-B3 by 
activating endothelial cell proliferation and motility [15].  
A potential mechanism of anti-angiogenesis for class 3 semaphorins is through 
competitive displacement of VEGF from neuropilin co-receptors. Competitive displacement 
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between VEGF165 and Sema3A has been demonstrated in neuropilin-1-overexpressing COS-7 
cells [16], but this conflicts with data suggesting that the binding sites of these two ligands on 
neuropilin-1 are distinct [17]. More recent data indicates that proteolytic processing of class 3 
semaphorins controls their ability to competitively displace VEGF by exposing a C-terminal 
arginine residue that interacts with the VEGF-binding site on neuropilin-1 [18,19].  
1.3 Therapeutic Targeting of Angiogenesis in Cancer 
Due to its importance in tumor angiogenesis, the VEGF pathway has been the target of 
multiple cancer therapies. Monoclonal antibodies have been used to target the pathway outside of 
cells, including the anti-VEGF antibody bevacizumab, the anti-VEGFR2 antibody ramucirumab, 
and the anti-NRP1 antibody MNRP1685A. Inside cells, small molecule tyrosine kinase inhibitors 
(TKIs) have been used to prevent VEGF receptor phosphorylation. FDA-approved VEGF 
receptor-targeting TKIs include sorafenib, sunitinib, pazopanib, and cabozantinib.  
VEGF-targeting therapies have had varying levels of success in clinical trials. The 
VEGF-neutralizing antibody bevacizumab is currently approved for treatment of colorectal [20], 
lung [21], brain [22,23], kidney [24,25], and cervical [26] cancers based on its ability to extend 
overall survival. Bevacizumab has failed to extend overall survival in pancreatic [27], breast 
[28,29], ovarian [30], and prostate [31] cancers. Despite extending the overall survival, overall 
response rates to bevacizumab are fairly low even in successful clinical trials, with 31% to 48% 
of patients responding. Although this represents a 10% to 20% improvement over placebo-treated 
patient cohorts, the low response rates demonstrate the need for improved patient selection. 
Similarly low response rates have been observed for ramucirumab in gastric cancer [32] and for 
the various TKIs in kidney [33], pancreatic [34], gastrointestinal stromal [35], and liver [36] 
cancers. A goal of personalized medicine is to create predictive biomarkers that would allow 
patients to be grouped into likely responders and non-responders at diagnosis; this would 
drastically improve response rates. 
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Table 1-1: Bevacizumab clinical trial results.  
Clinical trial data for response rates (RR, includes complete and partial responses), progression-
free survival (PFS), and overall survival (OS). 
 
1 Single-arm trial 
2 Median PFS and OS not reached because this was an adjuvant trial in non-metastatic disease, 
therefore PFS and OS rates are listed. 
 
No biomarkers have been found that are able to completely distinguish responders from 
non-responders for these drugs. Patients with higher baseline levels of plasma VEGF sometimes 
have better response rates to bevacizumab, but this trend does not always hold [39]. High baseline 
plasma sVEGFR2 [40] and low tumor neuropilin-1 [41] have also had associations with improved 
bevacizumab responsiveness in some trials. The failure of a single metric or univariate biomarker 
to adequately distinguish patients may be the result of the complexity of the VEGF pathway and 
other regulators of angiogenesis. Multivariate biomarkers that account for the levels of multiple 







813 44.8% vs. 34.8% 
(P = 0.004) 
10.6 vs. 6.2 
(P < 0.001) 
20.3 vs. 15.6 




878 35% vs. 15% 
(P < 0.001) 
6.2 vs. 4.5 
(P < 0.001) 
12.3 vs. 10.3 




85 28.2% 4.2 9.2 [23] 
Renal Cell 
Carcinoma 
649 31% vs. 13% 
(P = 0.0001) 
10.2 vs. 5.4 
(P = 0.0001) 
23.3 vs. 21.3 
(P = 0.336) 
[24, 
25] 
Cervical 452 48% vs. 36% 
(P = 0.008) 
8.2 vs. 5.9 
(P = 0.002) 
17.0 vs. 13.3 
(P = 0.004) 
[26] 
Gastric 774 46.0% vs. 37.4% 
(P = 0.0315) 
6.7 vs. 5.3 
(P = 0.0037) 
12.1 vs. 10.1 
(P = 0.10) 
[37] 
Pancreatic 535 13% vs. 10% 
N.S. 
3.8 vs. 2.9 
(P = 0.07) 
5.8 vs. 5.9 
(P = 0.95) 
[27] 
Ovarian 1,528 67% vs. 48% 
(P < 0.001) 
24.1 vs. 22.4 
(P = 0.04) 
NA [30] 
Breast 722 36.9% vs. 21.2% 
(P < 0.001) 
11.8 vs. 5.9 
(P < 0.001) 
26.7 vs. 25.2 




2,591 NA 83.7% vs. 82.7% 
(3-year PFS,  
P = 0.18) 
93% vs. 92% 
(at data cutoff, 
P = 0.23) 
[38] 
Prostate 1,050 49.4% vs. 35.5% 
(P = 0.0013) 
9.9 vs. 7.5 
(P < 0.001) 




components of the VEGF network may provide a more robust solution to the problem of 
predicting responders. 
1.4 Mathematical Models of Growth Factor Ligand-Receptor Networks 
Mathematical modeling has been used to further our understanding of the complexities of 
the VEGF pathway. Early models described the binding of VEGFA165 and VEGFA121 to the 
receptors VEGFR1, VEGFR2, and NRP1. The models comprise a system of nonlinear differential 
equations that included experimentally measured kinetic rate constants for ligand binding and 
receptor coupling reactions. This modeling approach has allowed for prediction of the effects of 
competitive PlGF binding on VEGF binding distributions [42], and has also led to an 
understanding of the mechanism by which NRP1 enhances the binding of VEGFA165 to VEGFR2 
[43].  
Computational models of the VEGF pathway have been expanded to include multiple cell 
types in multiple tissues of the body. These compartment models typically include three 
compartments: a diseased tissue, blood, and normal tissue. The normal compartment is a generic 
compartment comprising all normal tissues in the body, and the blood allows for transport 
between normal and diseased tissues. Reactions describing the transport of the soluble proteins in 
the model between compartments have been added. Diseased tissues have included tumors and 
ischemic muscles [44]. The role of a soluble form of VEGFR1, sVEGFR1, has been investigated 
in the context of compartment models [45]. Recently, the anti-VEGF antibody bevacizumab has 
been added into the model to create whole-body pharmacokinetic models [46,47]. In this work, 
we leverage models such as these. We expand the molecular complexity, and go beyond an 
'average patient' approach to create populations of individualized models. These will be useful in 
developing predictive biomarkers of VEGF-targeting therapies. They provide a framework in 
which the effects of inter-patient variability on drug response can be tested.  
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1.5 Cancer Bioinformatics 
Microarray and sequencing technologies have yielded insight into the abundances of 
molecules on a genome-wide scale. Efforts such as the Cancer Genome Atlas (TCGA) have 
produced large datasets from multiple cancer types describing gene copy number, expression, and 
methylation, as well as microRNA expression, protein expression, and mutations.  
1.5.1 Molecular Subtypes of Cancers 
Genomic data has been used to define molecular subtypes for many cancer types. In 
breast cancer, for example, hierarchical clustering was used to define the basal, luminal A, 
luminal B, and HER2-enriched molecular subtypes based on the expression of an “intrinsic” 
subset of genes that displayed high variability between tumor samples but low variability between 
different samples taken from identical tumors [48,49]. A classifier based on nearest centroid 
classification of 50 genes was developed, giving these subtypes the name “PAM50” [50]. 
Recently, an integrative analysis of copy number, DNA methylation, mRNA, microRNA, and 
protein measurements from the TCGA dataset yielded clusters that significantly overlapped with 
the PAM50 subtypes [51], reinforcing their utility. These molecular subtypes also overlap 
significantly with the level of three cell surface receptors that are evaluated using 
immunohistochemistry: estrogen receptor (ER), progesterone receptor (PR), and HER2. Tumors 
that are negative for all three of these receptors ("triple-negative") tend to have poorer prognoses 
due to a more invasive phenotype and fewer treatment options [52]. Triple-negative breast 
cancers (TNBC) tend to fall into the basal subtype, while ER+ tumors tend to be either luminal A 
or B. The PAM50 subtypes have prognostic significance and limited significance as predictors of 
treatment outcome.  
 Molecular subtypes have been defined in other cancer types based on TCGA data. 
Hierarchical clustering was used to divide glioblastoma samples into four subtypes [53,54] and to 
divide colorectal cancers into three subtypes [54]. Non-negative matrix factorization was used to 
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find four subtypes of ovarian cancer [55]. The molecular subtypes found in these studies all 
separated patients into groups with significantly different survival times. Beyond prognosis, 
however, further studies are needed to determine what role, if any, the subtypes may have in 
therapy selection. 
1.5.2 Predictive Biomarkers for Treatment 
Predictive biomarkers for targeted therapies have generally been unsuccessful. Notable 
exceptions include HER2 status, which is predictive of response to HER2-targeting drugs such as 
trastuzumab [56], pertuzumab [57], and lapatinib [58]. Tyrosine kinase inhibitors are sometimes 
effective only in tumors harboring a particular mutation, such as BRAF V600E for vemurafenib 
[59]. Multivariate gene expression signatures are not yet used for molecularly targeted therapies, 
but some have had success in predicting response to chemotherapy. The 21-gene OncotypeDx test 
for breast cancer is predictive of benefit from chemotherapy in ER+ patients [60]. 
There are several pitfalls in developing predictive biomarkers from genome-wide 
expression data. Simple linear, univariate biomarkers based on the level of expression of the 
target molecule often fail to adequately capture the complexity of signaling pathways. On the 
other hand, biomarkers learned from datasets containing measurements of thousands of genes 
may suffer from overfitting. Knowledge-based biomarkers may solve many problems associated 
with biomarker development. Extensive knowledge of the connections between molecules and the 
dynamics of their interactions derived from experiments can be used to inform the biomarker 
development process. The set of potential predictor variables can be limited to molecules relevant 
to the pathway of interest. Equations describing the rates of interactions between molecules in the 





2 Expression of VEGF and Semaphorin Genes Defines 
Subgroups of Triple Negative Breast Cancer 
2.1 Summary 
Triple negative breast cancers (TNBC) are difficult to treat due to a lack of targets and 
heterogeneity. Inhibition of angiogenesis is a promising therapeutic strategy, but has had limited 
effectiveness so far in breast cancer. To quantify heterogeneity in angiogenesis-related gene 
expression in breast cancer, we focused on two families – VEGFs and semaphorins – that 
compete for neuropilin co-receptors on endothelial cells. We compiled microarray data for over 
2,600 patient tumor samples and analyzed the expression of VEGF- and semaphorin-related 
ligands and receptors. We used principal component analysis to identify patterns of gene 
expression, and clustering to group samples according to these patterns. We used available 
survival data to determine whether these clusters had prognostic as well as therapeutic relevance. 
TNBC was highly associated with dysregulation of VEGF- and semaphorin-related genes; in 
particular, it appeared that expression of both VEGF and semaphorin genes were altered in a pro-
angiogenesis direction. A pattern of high VEGFA expression with low expression of secreted 
semaphorins was associated with 60% of triple-negative breast tumors. While all TNBC groups 
demonstrated poor prognosis, this signature also correlated with lower 5-year survival rates in 
non-TNBC samples. A second TNBC pattern, including high VEGFC expression, was also 




2.2.1 Data sets 
Published human breast cancer gene expression data sets were collated based on the 
following criteria: the tumors had to be untreated, primary tumors, and the gene expression had to 
be analyzed using the Affymetrix GeneChip! Human Genome U133A platform. Of the 98 data 
sets returned by searching for human breast tumors on the U133A platform in the GEO database, 
22 met the criteria of being untreated and primary as of April 13, 2012. If available, the following 
data were also collected: ER, PR, and HER2 immunohistochemistry (IHC), lymph node status, 
age at diagnosis, tumor stage, and tumor grade. The breast cancer data sets 
[61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80] (Table 2-1) were compiled into 
one expression data set and normalized using the justRMA function in the affy Bioconductor 
package of the R statistical software environment. Some samples were removed prior to 
normalization: 30 samples in GSE20194 were replicates, 47 samples in GSE5847 were stromal 
cells isolated by laser capture microdissection, and 20 samples in GSE5847 had received 
neoadjuvant chemotherapy prior to surgery when the sample was taken. Many of the samples in 
different data sets were found to be from the same patients; samples were removed so that each 
patient was represented in the final data set only once. After removal of samples, the data set 
consisted of 2,656 individual tumor samples and 42 normal samples. When multiple probe sets 
corresponded to a single gene, only the probe set with the highest variance across all samples was 
used to represent expression of the gene. In total, we analyzed the expression from 55 probe sets 
corresponding to 33 genes (Figure 2-1). 
The two TCGA data sets used for validation were current as of April 25, 2012. One data 
set consisted of 537 tumor samples analyzed on the Agilent G4502A microarray platform, while 
the other was an RNA-Seq data set consisting of 750 tumor samples analyzed on the Illumina 
HiSeq 2000 system. There were 481 patients overlapping between these two TCGA data sets. 
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This replication was allowed in order to show similar results using different gene expression 
measurement technologies. Positive and negative status for the receptors was assigned based on 
IHC if available, otherwise based on the gene expression measurements for the ESR1, PGR, and 
ERBB2 genes. 
 
Table 2-1: Breast cancer gene expression datasets 
As noted in the main text, samples must be untreated primary tumors. Unless otherwise noted, each sample 
in the datasets represents one tumor. The numbers of tumor samples are the actual number of samples used 






Dataset N Reference Notes 
GSE1456 159 65  
GSE1561 49 66 Core biopsy, >20% tumor cell content 
GSE2034 286 67 Tumor cell content >70%, all lymph-node negative 
GSE2603 99 68 Tumor cell content >70% 
GSE2990 104 69  
GSE3494 251 70  
GSE5327 58 71 All ER- 
GSE5847 28 72 47 stroma, 48 tumor (LCM); Surgical samples 
GSE7390 198 73  
GSE11121 200 74 Tumor cell content >40% 
GSE20194 42 75 Tumor cell content >70%, 30 replicates 
GSE20271 116 76  
GSE20437 42 77 Normal breast tissue (no tumors) 
GSE21217 11 78 Surgical samples 
GSE22093 68 79  
GSE22597 74 53  
GSE23988 61 79  
GSE24185 103 80  
GSE25066 508 81  
GSE31519 67 82  
GSE32072 25 83  
GSE36772 100 N/A  
GSE36773 49 N/A  
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Figure 2-1: Ligand-Receptor interactions for the VEGF and Semaphorin families.  
VEGF ligands bind to and signal through three RTKs: VEGFR1, VEGFR2, and VEGFR3 (blue). 
Neuropilins are in red, with numbers to distinguish between neuropilin-1 and neuropilin-2. 
Semaphorin ligands bind to and signal through Plexins A-D (green). Many (but not all) members 
of the VEGF and Sema3 families use Neuropilin 1 or 2 as a co-receptor for binding to the 
canonical signaling receptors. This competition for Neuropilin is thought to represent one 
mechanism by which VEGF and Semaphorin ligands antagonize each other; in addition, the 
downstream signaling of VEGFRs and Plexins can have opposite function. Note that not all splice 
isoforms of VEGF-A, VEGF-B, and PlGF can bind to the receptors indicated, and that kinetic 
rates of binding vary among isoforms. 
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2.2.2 Assignment of TN status and TN subtypes 
The assignment of triple negative status and subtype was made based on the gene 
expression levels of ESR1, PGR, and ERBB2 when IHC data were not available, as previously 
described by others [81]. A Gaussian distribution was fit based on expression of the three 
receptors for IHC TN samples, and another distribution was fit for IHC receptor-positive samples.  
Samples with no IHC data were classified by computing the probability of being TN based on the 
two density functions derived from samples with IHC data. Comparison of IHC data to 
expression-based assignments has demonstrated that misclassification of samples is rare (<3.6%) 
[81].   
Subtypes of the triple negative classification were assigned by calculating subtype 
centroids based on the classification used previously by others [50]: expression of ~2000 genes 
was used to compute centroids of each of the six subtypes based on 193 tumor samples. The 
classifier derived from this was tested using leave-one-out cross validation and classified 171 of 
the 193 samples correctly, for an accuracy of 88.6%. Testing the classifier trained with all 193 
samples resulted in correct classification of 187 samples, for an accuracy of 96.9%. This classifier 
was used to determine the subtypes of the remaining 582 triple negative samples.  
2.2.3 PAM50 intrinsic subtypes 
A previously used classifier for breast cancer involves the use of 50 genes to place 
tumors into one of five categories: basal, luminal A, luminal B, HER2-like, and normal-like. The 
method for classifying a new sample is to take the Spearman correlation coefficient of the 
expression of the 50 genes in the sample with each of the five class centroids. The class whose 
correlation coefficient is the highest is the class to which the sample belongs, unless all 
correlation coefficients are less than 0.1, in which case the sample is unclassified [82]. It should 
be noted that no genes in the PAM50 classifier overlap with the VEGF- and semaphorin-related 
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genes that we consider here; thus when we compare VEGF- and semaphorin-based clusters, we 
are considering two completely independent methods of classification. 
2.2.4 Differential expression 
Genes for VEGF and semaphorin ligands and receptors that were significantly different 
between two groups (e.g. tumor vs. normal, receptor-positive vs. triple negative, etc.) were 
determined by the Wilcoxon rank sum test. This was carried out using the wilcox.test function in 
R.  
2.2.5 Principal component analysis 
Principal component analysis (PCA) was used to reduce the dimensionality of the data 
sets from the 31 VEGF- and semaphorin-related genes under consideration to a smaller number of 
components that can reproduce most of the variability in the data. The components are linear 
combinations of the expression of the genes, and capture patterns of co-expression. The prcomp 
function in R was used to perform PCA. The columns of the x matrix returned by this function 
corresponded to the scores, while the columns of the rotation matrix corresponded to the gene 
loadings. For 2-D score plots where colors were used to show different groups of samples, the 
statistical significance of differences in PCA scores between the groups was determined using 
multivariate analysis of variance. The p-values were determined by comparing the Wilk’s lambda 
statistic to a chi-squared distribution.   
2.2.6 Logistic regression 
For triple-negative status, lymph node status, tumor stage, tumor grade, age at diagnosis, 
and tumor size, logistic regression models were fit based on the scores of the first eight principal 
components using the R function glm.  
2.2.7 Survival analysis 
The R package survival was used to perform survival analysis on tumor samples for 
which survival and clinical variables were available. A log-rank test was used to assess univariate 
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significance of factors. A Cox proportional hazards model was used for multivariate analysis of 
all factors. 
2.2.8 Cluster analysis 
K-means clustering was performed on the 2656-sample data set consisting of all of the 
breast tumors, as well as the 775-sample data set consisting of all triple negative tumors. The R 
function kmeans was used for clustering. To ensure that the algorithm converged to the global 
minimum instead of a local minimum, clustering was performed 50 times and the solution with 
the lowest within-class sum of squares was used to determine the cluster membership of each 
sample. 
Consensus K-means clustering was used to assess the stability of the clusters. This 
consisted of performing the clustering algorithm 100 times on different subsets of the data set, 
and then computing the fraction of iterations in which any pair of samples were found in the same 
cluster. At each iteration, the sample subsets were determined by taking a random sample without 
replacement whose size was 80% of the data set. The consensus matrix is a visual representation 
of the fraction of iterations in which any pair of samples co-clustered. The cumulative distribution 
of the consensus matrix across all possible sample pairs was used to determine the number of 
clusters. The appropriate number of clusters was the cluster number at which no further increases 
in the area under the cumulative distribution curve occurred. Typically, the relative change in area 
is close to zero above a certain value of K. For example, in the all-tumor data set and the TNBC-
only data set, values of K greater than and equal to 5 resulted in low relative area changes. To 
select the appropriate number of clusters from these cases, the consensus matrices were 
investigated to determine which cluster number resulted in the most off-diagonal white space 
[82].     
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2.2.9 Visualization of data 
Gene expression differences between tumor and normal samples were plotted in Figures 
2-2A and 2-2B as the log of the ratio of the two means. Error bars corresponded to the 99% 
confidence interval of the log ratio derived from the Wilcoxon rank sum test. The range of gene 
expression across groups was shown in boxplots with the extreme ends of the boxes 
corresponding to the 25th and 75th percentile of the data and the line inside the box corresponding 
to median. The whiskers extended to the furthest point outside of the boxes that still fell within 
1.5 times the interquartile range from the nearest end of the box, where the interquartile range 
was the difference between the 75th and 25th percentiles.  
Heatmaps of gene expression data were generated in R using the image function. Data 
were scaled (zero-mean, unit-variance) and assigned colors, with red corresponding to high 
expression and green corresponding to low expression. Ordering of genes in the heatmaps was 
performed using the hclust function in R with the complete-linkage agglomeration method. When 
dendrograms were used, they were generated using the plot.dendrogram function in R. 
2.3 Results 
2.3.1 Expression patterns defining tumor and normal tissue 
The 2,656 tumor samples were compared to 42 normal samples to identify differentially 
expressed genes. Overall, 20 out of 29 of the ligand probe sets differed between tumor and 
normal tissues at a significance level of 0.01 (Figure 2-2A). All of the VEGF ligands were up-
regulated in tumors except PlGF. PlGF had two probe sets on the U133A platform: one was 
down-regulated and the other did not differ significantly between normal and tumor tissues. 
Semaphorin ligand expression differences varied, with a mix of up- and down-regulation. Ligands 
in Figure 2-2A were annotated on the left axis with a color of red if they were known to have pro-
angiogenic functions, blue for anti-angiogenic functions, gray if they had been shown to both 
promote and inhibit angiogenesis in different studies, or white if no data were available 
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[8,11,12,13,14,15,83,84,85,86,87,88,89,90,91,92,93,94,95,96]. In general, class-3 semaphorins 
inhibit angiogenesis, while the other four classes have varying effects. 
Although 20 out of the 26 receptor probe sets differed from normal expression at a 
significance level of 0.01 (Figure 2-2B), the overall magnitude of the fold change between tumor 
and normal tissue was less for receptors than for ligands: the mean absolute difference was 0.58 
for ligands (mean of all points in Figure 2-2A) compared to 0.32 for receptors (mean of all points 
in Figure 2-2B). Most receptors that were differentially expressed were up-regulated, with the 
exception of FLT4 (VEGFR3) and PLXNA1.  
We used principal component analysis (PCA) to determine patterns of covariation in gene 
expression between tumor and normal samples. Projection of the gene expression data onto the 
plane defined by principal components 1 and 4 (PC1, PC4) showed the best separation between 
tumor and normal samples (Figure 2-2C). Normal samples showed moderate values of PC1 and 
high values of PC4; tumor samples had a broader range of PC1 values and lower values of PC4. 
High PC1 scores were associated with high expression of VEGFC, KDR, NRP1, and PLXNC1, 
and low expression of SEMA3A, SEMA7A, FLT1, and FLT4. Low PC1 scores were associated 
with the opposite expression pattern. Low PC4 scores were associated with a pro-angiogenesis 
signature, a combination of high expression of VEGFA, SEMA4D, NRP2, and PLXNA1, and 
low expression of several secreted semaphorins: SEMA3B, SEMA3C, SEMA3E, SEMA3F, and 
SEMA3G. The advantage of the PCA-based approach for comparing tumor and normal samples 
over the differential expression analysis used in Figures 2-2A and 2-2B was that patterns of co-
expression could be observed. For example, KDR expression by itself was not significantly 
altered between tumor and normal samples (Figure 2-2B), but co-expression of KDR with 




Figure 2-2: Differences in expression patterns of VEGF- and semaphorin-related genes 
between normal breast tissue (n=42) and breast tumors (n=2,656).  
A-B, Differences in mean expression with 99% confidence intervals as determined by the 
Wilcoxon rank sum test for (A) ligands and (B) receptors at the probe level. Ligands are marked 
with the following colors to denote known effect on angiogenesis: red for pro-angiogenic, blue 
for anti-angiogenic, gray for context-dependent (could be pro-or anti-angiogenic) and white for 
unknown. Genes for which expression is significantly altered in tumors are denoted by * 
(p<0.001) and the direction noted by an arrow. C-D, Principal component analysis shows 
separation of tumors from normal samples based on first and second principal component scores 
(C), with corresponding gene expression patterns given by the loadings for these components (D). 
Gene labels are only shown for genes whose loading vectors onto PC1 and PC4 exceed a 
magnitude of 0.23. Circles denote the loading of genes whose names do not appear.  
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2.3.2 VEGF and semaphorin gene expression are differentially regulated in triple 
negative breast cancer 
To determine patterns in VEGF and semaphorin expression that may be important in 
distinguishing various breast cancer subgroups, we performed PCA on the expression 
measurements for the 31 VEGF- and semaphorin-related genes in the data set consisting of 2,656 
tumors. We compared the scores obtained from PCA with commonly used clinical variables and 
found that the principal components had the most significant associations with triple negative 
status (Figure 2-3C), as indicated by the large logistic regression coefficients. Some significant 
associations were found between the principal components and lymph node status (Figure 2-3D) 
and tumor grade (Figure 2-3E), but the coefficients were much smaller than those for triple 
negative status. Tumor stage was not associated with the components at all (Figure 2-3F). 
Additionally, we noted that applying PCA to the VEGF-related gene subset alone failed to 
distinguish TNBC samples from receptor-positive samples as effectively as the combined data set 
(Figure 2-3A). Applying PCA to the semaphorin-related gene subset alone resulted in some 
significant associations with triple-negative status (Figure 2-3B). The NRP1 and NRP2 genes 
were included in both subsets. Together, this suggests that the (indirect) interactions between the 
VEGFs and the semaphorins lead to different neuropilin-regulated signaling activities in TNBC 
tumors compared to receptor-positive tumors.  
When applying PCA to the combined VEGF and semaphorin data set, the projection of 
the data onto the fourth principal component (PC4a, “a” to denote the all-tumor data set) provided 
the highest degree of separation between TNBC samples and the rest of the tumors (Figure 2-
4A), with low values of PC4a corresponding to TNBC samples. A group of tumors also scored 
highly on PC3a. A relatively large proportion of these were TNBC samples that did not score low 
on PC4a. PC1a had a slight association with TNBC status but only in samples that scored low on 
PC4a, while PC2a did not appear to have any association with TNBC status. PC4a also was  
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Figure 2-3: Relationship between PCA scores and TN status. 
A-B, Logistic regression coefficients for the first eight PCA scores for VEGF-related genes only 
(A) and for the semaphorin related genes only (B). The probe sets for NRP1 and NRP2 were 
included in both subsets of the data. C-F, Logistic regression coefficients for the combined 
VEGF/Sema set for triple negative status (C), lymph node status (D), tumor stage (E), and tumor 




Figure 2-4: Triple negative breast cancers and the mesenchymal stem-like (MSL) subtype of 
triple negative breast cancers are associated with increased pro-angiogenic gene expression 
and decreased anti-angiogenic gene expression.  
A-B, PCA scores (A) and loadings (B) for VEGF- and semaphorin-related genes in all tumors. 
Gene names are only shown for probes whose loadings on the two principal components 
exceeded a radius of 0.2 from the origin. Circles denote genes whose names do not appear. 
Triple-negative (TN) samples project to lower values of tumor PC4a, corresponding to high 
VEGFA and low SEMA3 expression. C-D, PCA scores (C) and loadings (D) for VEGF- and 
semaphorin-related genes in only the TN samples. The MSL subtype projected to low values of 
TNBC PC2t, corresponding to up-regulation of VEGFC, SEMA3G, and SEMA5A and down-
regulation of VEGFA.  
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significantly associated with the basal subtype (as defined by the PAM50 gene signature classifier 
described previously [49]) (data not shown), consistent with the similarities between TNBCs and 
the basal subtype.  
Low PC4a scores were associated with a pro-angiogenic signature consisting of high 
expression of VEGFA, SEMA4D, NRP2, and PLXNA1 and low expression of SEMA3B, 
SEMA3C, SEMA3E, SEMA3F, and SEMA3G. High PC3a scores were associated with high 
expression of VEGFC, SEMA3A, SEMA3G, SEMA5A, KDR, and FLT4, and low expression of 
VEGFA (Figure 2-4B). In addition to the established roles of VEGFA and VEGFC as promoters 
of angiogenesis, published experimental data has shown that other genes associated with low 
PC4a and high PC3a, SEMA4D and SEMA5A, also have pro-angiogenic function [14,15,91]. 
Interestingly, three of the ligands with reduced expression in high PC3a and low PC4a samples, 
SEMA3B, SEMA3F, and SEMA3G, had both anti-angiogenic and tumor suppressor functions 
[11,12,83,88,89,90]. The role of SEMA3C in angiogenesis has not been well-defined, but like 
other class-3 semaphorins, it binds to neuropilin receptors. Thus, it may impair signaling by 
members of the VEGF family by competing for neuropilin.  
Examining the correlations between PC4a scores and all genes whose expression was 
measured on the U133A platform revealed that the ESR1 gene, which encodes ER, had the 
second highest correlation with PC4a of all genes (data not shown). Other transcription factors 
associated with ER, such as GATA3 and FOXA1, had high correlations as well. This indicated 
that the association between PC4a score and TN status may arise primarily because of an 
association with ER, as opposed to PR or HER2. ER, PR, and HER2 did not appear in the list of 
the most correlated genes with PC3a scores (data not shown).   
2.3.3 The MSL subtype differs significantly from other TNBC subtypes 
Next we examined VEGF and semaphorin expression in TNBC samples assigned to the 
TNBC subtypes discovered in Lehmann et al [81]. PCA of VEGF and semaphorin expression for 
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only the TNBC samples revealed that of all of the subtypes, the mesenchymal stem-like (MSL) 
subtype was most distinguishable from the others (Figure 2-4C). The MSL subtype projected to 
low values of the second principal component (PC2t, “t” to denote the TNBC-only data set). The 
gene expression pattern corresponding to low PC2t included low expression of VEGFA and high 
expression of VEGFC, SEMA5A, and SEMA3G (Figure 2-4D). This was similar to the PC3a 
from the analysis of all tumors in the previous section (Figure 2-4B), except that the signs were 
reversed. There was substantial overlap between the triple negative tumors that had high PC3a 
scores in Figure 2-4A and the tumors that had low PC2t scores in Figure 2-4C, indicating that the 
MSL subtype could likely be distinguished even in the PCA of all of the tumors.    
The median expression of VEGFA, VEGFC, SEMA5A, and SEMA3G in the MSL 
subtype was closer to the median of receptor-positive tumors than to that of TNBC samples. In 
the case of VEGFA, SEMA5A, and SEMA3G, the expression levels in the MSL subtype were 
closer to those of normal tissues than the tumor average. On the other hand, VEGFC was 
expressed at higher levels on average than in any of the other groups, indicating that this 
subgroup may be susceptible to angiogenesis inhibitors that target VEGFC instead of VEGFA. 
2.3.4 Consensus clustering defines VEGF- and semaphorin-based tumor subtypes 
We used consensus K-means clustering to determine VEGF- and semaphorin-related 
subtypes independent of any other classifications. This differed from the PCA-based clusters in 
Figure 2-4 in that all gene expression variation was analyzed here to determine the natural 
clusters that arise in VEGF- and semaphorin-related gene expression. Consensus clustering 
revealed 7 clusters (labeled A-G) for "all tumors" data (data not shown), and 5 clusters (labeled J-
N) for "TNBC-only" data (data not shown). The gene expression for the seven tumor clusters is 
illustrated in the heatmap in Figure 2-5, with the clusters arranged by the number of TNBCs 
present in decreasing order. 
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Figure 2-5: Heatmap of the 7 VEGF/Sema-based tumor clusters.  
Samples are ordered across the columns by cluster membership as determined by consensus K-
means clustering. The clusters are ordered by TN content, with cluster A on the left having the 
highest percentage of TNBCs. The VEGF/Sema-based clusters are able to differentiate the basal 
intrinsic subtype from the other intrinsic (PAM50) subtypes. As previously noted, the basal 
subtype is strongly associated with triple negative tumors (third and fourth bars: black for basal 
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TNBCs and non-basal TNBCs, respectively). Other breast cancer-related genes have expression 
patterns that align with the VEGF/Sema-based clusters. 
 
 
High VEGFA-expressing clusters. The first two clusters (A and B) in Figure 2-4 possessed the 
pro-angiogenic PC4a gene expression signature noted in Figure 2-3, namely high VEGFA 
expression and low expression of SEMA3B/3C/3F. Cluster A is distinguished from cluster B by 
higher expression of FLT1 (VEGFR1), FLT4 (VEGFR3), and several semaphorins (including 
SEMA3A), and lower expression of VEGFC, KDR (VEGFR2), and NRP1. Both clusters have 
high percentages of TNBCs (78% and 66%, respectively). Using the intrinsic classifier (PAM50, 
Figure 2-4), these two clusters were found to contain most of the basal subtype tumors. As 
expected, most of the TN tumors were basal as well (rows 3 and 4 of Figure 2-4 compare the 
overlap between the TN and basal subtypes). Both of these clusters had low expression of the 
genes encoding for ER and PR (ESR1 and PGR) and of some of their associated transcription 
factors (GATA3, FOXA1, MYB), and high expression of proliferation-related genes (the 
basal/luminal panel in Figure 2-5), consistent with the basal subtype.   
High VEGFR1/VEGFR3-expressing cluster. Cluster C in Figure 2-5 had high expression of 
FLT1 (VEGFR1), FLT4 (VEGFR3), SEMA3A, and some other semaphorins, with low 
expression of VEGFA, VEGFC, KDR (VEGFR2), NRP1, SEMA3C, PLXNA1, and PLXND1. 
This cluster also had a relatively high percentage of TNBCs (43%), but with a lower amount of 
basal subtype tumors than the high VEGFA-expressing clusters. This indicated that although 
many TNBCs had the pro-angiogenic PC4a signature, it was not strictly required for a tumor to 
be triple-negative. This cluster had low expression of the claudin genes CLDN3, CLDN4, and 
CLDN7, raising the possibility that tumors in this cluster were members of the claudin-low 
subtype, a group of breast tumors known for their invasive, mesenchymal-like behavior. 
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High VEGFC-expressing cluster. Cluster D in Figure 2-5 had high expression of a group of 
genes including VEGFC, KDR (VEGFR2), NRP1, and SEMA5A. This corresponded to the 
alternative pro-angiogenic TNBC PC2t signature noted in Figure 2-4. This cluster had some 
TNBCs (16%). Significant overlap was noted between this cluster and the luminal A subtype of 
the PAM50 intrinsic classifier; 67% of cluster D tumors were luminal A, representing 30% of all 
luminal A tumors. Cluster D was notable in that it had the highest expression of transcription 
factors implicated in the epithelial-to-mesenchymal transition (EMT), including SNAI2, 
TWIST1, ZEB1, and ZEB2 (the panel labeled “EMT” in Figure 2-5). This could indicate a role 
for VEGFC-mediated signaling in tumors undergoing an EMT.  
High SEMA3-expressing clusters. Clusters F and G in Figure 2-5 had the anti-angiogenic high 
PC4a signature described previously: high expression of the anti-angiogenic semaphorins 
SEMA3B, SEMA3E, and SEMA3F, with low expression of VEGFA. These clusters had the 
lowest number of TNBCs and were mostly luminal A or B when classified into the PAM50 
intrinsic subtypes. The pattern of expression of luminal markers and proliferation-related genes 
was opposite to that noted for the high VEGFA-expressing clusters: expression of ESR1, PGR, 
and associated transcription factors was high while expression of proliferation-related genes was 
low.  
2.3.5 Consensus clustering defines VEGF- and semaphorin-based TNBC subtypes 
The 5 TNBC clusters, denoted J-N (Figure 2-6), were ordered as closely as possible to 
the tumor clusters in Figure 2-5. Thus the majority of samples in cluster A of Figure 2-5 fall into 
cluster J of Figure 2-6, and so on. The relationship is not perfect; many samples are differentially 
classified between the two cluster analyses.  
The five TNBC clusters had similar expression patterns to the clusters described above 
for all tumors. TNBC clusters J and K had higher VEGFA expression on average, and as with 
clusters A and B, were differentiated by the pattern of high FLT1, FLT4, SEMA3A in cluster J  
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Figure 2-6: Heatmap of the 5 VEGF/Sema-based TNBC clusters. 
Consensus K-means clusters of only the TNBC data are arranged according to the ordering from 
Figure 2-5, in that the TNBCs that appeared in tumor cluster A generally now appear in TNBC 
cluster J (although the correspondence is not perfect) and so on for the other clusters. The 
VEGF/Sema-based clusters are able to differentiate the MSL subtype from Lehmann et al. 
(cluster M) from the other TNBC subtypes. Claudin-low subtype-related patterns of gene 
expression in the panel labeled “EMT” were associated with cluster M, the MSL-enriched cluster.  
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and high KDR, NRP1 in cluster K. Clusters L and M had lower VEGFA expression, with cluster 
L expressing high levels of PGF, FLT1, FLT4, and SEMA3A, and cluster M expressing high 
levels of VEGFC, KDR, and NRP1. Cluster D had low PC2t scores from Figure 2-4C/D. The 
fifth cluster was not particularly distinguishable from the other TNBC clusters. Notably, all the 
clusters except cluster M were heavily populated by tumors of the basal PAM50 intrinsic subtype. 
This was seen for clusters A and B in the all-tumor data set (Figure 2-5), but not for clusters C 
and E. This is further evidence for the association between the basal subtype and TNBC; basal 
tumors comprised a small minority of clusters C and E in Figure 2-5, but this minority became 
the majority in Figure 2-6 when only the TN tumors were considered. 
The TNBC subtypes found in Lehmann et al [81] had some associations with the VEGF-
/Sema-based clusters found here. Of tumors in the MSL subtype, 81% were found in cluster M, 
comprising 65% of the tumors in that cluster. This corresponds to the PCA results that 
demonstrated a strong association of PC2t with the MSL subtype. Most of the other subtypes 
were evenly distributed across the clusters, with the exception of the basal-like 1 (BL1) subtype, 
which comprised 66% of cluster J.  
Patterns of expression for other genes when sorted in the order of the TNBC clusters 
were less apparent in Figure 2-6 than in Figure 2-5, with cluster M showing the most significant 
regulation. Growth-associated genes such as FOXM1, AURKB, and MKI67 were strongly down-
regulated in this cluster while the EMT-associated transcription factors SNAI2, TWIST1, ZEB1, 
and ZEB2 were up-regulated. Notably, the claudin genes CLDN3, CLDN4, and CLDN7 were 
down-regulated the most in this cluster, consistent with the observation that the MSL subtype and 
claudin-low subtype are closely related [97]. 
2.3.6 Validation using TCGA data 
Using two TCGA data sets consisting of 537 tumors quantified using a different 
microarray platform (Figures 2-7A and 2-7B) and 750 tumors quantified using an RNA-Seq  
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Figure 2-7: Validation of VEGF- and Semaphorin-related gene expression differences 
between triple-negative and non-TN breast cancers using TCGA data. 
A-B, Principal component analysis of TCGA microarray data set consisting of 537 breast tumors. 
C-D, Principal component analysis of TCGA RNA-Seq data set consisting of 750 tumors. Both 
data sets were processed to gene-level measurements (rather than probe-level) prior to 
downloading. Tumors were classified as triple negative based on gene expression data for the 
ESR1, PGR, and ERBB2 genes as described in the Methods, all of which had clear bimodal 
distributions.  
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platform (Figures 2-7C and 2-7D), we showed that the same patterns of gene expression that 
distinguish TNBCs from other tumors could be found in other patients using different 
technologies. PCA scores between the two platforms used in the TCGA datasets had strong 
correlations (data not shown). Patterns of gene expression associated with the 2,656-tumor dataset 
were found in both TCGA datasets (data not shown), including the low PC4a gene expression 
signature of high VEGFA and low SEMA3B, SEMA3C, SEMA3F, and PLXNB1. Some 
additional genes were altered consistently in the two validation data sets as well: SEMA5B, 
SEMA7A, and PLXNA1. All three of these had similar expression patterns to that of VEGFA.  
2.3.7 Survival analysis of clusters  
We performed Kaplan Meier survival analysis on the tumors to determine the impact of 
the PCA-derived clusters on patient prognosis. Triple negative status and increasing stage of the 
tumor were both correlated with poorer prognoses as expected (Figures 2-8A and 2-8B). 
Multivariate survival analysis using a Cox proportional hazards model showed that tumor stage, 
lymph node status, PC3a score, and PC4a score were all independent prognostic factors. 
Interestingly, triple negative status, which was clearly correlated with poor survival, was not 
significant in the multivariate model (p=0.06). The likely reason for this is that TN status is also 
highly correlated with PC4a scores. There were more non-TNBC samples with low PC4a scores 
(n=89) than TNBC samples with high PC4a scores (n=29), possibly resulting in a stronger 
survival effect from PC4a score than from TN status (Figure 2-8C). We also examined the 
interaction of ESR1 expression with PC4a; both low ESR1 expression and low PC4a scores were 
significantly associated with poor prognoses (Figure 2-9). Interestingly, PC4a score was 
significantly associated with survival in a subgroup consisting of tumors with high ESR1 
expression. Although ER+ tumors are already associated with effective therapies, combination of 
existing therapies with angiogenesis inhibition may provide additional benefits for these low 
PC4a, ER+ tumors. 
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Figure 2-8: Angiogenesis gene expression subgroups correlate with survival. 
A-D, Survival curves for tumor samples that had available survival data. A log-rank test was used 
to determine p-values. Triple negative (TN) status was associated with worse prognosis for 572 
patients with survival data (A). Higher tumor stage correlated with worse prognosis in 508 
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patients with available stage and survival data (B). Non-TNBC patients with low PC4a scores had 
poor prognoses similar to the TNBC patients (C). Patients in the HER2-enriched PAM50 subtype 
had significantly poorer prognoses if they also had low PC4a scores (D). E-F, Schematic of 
VEGF/semaphorin competition in the tumor microenvironment. The gene expression patterns of 
the different subgroups of TNBC and other cancers suggest different regulation of pro- and anti-
angiogenesis pathways. The case with high expression of VEGFA and low SEMA3B, which 
corresponds to the high PC4a group, results in increased signaling through VEGF receptors such 
as VEGFR2 (blue). Most TNBC fit this profile, although many non-TNBC did also and these 
showed decreased 5-year survival similar to TNBC (C). Lower expression of VEGFA with high 
SEMA3B, corresponding to the low PC4a group, results in reduced signaling through VEGF 
receptors and more signaling through semaphorin receptors such as PLXNA1 (green). Note that 
these schematics only consider receptor expression. 
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Figure 2-9: Survival analysis based on PC4a and ESR1 expression. 
A, Low PC4a scores and low ESR1 expression ("LowPC4a/LowESR1") were both associated 
with poorer prognoses. In high ESR1-expressing tumors ("HighESR1"), low PC4a scores resulted 
in poor prognosis as well, while high PC4a scores resulted in significantly better prognoses. B, 
Cox proportional hazard models reinforced the overall independence of ESR1 expression and 
PC4a score. Both factors were significantly associated with survival in a model of all tumors with 
survival data (top panel). In tumors with low ESR1 expression (middle panel), neither factor was 
significant. In a model of tumors with high ESR1 expression (bottom panel), PC4a score, but not 
ESR1 expression, had significant association with survival. 
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Figure 2-10: Association between PC4a score in the five PAM50 subtypes. 
A, Cox proportional hazard models for each PAM50 subtype demonstrated that PC4a score only 
was significantly associated with survival in the HER2-enriched subtype, while ESR1 expression 
was not significantly associated with survival in any of the subtypes. Hazard ratios indicate the 
effect of increasing PC4a score or ESR1 expression; thus, a lower hazard ratio indicates that high 
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PC4a scores are associated with improved prognosis. PC4a scores and ESR1 expression were 
included as continuous variables. B, PC4a scores below the median were typically associated 
with poorer prognoses except in the basal subtype. As the basal subtype is associated with low 
PC4a scores, very few samples in the basal subtype had high PC4a scores. This low number of 
samples explains the steep drop-off in the upper left plot. 
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Survival analysis by cluster (data not shown) showed that tumor clusters F and G had 
significantly better outcomes than the rest of the clusters. These were the only clusters that had 
both low PC3a scores and high PC4a scores (both anti-angiogenic signatures), reinforcing the 
prognostic value of these two principal components. The five TNBC clusters found here did not 
have significantly different prognoses; instead the survival curves of the clusters shared the same 
poor prognosis characteristic of TNBCs (data not shown). Despite the lack of variability, the 
differences in patterns of VEGF and semaphorin gene expression may indicate different growth 
factor dependencies. For example, VEGFC-targeting therapies may be more effective in cluster 
M, while the rest may benefit more from VEGFA-targeting therapies. 
Within each PAM50 subtype, ESR1 was not significant (Figure 2-10A) while PC4a 
score was significantly associated with survival only in the HER2-enriched subtype (Figures 2-
8D and 2-10B). The lack of association between survival and PC4a in the basal and luminal 
PAM50 groups is not unexpected since PC4a is somewhat consistent within these groups (low in 
basal, high in luminal, as shown in the heatmap in Figure 2-5). The prognostic effects of PC4a 
score in the HER2-enriched subtype could indicate that a low-PC4a subgroup of patients treated 
with HER2-targeting therapy may benefit from the addition of an anti-angiogenic drug to their 
treatment. Overall the association of survival and PC4a score in particular subtypes may aid in 
selecting patients where anti-angiogenic therapy would provide the greatest benefit.  
2.4 Discussion 
Just as individuals have distinct genomic and gene expression profiles, so too the tumors of 
each individual are distinct. Understanding and quantifying this variability and individuality is 
crucial for the development and targeting of therapeutics for diseases as complex and 
heterogeneous as cancer. Triple negative breast cancers (TNBCs), in particular, are a diverse and 
difficult-to-treat set of tumors defined primarily by molecular targets for treatment that they do 
not express, rather than targets that they do express. Angiogenesis, a blood vessel morphogenesis 
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process underpinning the growth and metastasis of most tumors, is a possible common target for 
TNBCs, and vascular endothelial growth factor (VEGF) has been targeted in breast cancer as a 
key regulator of angiogenesis. However, this has succeeded only for a subset of breast cancer 
patients, and thus understanding which subsets of patients may be responsive to this treatment is 
desirable. This requires data from a large number of patients, and we used one type of patient 
population data, gene expression microarrays, to quantify changes in VEGF and semaphorin 
expression to define relevant patient subgroups.  
A high proportion of the genes considered here were significantly different between 
normal breast tissue and breast tumors (34/55 probe sets with p<0.001). This high rate of 
significance may be an indicator that these genes are heavily regulated by the genomic changes 
that occur in tumors. Alternatively, the low number of normal samples (n=42) relative to tumor 
samples (n=2,656) may result in an unrealistic estimate for significance. It is important to note 
that the range/variability in tumor expression is very high compared to the normal samples, as 
indicated by the standard deviations of each group (data not shown). Although the mean values of 
expression for tumors and normal tissues may differ, the range of tumor expression often overlaps 
the range of normal expression. This makes individual genes poor biomarkers; however, they can 
be combined to identify tumor subgroups that correlate with differences in tumor characteristics. 
The overall expression changes were consistent with previously reported breast cancer 
data of these genes at the mRNA and protein level. The increased expression of VEGFA in 
TNBCs compared to non-TNBCs was consistent with previous work that found an approximately 
3-fold increase of VEGF as measured by ELISA of intra-tumoral samples from 679 patients [98]. 
VEGFR2 (KDR) was previously found to be significantly associated with TNBC in a panel of 
tissue microarrays from 564 patients [98]. This is consistent with our results, which showed a 
relatively high loading of KDR on the principal component associated with VEGFC, NRP1, and 
PLXND1, which had the second highest association with triple-negative (TN) status in the all-
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tumor data set. The increased expression of VEGFC in TNBC samples found here has also been 
demonstrated in IHC of breast cancer sections, where VEGFC stained positively in TNBCs 
significantly more often than in non-TNBCs [99]. Studies examining the amount of semaphorins 
and plexins expressed in breast cancer patients by TNBC and non-TNBC subgroups are not 
available, but there are some reports comparing their expression in normal breast and tumor 
tissue. SEMA3A, SEMA3B, SEMA3F, PLXNA1, and PLXNA3 were all shown by IHC to 
decrease as tumors progressed, while NRP1 increased and NRP2 stayed the same [100]. Another 
study showed the same pattern for PLXNA3 expression, while also showing that SEMA4F 
expression increased as tumors progressed [101]. 
Using multiple clustering and analysis algorithms, we have revealed patterns of gene 
expression associated with the triple-negative subtype of breast cancer that may indicate a higher 
collective pro-angiogenesis activity (Figure 2-5, tumor clusters A-C). In addition to up-regulation 
of the well-known angiogenic growth factor VEGFA in clusters A and B, several anti-angiogenic 
semaphorins were down-regulated. SEMA3B and SEMA3F have both anti-tumorigenic and anti-
angiogenic properties [11,12,83,88,89,102,103]. SEMA3C, whose role in angiogenesis is less 
well-understood [84,85], was also consistently down-regulated in tumors with high expression of 
VEGFA. Given that class-3 semaphorins compete with VEGF for binding to neuropilin co-
receptors, this overall pattern of gene expression may enhance VEGF signaling in three ways: 
directly by increasing the amount of VEGFA; indirectly by reducing the amount of competitive 
inhibition for neuropilin; and decreasing anti-angiogenic Sema-Plexin signaling. The survival 
analysis in Figure 2-8C demonstrates the significance of this high-VEGF/low-Sema3 signature; 
patients with this signature have similar poor prognoses regardless of their triple negative status. 
The activity of angiogenesis in the TNBC-enriched cluster C from Figure 2-5 is less clear: 
VEGFA is down-regulated, while several semaphorins with both pro-angiogenic (SEMA6B and 
SEMA7A) and anti-angiogenic (SEMA3A and SEMA4A) effects are up-regulated.  
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 What do these different gene-expression subgroups mean for treatment? We would 
hypothesize that high-VEGFA-expressing tumors would be more vulnerable to anti-VEGF 
treatment. Clinical trial results for the anti-VEGF drug bevacizumab have thus far not shown an 
increased efficacy in triple-negative subtypes [29,76,104,105,106]; instead, similar improvements 
have been seen in both triple negative and hormone receptor positive cancers (all cases were 
HER2-negative). However, we note that the high-VEGFA, low-Sema3 pattern (clusters A and B 
in Figure 2-5) makes up only 69% of all TNBC samples, and that 12% of non-TNBC samples 
can be classified as having a similar gene expression profile, possibly confounding this analysis.  
Other clusters found in the tumor data may be less susceptible to inhibition of 
angiogenesis. The clusters with high expression of class-3 semaphorins would likely not benefit 
from this type of therapy because class-3 semaphorins function as endogenous inhibitors of 
angiogenesis. These tumors would be expected to be less aggressive; survival curves for patients 
with high class-3 semaphorin expression have the best prognoses (high PC4a in Figure 2-8C).  
The gene expression pattern consisting of high expression of VEGFC, PlGF, NRP1, and 
PLXND1 and low class-3 semaphorin expression (PC3a in Figure 4-4A/B) is also likely to be 
pro-angiogenic. However, it would not be expected to benefit from an anti-VEGFA therapy; 
instead, a different target would be needed to inhibit angiogenesis.  This is supported by a report 
that low IHC staining of VEGFC and NRP1 is associated with improved progression-free 
survival in patients receiving bevacizumab, while the level of VEGFA was not associated with 
changes in progression-free survival [107].   
The TNBC subtypes previously identified [81] demonstrated similar expression of 
VEGF- and semaphorin-related genes with the exception of the mesenchymal stem-like subtype. 
This subtype was noted for its enrichment of genes involved with migration and growth factor 
pathways, including KDR [81]. Here, we found a cluster of angiogenesis-related genes with 
increased expression in the MSL subtype, including VEGFC and KDR (TNBC cluster M in 
 41 
Figure 2-6, corresponding to tumor cluster D in Figure 5-5). Notably, however, VEGFA 
expression was decreased, indicating that although angiogenesis may occur in tumors of this 
subtype, VEGFA-targeted therapies are not likely to be successful inhibitors. In the analysis of all 
tumors, this VEGFC-dominated signature (tumor cluster D) was present in 18.5% of tumors. This 
cluster had a low proportion of triple negative tumors, raising the possibility that the MSL 
subtype may not just be a small subgroup within TNBCs, but a therapeutically relevant subgroup 
of breast cancers as a whole.  
The concordance of the VEGF-/Sema-based clusters that we found here with expression 
patterns of genes associated with the basal/luminal distinction and EMT suggests that different 
breast cancer subtypes utilize the VEGF and semaphorin signaling pathways in consistently 
different ways. In particular, basal tumors with high expression of growth-associated genes such 
as MKI67 and AURKB tend to have higher levels of VEGFA, presumably to provide the rapidly 
proliferating cells with sufficient vasculature. On the other hand, tumors with low expression of 
growth-associated genes but high expression of EMT-associated transcription factors such as 
SNAI2 and TWIST1 have low VEGFA expression and high VEGFC expression. The 
lymphangiogenic VEGFC may facilitate invasion by allowing tumor cells to travel through the 
lymphatics, a commonly used route of metastasis in breast cancer [99]. This highlights the 
usefulness of this study not just in targeting anti-angiogenic therapies, but in understanding tumor 
biology as well.  
One limitation of using gene expression microarrays on tumor samples taken from 
biopsies or surgeries is that the samples are heterogeneous. Along with the tumor cells they also 
contain stromal cells, including endothelial cells, fibroblasts, and immune cells. The expression of 
most of the ligands considered here can be assumed to be predominantly attributable to 
expression in the tumor cells, but for receptor expression the analysis is less straightforward. This 
is particularly true for receptors whose primary function of interest is on a cell type making up a 
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small percentage of the total, e.g. endothelial cells. Their expression may be up-regulated in those 
cells but down-regulated in the more numerous cell type, resulting in detection of no or opposite 
change in expression in the microarray measurement of the heterogeneous sample. 
Immunohistochemistry can address this issue by measuring the cell-type-specific protein 
expression. For example, studies in a wide range of breast tumors have shown that NRP1 and 
NRP2 are both expressed on almost all endothelial cells, but very rarely on breast tumor cells 
[108,109]. Conversely, PLXNB1 has been shown to be expressed on the surface of tumor cells, 
but less so on neighboring endothelial cells [110]. Thus, differences in expression of NRP1 and 
NRP2 measured by microarray can be assumed to be primarily due to endothelial cells, and 
differences in PLXNB1 due to tumor cells. Laser capture microdissection or other sorting 
methods could also resolve cell type differences by isolating specific cell types prior to analyzing 
gene expression. Methods such as these will be particularly useful in determining the relative 
amount of VEGF signaling taking place in tumor and endothelial cells.   
We have yet to determine whether the VEGF- and Semaphorin-based clusters found here 
are recapitulated in gene expression data for breast cancer cell lines. Extensive work has been 
done to characterize the subtypes found in these cell lines and the differential susceptibility of the 
cell lines to various therapeutics [111,112]. Many aspects of VEGF and semaphorin signaling 
depend on other cells in the tumor microenvironment, in particular endothelial cells and tumor 
stromal cells, and an analysis of cell lines could aid in determining which differentially expressed 
ligands in the present study arise due to tumor cells and which are due to stromal cells; as well as 
insight into whether observed receptor expression variation is due to tumor cells or tumor-
associated endothelial cells. 
We analyzed survival data in part to assess whether the VEGF- and Semaphorin-based 
clusters were associated with prognosis of breast cancer patients. The high correlation of VEGF- 
and Semaphorin-related gene expression with existing prognostic indicators such as TN status 
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confounds the analysis and makes it impossible to determine from this data why some patients 
have poorer prognoses. However, we used a multivariate Cox proportional hazards model and 
Kaplan-Meier plots to demonstrate that a subgroup of ER+ tumors with the pro-angiogenic PC4a 
signature had poorer prognosis. Thus, the pro-angiogenic PC4a signature may have a role in 
severity of the disease, independent of ER or TN status. To determine the actual significance of 
the VEGF- and Semaphorin-based groups found here, experimental models of breast tumors are 
needed. Tumor xenografts in immunocompromised mice could be used to measure the growth 
and invasion of tumors of the various subtypes. This type of experimental model provides the 
advantage of allowing for other processes that contribute to cancer progression other than tumor 
cell growth, including angiogenesis. Targeted VEGF inhibitors and inhibitors of VEGF-pathway 
receptors could be administered to show whether the VEGF-/Semaphorin-based signature found 
here is truly relevant in tumorigenesis.  
Computational models of VEGF and Semaphorin ligand-receptor interactions will be 
useful in unraveling the effects of the expression changes found here. The large number of 
proteins involved, combined with the complexity of their interactions, will make it necessary to 
use models to understand the overall effect of the expression patterns on signaling through VEGF 
receptors. Models of VEGF signaling [47,113,114] can be extended to include the Semaphorins 
found to be relevant in the current study. These models will enable prediction of patients expected 
to respond to existing therapies and can suggest effective therapeutic targets. 
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3 VEGF/Semaphorin Expression Subgroups Across Cancer 
Types 
3.1 Summary 
Therapies targeting angiogenesis are approved for use in treating multiple types of cancer, 
but the response rates to these drugs are typically relatively low. Biomarkers that are predictive of 
response are needed to so that responders can be identified while pursuing alternate therapies for 
resistant patients. We determined VEGF and Semaphorin patterns of expression in seven cancer 
types – breast adenocarcinoma, colon adenocarcinoma, glioblastoma, renal cell carcinoma, lung 
adenocarcinoma, serous ovarian cystadenocarcinoma, and prostate adenocarcinoma – using 
multivariate statistical methods. Clustering revealed VEGF/Sema subgroups in most types of 
cancer, some of which overlapped significantly with existing transcriptomic subtypes. Using 
principal component analysis, we found multivariate patterns of altered VEGF/Sema expression 
suggestive of pro-angiogenic activity in some subgroups. These VEGF/Sema patterns had 
prognostic significance in several cancer types, suggesting that these subgroups may be enriched 
with aggressive tumors in which anti-angiogenic therapies would be of clinical benefit. 
3.2 Methods 
3.2.1 Data sets 
 All gene expression data was obtained from the Cancer Genome Atlas (TCGA). Only 
data from primary tumors was used. The types of cancers included here were: breast 
adenocarcinoma (N=914); colon adenocarcinoma (N=192); glioblastoma (N=155); renal cell 
carcinoma (N=480); lung adenocarcinoma (N=488); serous ovarian cystadenocarcinoma (N=262); 
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and prostate adenocarcinoma (N=176). Here, we considered only the expression of the 39 genes 
encoding ligands and receptors in the VEGF and Semaphorin families.  
3.2.2 Transcriptomic subtypes 
Subtypes previously defined in TCGA studies are referred to here as “transcriptomic 
subtypes” because they were defined based on a global clustering analysis of gene expression. 
Most samples in the TCGA datasets had transcriptomic subtype information available. When 
subtype information was not available, we built a nearest shrunken centroid classifier using the 
pamr function in R using the expression of all of the genes. We chose the shrinkage threshold 
with 10-fold cross-validation. 
3.2.3 Statistical analyses 
 All methods used in this chapter were described previously: PCA (Chapter 2.2.5), 
consensus K-means cluster (Section 2.2.8), and Kaplan-Meier survival analysis (Chapter 2.2.7).  
3.3 Results 
3.3.1 VEGF/Sema-based clusters overlap with transcriptomic subtypes 
 We used consensus K-means clustering to group patients according to VEGF/Sema gene 
expression. We were able to find an optimal number of clusters in almost all cancer types; 
prostate adenocarcinoma was the one type where consistent partitioning of samples did not occur. 
We explore prostate cancer further in Chapter 4. For the other cancer types, we found five breast 
cancer clusters, five colon cancer clusters, four glioblastoma clusters, four renal cell carcinoma 
clusters, six lung cancer clusters, and five ovarian cancer clusters (labeled at the bottom of each 
heatmap in Figure 3-1).  
 In most cancer types, at least one VEGF/Sema cluster had significant overlap with a 
previously defined transcriptomic subtype. As noted in Chapter 2, the VEGF/Sema cluster with 
high VEGFA expression and low class 3 Semaphorin expression (labeled as Cluster 1 in Figure  
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Figure 3-1: VEGF/Sema clustering across cancers. 
K-means clustering revealed between four and six clusters in breast adenocarcinoma (A), colon 
adenocarcinoma (B), glioblastoma (C), renal cell carcinoma (D), lung adenocarcinoma (E), and 
ovarian cystadenocarcinoma (F). VEGF/Sema expression-based cluster numbers are shown at the 
bottom of each heatmap, with tick marks separating clusters. Of the 39 VEGF/Sema genes, only 
the 16 with the highest inter-cluster variance are shown. Colors corresponding to transcriptomic 
subtypes are shown along the top bar of each heatmap. 
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3-1A) was strongly associated with the basal-like subgroup, which also significantly overlaps 
with triple-negative tumors. We assessed the significance of cluster-subtype overlap using 
Fisher’s exact test. The top ten most significant pairs (Table 3-1) included pairs from all cancer 
types except renal cell carcinoma and prostate cancer. 
3.3.2 High VEGFA/low Sema3 pattern is unique to triple-negative breast cancer 
 The pattern of high VEGFA expression and low SEMA3B, SEMA3C, SEMA3D, and 
SEMA3F expression was observed in basal samples in this data set (Figure 3-2A). This was 
expected as this TCGA data was used in Section 2 as a validation data set. Surprisingly, this 
pattern of pro-angiogenic gene expression was not observed in any subtype in any other cancer 
types.  
A pro-angiogenic pattern involving up-regulation of VEGFC, KDR, and NRP1 was 
observed in several subtypes. This pattern was present in the MSI-CIMP subtype of colon cancer 
(Figure 3-2B) and partially present in the mesenchymal subtype of glioblastoma (Figure 3-2C; 
KDR was not up-regulated in this case). These three genes were also simultaneously down-
regulated in the luminal B subtype of breast cancer (PCA plot not shown, but pattern visible in 
VEGF/Sema cluster 2 in Figure 3-1A).   
Other patterns of VEGF/Sema expression associated with transcriptomic subtypes lacked 
pro-angiogenic signatures in the sense that they did not include traditional drivers of angiogenesis 
such as VEGFA and VEGFC. Nonetheless, some signatures indicated a potential role for 
angiogenesis: in the ovarian cancer proliferative subtype, PGF was up-regulated, along with 
SEMA6A and SEMA4F, two semaphorins with links to tumor progression [115,116]. 
3.3.3 A VEGF/Sema glioblastoma subtype improves prognostic classification 
 We performed Kaplan-Meier survival analysis using both the VEGF/Sema clusters and 
the previously-defined transcriptomic subtypes to determine whether the VEGF/Sema clusters 
improve our ability to separate patients on the basis of overall survival. In most cases, the  
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Figure 3-2: Multivariate patterns of VEGF/Sema expression in cancer subtypes. 
A-D, PCA of VEGF/Sema expression in breast (A), colon (B), brain (C), and ovarian (D) cancers 
revealed that some transcriptomic subtypes were easily distinguishable based only on expression 
of VEGF- and Sema-related genes. For each cancer type, the left panel shows the scores 
(projection of the samples onto the principal components), while the right panel shows the 
loadings (projection of genes onto the principal components). Dot colors in the scores plot 
correspond to transcriptomic subtypes as indicated. Gene names were displayed on the loadings 
plots if the loading magnitude exceeded a certain threshold. 
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Figure 3-3: VEGF/Sema clusters with prognostic significance. 
Whereas transcriptomic subtypes of glioblastoma were unable to differentiate patients on the 
basis of prognosis (A), VEGF/Sema cluster 1 of glioblastoma (B) did have significantly shorter 
time to death. The transcriptomic clusters of renal cell carcinoma had prognostic significance (C), 
but VEGF/Sema cluster 4 (D) was more effective in distinguishing a subset of patients with poor 
prognosis. 
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performances of the two groupings were similar: if the transcriptomic subtypes were capable of 
finding significant survival differences, the VEGF/Sema clusters were as well; on the other hand, 
if the transcriptomic subtypes did not perform well, the VEGF/Sema cluster also did not.  
One exception was VEGF/Sema cluster #1 of the glioblastoma data set, characterized by up-
regulation of VEGFC and NRP1. This cluster had significantly worse outcomes than any other 
cluster (Figure 3-3B, P=0.008). The transcriptomic subtypes were unable to separate patients into 
groups with different outcomes (Figure 3-3A, P=0.57). It should be noted that although 
VEGF/Sema cluster #1 was strongly associated with the mesenchymal subtype, it did not consist 
exclusively of mesenchymal tumors, nor were all of the mesenchymal subtype tumors in this 
cluster.  
Another cluster with prognostic significance was VEGF/Sema cluster #4 in the renal cell 
carcinoma dataset (Figure 3-3D). Although the transcriptomic subtypes did differ in prognoses 
(Figure 3-3C), the survival curve for VEGF/Sema cluster #4 was lower than any of the curves 
defined by the transcriptomic subtypes. This VEGF/Sema cluster was associated with high 
expression of PLXNB3 (Figure 3-1D), which can promote angiogenesis through interactions 
with its ligand SEMA5A [15]. 
3.4 Discussion 
The ability of K-means clustering to identify distinct groups based on VEGF/Sema 
expression in all cancer types (with the exception of prostate) suggests that alterations to VEGF 
signaling are common across cancer types. Furthermore, based on our analysis, these alterations 
are expected to be found only in subgroups within each cancer type. Thus, additional research is 
needed to elucidate the role that particular VEGF/Sema expression patterns have and how any 
pro-angiogenic alterations can be therapeutically reversed.  
The overlap of VEGF/Sema-based clusters with some subtypes derived from transcriptomic 
data suggests that existing subtypes may serve as useful biomarkers. Some evidence exists for the 
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performance of transcriptomic subtypes as anti-VEGF biomarkers. Bevacizumab given in the 
neoadjuvant setting was more effective in triple-negative breast cancers than in hormone 




4 Dysregulation of the VEGF and Semaphorin Ligand-
Receptor Families in Prostate Cancer Metastasis 
4.1 Summary 
The vascular endothelial growth factor (VEGF) family is central to cancer angiogenesis. 
However, targeting VEGF as an anti-cancer therapeutic approach has shown success for some 
tumor types but not others. Here we examine the expression of the expanded VEGF family in 
prostate cancer, including the Semaphorin (Sema) family members that compete with VEGFs for 
Neuropilin binding and can themselves have pro- or anti-angiogenic activity. First, we used 
multivariate statistical methods, including partial least squares and clustering, to examine 
VEGF/Sema gene expression variability in previously published prostate cancer microarray 
datasets. We show that unlike some cancers, such as kidney cancer, primary prostate cancer is 
characterized by both a down-regulation of the pro-angiogenic members of the VEGF family and 
a down-regulation of anti-angiogenic members of the Sema family. We found pro-
lymphangiogenic signatures, including the genes encoding VEGFC and VEGFD, associated with 
primary tumors that ultimately became aggressive. In contrast to primary prostate tumors, 
prostate cancer metastases showed increased expression of key pro-angiogenic VEGF family 
members and further repression of anti-angiogenic class III Sema family members. Given the lack 
of success of VEGF-targeting molecules so far in prostate cancer, this suggests that the reduction 
in anti-angiogenic Sema signaling may potentiate VEGF signaling and even promote resistance to 
VEGF-targeting therapies. Inhibition of the VEGF 'accelerator' may need to be accompanied by 
promotion of the Sema 'brake' to block cancer angiogenesis. To leverage our mechanistic 
understanding, and to link multigene expression changes to outcomes, we performed 
individualized computational simulations of competitive VEGF and Sema receptor binding across 
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many tumor samples. The simulations suggest that loss of Sema expression promotes 
angiogenesis by lowering plexin signaling, not by potentiating VEGF signaling via relaxation of 
competition. The model also predicts that targeting Neuropilins might be problematic due to 
reduction in anti-angiogenesis signaling of Plexins confounding the reduction in pro-angiogenesis 
signaling of VEGFRs. 
4.2 Methods 
A flowchart of the overall procedure of this study is shown in Figure 4-1. 
4.2.1 Data 
The datasets used in this study (Table 4-1), were obtained from the TCGA website 
(http://cancergenome.nih.gov/) or from the National Center for Biotechnology Information 
(NCBI) Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/). The 
majority of samples were from primary, untreated tumors, but some datasets also included normal 
prostate tissue samples and tumors that had metastasized from the prostate to various locations in 
the body. The data for these samples were included in the analysis, in separate groups distinct 
from the primary tumors. Outcome data (time until death) was not available, with the exception 
of some TCGA samples. The TCGA and GSE21034 datasets included biochemical recurrence 
(BCR) data, with times indicating the duration between sample collection and either BCR or 
BCR-free follow-up. 
4.2.2 Comparison of prostate tissue types 
To assess univariate differences in gene expression across prostate tissue types (normal 
tissue, primary tumors, and metastatic tumors), we performed Welch two-sample unpaired t-tests 
in R using the t.test function. P-values were subjected to multiple testing correction using the 
Benjamini-Hochberg procedure [117].  
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Figure 4-1: Flowchart of methods used in prostate cancer analysis. 
All three tissue types were used for PLS-DA of tissue-specific differences in VEGF/Sema 
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Table 4-1: Prostate cancer datasets.  
Dataset Platform Tissue Types Notes Reference 






































21 normal donors 
18 metastases 



















To compare prostate cancer tissue types (normal, primary tumor, metastasis), we used 
PLS-DA, which finds latent variables that are aligned with the direction of most co-variability 
between the gene expression data and the output class variable. We used the plsda function in the 
mixOmics package in R. The function results in a decomposition of the gene expression matrix X 
= TP + E, where T is the scores matrix, P is the loadings matrix, and E is a residuals matrix. The 
function also decomposes the output matrix Y = TQ + F, where Q is the Y-loadings matrix and F 
is a residuals matrix. A PLS weights matrix, W, is also returned for predicting the scores from the 
gene expression data, T = XW. Thus, if an output is unknown for a particular sample, the output 
can be predicted from the gene expression data using Y = XWQ'. 
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Training errors were determined by training a PLS-DA classifier using all samples, and 
then performing classification on the samples. The number of misclassified samples divided by 
the total number of samples was the training error. To estimate the generalization error of the 
PLS-DA classifiers, we used leave-one-out cross-validation (LOOCV). The generalization error 
was the number of misclassified samples divided by the total number of samples. The PLS-DA 
classification was performed n times, where n was the number of samples in the data matrix. At 
each iteration, one sample was held out and a classifier was trained on the data consisting of n-1 
samples. Then, the expression data for the held out sample was used to predict the class of the 
held out sample using Y = XWQ'. 
We used three types of plots to show differences in gene expression between tissue types 
(e.g. Figures 4-3A through 4-3D): density plots show differences in the shapes of the 
distributions, with the densities estimated using the R function density with default kernel 
bandwidth; box plots show the range of variation with statistics such as the median and quartiles; 
and spike plots showed the individual points to emphasize the range. 
4.2.3 Prognostic significance of PLS-DA biomarkers 
Data for time to follow-up or biochemical recurrence (BCR) was used to analyze survival 
of patients in distinct clinical or PLS-DA-derived groups. Log rank tests were used to determine 
differences in the Kaplan-Meier survival estimates between two classes, and Cox proportional 
hazard models were used to compare the effects of multiple continuous variables. We used the 
survfit and coxph functions in the survival package in R.  
4.2.4 Comparison of multiple tumor samples from single patient 
To assess the similarity of tumors from different metastatic sites within the same patient, 
we scaled the metastatic tumor data in GSE38241 by subtracting the mean expression of each 
gene in the normal samples. Then we grouped the metastasis samples with K-means clustering 
using the kmeans function in R. The kmeans function was executed 20 times to avoid local 
 57 
minima; the cluster membership that gave the lowest within-cluster sum of squares was the one 
that the kmeans function returned. The number of clusters to be found is pre-specified. To choose 
the appropriate number of clusters, consensus clustering is performed. This entails clustering 100 
times on random subsets of the data. This process results in a consensus matrix, which describes 
the co-clustering frequency of any two samples across consensus runs. Ideally, all values in this 
matrix will either be 1 (always in the same cluster) or 0 (never in the same cluster). The 
appropriate number of clusters is chosen as the value of K that has the most consensus matrix 
values near 1 and 0. 
4.2.5 Other gene expression-based biomarkers 
We also analyzed other biomarkers using the PLS-DA methodology just described. Some 
were based on commercially available prostate cancer diagnostics tests, such as OncotypeDx, 
Decipher, and Prolaris. In these cases, we used the genes in the diagnostic test in PLS-DA 
models, rather than the proprietary algorithms.  
4.2.6 Simulation of VEGF/Sema binding 
To assess the effects of patient tumor gene expression on VEGF and semaphorin 
signaling, we built a model of ligand-receptor binding that encompassed all VEGF proteins for 
which gene expression data was available, all class 3 semaphorins, and all receptors known to 
bind these ligands. We expanded our validated kinetic model comprising interactions between 
two isoforms of VEGF-A (VEGF121 and VEGF165), VEGFR-1, VEGFR-2, Neuropilin-1, 
Neuropilin-2 and soluble VEGFR-1 (sVEGFR-1) [47,113,123,124] to include the additional 
encoded VEGF and Sema family proteins. The scope of some of these modeling studies has 
included the entire body so that drug pharmacokinetics could be studied [47,123]; here, we limit 
the scope of the model to a single compartment representing a tumor and the surrounding 
microvasculature, justified by our results showing the small size of interaction effects between the 
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tumor compartment and other compartments. We use this model to study only the effects of gene 
expression variation.  
Geometry. We assumed that the tumor volume consisted only of tumor cells, endothelial cells, 
and the interstitial space between these cells. The interstitial space available to ligands and the 
surface area to volume ratios of the two cell types were as previously described ([113] and Table 
4-2).  
Table 4-2: Geometric parameters. 
Parameter Value Units Ref. 
Microvessel surface area to volume 
ratio 
105 cm2/cm3 tissue [113] 
Tumor surface area to volume ratio 1534 cm2/cm3 tissue [113] 
Endothelial cell surface area 1!10-5 cm2 [113] 
Tumor cell surface area 1!10-5 cm2 [113] 
Interstitial volume fraction 0.58 cm3/cm3 tissue [113] 
 
Kinetics. Rate constants for the association and dissociation reactions between the two major 
VEGF-A isoforms, VEGF-A165 and VEGF-A121, and VEGFR-1, VEGFR-2, and Neuropilin-1 
were as previously described ([124], Tables 4-3 and 4-4). The interaction of VEGF-A165 with 
Neuropilin-2 and coupling between Neuropilin-2 and VEGFR-1/VEGFR-2 were as described in 
[47] (Tables 4-3 and 4-4). Interactions of sVEGFR-1 with the two VEGF-A isoforms and 
Neuropilin-1 were as described in [123] (Table 4-3).  
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VEGFA165 + VEGFR1 " VEGFA165-R1 3!107 1!10-3 33 [113] 
VEGFA165 + VEGFR2 " VEGFA165-R2 1!107 1!10-3 100 [113] 
VEGFA165 + NRP1 " VEGFA165-NRP1 3.125!106 1!10-3 320 [113] 
VEGFA165 + NRP2 " VEGFA165-NRP2 1!106 1!10-3 320 [113] 
VEGFA121 + VEGFR1 " VEGFA121-R1 3!107 1!10-3 33 [113] 
VEGFA121 + VEGFR2 " VEGFA121-R2 1!107 1!10-3 100 [113] 
VEGFA121 + R1-NRP1 " VEGFA121-R1-
NRP1 
3!107 1!10-3 33 [113] 
VEGFA121 + R1-NRP2 " VEGFA121-R1-
NRP2 
3!107 1!10-3 33 [113] 
PlGF1 + VEGFR1 " PlGF1-R1 4.3!106 1!10-3 230 [125] 
PlGF1 + R1-NRP1 " PlGF1-R1-NRP1 4.3!106 1!10-3 230 b 
PlGF1 + R1-NRP2 " PlGF1-R1-NRP2 4.3!106 1!10-3 230 b 
PlGF2 + VEGFR1 " PlGF2-R1 4.3!106 1!10-3 230 [125] 
PlGF2 + NRP1 " PlGF2-NRP1 3.125!106 1!10-3 320 a 
PlGF2 + NRP2 " PlGF2-NRP2 3.125!106 1!10-3 320 a 
VEGFB167 + VEGFR1 " VEGFB167-R1 4.3!106 1!10-3 230 b 
VEGFB186 + VEGFR1 " VEGFB186-R1 4.3!106 1!10-3 230 b 
VEGFB167 + NRP1 " VEGFB167-NRP1 3.125!106 1!10-3 320 a 
VEGFB186 + NRP1 " VEGFB186-NRP1 3.125!106 1!10-3 320 a 
VEGFC + VEGFR2 " VEGFC-R2 2.4!106 1!10-3 410 [126] 
VEGFC + VEGFR3 " VEGFC-R3 7.4!106 1!10-3 135 [126] 
VEGFC + NRP2 " VEGFC-NRP2 3.125!106 1!10-3 320 a 
VEGFD + VEGFR2 " VEGFD-R2 2.4!106 1!10-3 410 c 
VEGFD + VEGFR3 " VEGFD-R3 7.4!106 1!10-3 135 c 
VEGFD + NRP2 " VEGFD-NRP2 3.125!106 1!10-3 320 a 
Sema3A + NRP1 " Sema3A-NRP1 1!106 1!10-3 1000 [127] 
Sema3B + NRP1 " Sema3B-NRP1 1!106 1!10-3 1000 d 
Sema3B + NRP2 " Sema3B-NRP2 1!106 1!10-3 1000 d 
Sema3C + NRP1 " Sema3C-NRP1 7.7!105 1!10-3 1300 [127] 
Sema3C + NRP2 " Sema3C-NRP2 5.9!105 1!10-3 1700 [127] 
Sema3D + NRP1 " Sema3D-NRP1 1!106 1!10-3 1000 d 
Sema3D + NRP2 " Sema3D-NRP2 1!106 1!10-3 1000 d 
Sema3E + PLXND1 " Sema3E-PD1 7.7!106 1!10-3 130 [86] 
Sema3F + NRP2 " Sema3F-NRP2 6.7!105 1!10-3 1500 [127] 
Sema3G + NRP2 " Sema3G-NRP2 1!106 1!10-3 1000 d 
Sema3A + PlxnAi-NRP1 " Sema3A-NRP1-
PAi 
6.3!106 1!10-3 190 [127]e 
Sema3A + PlxnD1-NRP1 " Sema3A-NRP1-
PD1 
1!106 1!10-3 1000 d 
Table 4-3 continued on next page 
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Sema3B + PlxnAi-NRP1 " Sema3B-NRP1-
PAi 
1!106 1!10-3 1000 d 
Sema3B + PlxnAi-NRP2 " Sema3B-NRP2-
PAi 
1!106 1!10-3 1000 d 
Sema3C + PlxnAi-NRP1 " Sema3C-NRP1-
PAi 
8.5!105 1!10-3 1200 [127] 
e 
Sema3C + PlxnAi-NRP2 " Sema3C-NRP2-
PAi 
3.9!105 1!10-3 2300 [127] 
e 
Sema3C + PlxnD1-NRP1 " Sema3C-NRP1-
PD1 
1!106 1!10-3 1000 d 
Sema3C + PlxnD1-NRP2 " Sema3C-NRP2-
PD1 
1!106 1!10-3 1000 d 
Sema3D + PlxnAi-NRP1 " Sema3D-NRP1-
PAi 
1!106 1!10-3 1000 d 
Sema3D + PlxnAi-NRP2 " Sema3D-NRP2-
PAi 
1!106 1!10-3 1000 d 
Sema3F + PlxnAi-NRP2 " Sema3F-NRP2-
PAi 
2.7!106 1!10-3 440 [127] 
e 
Sema3G + PlxnAi-NRP2 " Sema3G-NRP2-
PAi 
1!106 1!10-3 1000 d 
VEGF165 + sVEGFR1 " VEGF165-sR1 3!107 1!10-3 33 [123] 
VEGF121 + sVEGFR1 " VEGF121-sR1 3!107 1!10-3 33 [123] 
PlGF1 + sVEGFR1 " PlGF1-sR1 4.3!106 1!10-3 230 b 
PlGF2 + sVEGFR1 " PlGF2-sR1 4.3!106 1!10-3 230 b 
VEGFB167 + sVEGFR1 " VEGFB167-sR1 4.3!106 1!10-3 230 b 
VEGFB186 + sVEGFR1 " VEGFB186-sR1 4.3!106 1!10-3 230 b 
sVEGFR1 + NRP1 " sR1-NRP1 5.56!106 1!10-2 1800 [123] 
sVEGFR1 + NRP2 " sR1-NRP2 5.56!106 1!10-2 1800 f 
VEGF121 + sR1-NRP1 " VEGF121-sR1-NRP1 3!107 1!10-3 33 [123] 
PlGF1 + sR1-NRP1 " PlGF1-sR1-NRP1 4.3!106 1!10-3 230 b 
VEGF121 + sR1-NRP2 " VEGF121-sR1-NRP2 3!107 1!10-3 33 [123] 
PlGF1 + sR1-NRP2 " PlGF1-sR1-NRP2 4.3!106 1!10-3 230 b 
VEGF121-sR1 + NRP1 " VEGF121-sR1-NRP1 5.56!106 1!10-2 1800 [123] 
PlGF1-sR1 + NRP1 " PlGF1-sR1-NRP1 5.56!106 1!10-2 1800 f 
VEGF121-sR1 + NRP2 " VEGF121-sR1-NRP2 5.56!106 1!10-2 1800 f 
PlGF1-sR1 + NRP2 " PlGF1-sR1-NRP2 5.56!106 1!10-2 1800 f 
VEGF165 + ECM " VEGF165-ECM 4.2!105 1!10-2 23800 [113] 
PlGF2 + ECM " PlGF2-ECM 1!107 1!10-2 1000 [128]g 
sVEGFR1 + ECM " sR1-ECM 4.2!105 1!10-2 23800 [123] 
a No Kd data available; assumed same as Kd for VEGFA165-NRP1 
b No Kd data available; assumed same as Kd for PlGF-VEGFR1 
c No Kd data available; assumed same as Kds for VEGFC binding to VEGFR-2 and VEGFR-3 
d No Kd data available; assumed Kd of 1 nM (the middle of the range of available Sema3 Kds) 
e The Kd listed is an overall Kd for the cells expressing both NRP1 and PlxnA1 
f Assumed to be the same as sVEGFR1 binding to NRP1 
g In [128], PlGF2 on average has 26-fold lower affinity for ECM proteins that VEGFA165 
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Table 4-4: Rate constants of receptor coupling reactions. 





VEGFR1 + NRP1 " R1-NRP1 1!1014 1!10-2 [113] 
VEGFR1 + NRP2 " R1-NRP2 1!1014 1!10-2 [47] 
PlxnAi + NRPj " PAi-NRPj 1!1014 1!10-2 a 
PlxnD1 + NRPj " PD1-NRPj 1!1014 1!10-2 a 
VEGF121-R1 + NRP1 " VEGF121-R1-NRP1 1!1014 1!10-2 [113] 
PlGF1-R1 + NRP1 " PlGF1-R1-NRP1 1!1014 1!10-2 [113] 
VEGF165-R2 + NRP1 " VEGF165-R2-NRP1 3.1!1013 1!10-3 [113] 
VEGF165-NRP1 + VEGFR2 " VEGF165-R2-
NRP1 
1!1014 1!10-3 [113] 
VEGF165-R2 + NRP2 " VEGF165-R2-NRP2 3.1!1013 1!10-3 [47] 
VEGF165-NRP2 + VEGFR2 " VEGF165-R2-
NRP2 
1!1014 1!10-3 [47] 
VEGFC-R2 + NRP2 " VEGFC-R2-NRP2 3.1!1013 1!10-3 [47] 
VEGFC-NRP2 + VEGFR2 " VEGFC-R2-
NRP2 
1!1014 1!10-3 [47] 
VEGFC-R3 + NRP2 " VEGFC-R3-NRP2 3.1!1013 1!10-3 [47] 
VEGFC-NRP2 + VEGFR3 " VEGFC-R3-
NRP2 
1!1014 1!10-3 [47] 
VEGFD-R2 + NRP2 " VEGFD-R2-NRP2 3.1!1013 1!10-3 [47] 
VEGFD-NRP2 + VEGFR2 " VEGFD-R2-
NRP2 
1!1014 1!10-3 [47] 
VEGFD-R3 + NRP2 " VEGFD-R3-NRP2 3.1!1013 1!10-3 [47] 
VEGFD-NRP2 + VEGFR3 " VEGFD-R3-
NRP2 
1!1014 1!10-3 [47] 
Sema3A-NRP1 + PlxnAi " Sema3A-NRP1-
PAi 
1!1014 1!10-2 a 
Sema3A-NRP1 + PlxnD1 " Sema3A-NRP1-
PD1 
1!1014 1!10-2 a 
Sema3B-NRP1 + PlxnAi " Sema3B-NRP1-PAi 1!1014 1!10-2 a 
Sema3B-NRP2 + PlxnAi " Sema3B-NRP2-PAi 1!1014 1!10-2 a 
Sema3C-NRP1 + PlxnAi " Sema3C-NRP1-PAi 1!1014 1!10-2 a 
Sema3C-NRP1 + PlxnD1 " Sema3C-NRP1-
PD1 
1!1014 1!10-2 a 
Sema3C-NRP2 + PlxnAi " Sema3C-NRP2-PAi 1!1014 1!10-2 a 
Sema3C-NRP2 + PlxnD1 " Sema3C-NRP2-
PD1 
1!1014 1!10-2 a 
Sema3D-NRP1 + PlxnAi " Sema3D-NRP1-
PAi 
1!1014 1!10-2 a 
Sema3D-NRP2 + PlxnAi " Sema3D-NRP2-
PAi 
1!1014 1!10-2 a 
Sema3F-NRP2 + PlxnAi " Sema3F-NRP2-PAi 1!1014 1!10-2 a 
Table 4-4 continued on next page 
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Sema3G-NRP2 + PlxnAi " Sema3G-NRP2-
PAi 
1!1014 1!10-2 a 
The letter i refers to the four class A Plexins 
The letter j refers to the two Neuropilins 
a Assumed diffusion-limited kinetics when no experimental data was available 
 










VEGF-A165 45 100 2.22 [9,10,11,13] 
VEGF-A121 45 100 2.22 [9,10,11,13] 
sVEGFR1 110 100 0.91 [129,130,131] 
PlGF-1 56 10 0.18 [125,132,133] 
PlGF-2 64 10 0.16 [125,132,133] 
VEGF-B167 42 100 2.4 [134] 
VEGF-B186 60 100 1.7 [134] 
VEGF-C 26 1000 38 [132] 
VEGF-D 26 100 3.8 [135] 
Sema3A 86 10000 116 a 
Sema3B 81 10000 123 b 
Sema3C 83 10000 120 b 
Sema3D 86 10000 116 b 
Sema3E 86 10000 116 b 
Sema3F 86 10000 116 b 
Sema3G 84 10000 119 b 
a No cancer-specific measurements available, but [136] has healthy measurements 
b Assumed the same order of magnitude as Sema3A 
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Table 4-6: Model parameters. 
Parameter Value Units Referenc
e 
VEGF-A165 secretion rate a 0.027 #/cell/sec b 
VEGF-A121 secretion rate a 0.013 #/cell/sec b 
sVEGFR1 secretion rate a 0.059 #/cell/sec b 
PlGF-1 secretion rate a 0.00026 #/cell/sec b 
PlGF-2 secretion rate a 0.00011 #/cell/sec b 
VEGF-B167 secretion rate a 0.017 #/cell/sec b 
VEGF-B186 secretion rate a 0.029 #/cell/sec b 
VEGF-C secretion rate a 0.96 #/cell/sec b 
VEGF-D secretion rate a 0.096 #/cell/sec b 
Sema3A secretion rate a 0.97 #/cell/sec b 
Sema3B secretion rate a 1.50 #/cell/sec b 
Sema3C secretion rate a 1.02 #/cell/sec b 
Sema3D secretion rate a 1.41 #/cell/sec b 
Sema3E secretion rate a 0.0046 #/cell/sec b 
Sema3F secretion rate a 0.52 #/cell/sec b 
Sema3G secretion rate a 0.69 #/cell/sec b 
Endothelial VEGFR1 3,750 #/cell [47] 
Endothelial VEGFR2 300 #/cell [47] 
Endothelial VEGFR3 1,000 #/cell c 
Endothelial NRP1 20,000 #/cell [47] 
Endothelial NRP2 20,000 #/cell [47] 
Endothelial PLXNA1 1,000 #/cell c 
Endothelial PLXNA2 1,000 #/cell c 
Endothelial PLXNA3 1,000 #/cell c 
Endothelial PLXNA4 1,000 #/cell c 
Endothelial PLXND1 1,000 #/cell c 
Tumor VEGFR1 a 1,100 #/cell [47] 
Tumor VEGFR2 a 550 #/cell [47] 
Tumor VEGFR3 a 1,000 #/cell c 
Tumor NRP1 a 39,500 #/cell [47] 
Tumor NRP2 a 39,500 #/cell [47] 
Tumor PLXNA1a 1,000 #/cell c 
Tumor PLXNA2a 1,000 #/cell c 
Tumor PLXNA3a 1,000 #/cell c 
Tumor PLXNA4a 1,000 #/cell c 
Tumor PLXND1a 1,000 #/cell c 
ECM concentration 0.75 µM [113] 
Receptor internalization rate 2.8!10-4 sec-1 [113] 
a These parameters vary based on expression of the corresponding genes. 
b These parameters were tuned to yield the target concentrations in Table S11. 
C No experimental data for Plexin cell surface densities are available, therefore 1,000 was 
chosen as it falls in the middle of the range of receptor densities. 
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For reactions whose rate constants were not directly known, we assumed a koff of 1x10-3 
sec-1 (consistent with measured off rates for this family) and calculated kon as koff/Kd, where Kd is 
the measured dissociation constant obtained from the literature. Dissociation constants for the 
interactions of PlGF-1 and PlGF-2 with VEGFR-1 were available [125], but no data was 
available for the binding of PlGF-2 to Neuropilin-1, thus it was estimated to be the same as for 
the binding of VEGF-A165 to Neuropilin-1. Dissociation constants were not available for the two 
isoforms of VEGF-B, VEGF-B167 and VEGF-B186, for their receptors VEGFR-1 and Neuropilin-
1. We used the same rate constants for these two reactions as PlGF-2. Dissociation constants were 
available for the binding of VEGF-C to VEGFR-2 and VEGFR-3 [126], but not for the binding of 
VEGF-C to Neuropilin-2. In this case, we assumed the same kinetics as the binding of VEGF-
A165 to Neuropilin-1. No dissociation constants were available for the binding of VEGF-D to its 
receptors, VEGFR-2, VEGFR-3, and Neuropilin-2, therefore we used the same rate constants as 
VEGF-C. 
For class 3 Semaphorin binding to Neuropilins and Neuropilin/Plexin complexes, 
dissociation constant data was only available for the binding of Sema3A and Sema3C to 
Neuropilin-1 and Neuropilin-1/Plexin-A1 complexes, and for the binding of Sema3C and Sema3F 
to Neuropilin-2 and Neuropilin-2/Plexin-A1 complexes ([127] and Table 4-3). The on rate 
constants kon for the binding of these Semaphorins to their respective Neuropilins could be 
estimated directly from the dissociation constants, but the values of kon for binding of 
Semaphorins to Neuropilin/Plexin complexes had to be determined from simulations due to the 
presence of both Neuropilin and Neuropilin/Plexin complexes. We assumed that the kinetics of 
coupling between the Neuropilin and Plexin receptors occurred with identical rates constants to 
those for VEGFR1 and Neuropilin-1 coupling (Table 4-4). Data was also available for the 
binding of Sema3E to its receptor Pleixn-D1 ([86] and Table 4-3). 
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Receptor densities. As the amount of receptors on the surface of cells in vivo is difficult to 
measure, we use quantitative flow cytometry data of cultured cell lines where available. The 
densities of VEGFR-1, VEGFR-2, and NRP-1 have previously been measured in this way and 
used in computational models ([47] and Table 4-6). We assumed NRP-2 densities were similar to 
NRP-1 as in [47]. To our knowledge, VEGFR-3 and Plexin levels have not been measured on 
endothelial or tumor cells; therefore, we set the density of each of these receptors to 1,000, which 
falls in the middle of the range of cell surface densities in our model. 
Ligand secretion rates. We adjusted ligand secretion rates so that the steady-state concentrations 
of free ligands matched pre-determined target concentrations. The target concentrations were 
derived from published measurements of plasma concentrations in cancer patients. Actual 
interstitial ligand concentrations would likely be higher than plasma concentrations, but published 
data of interstitial concentrations are rare due to the difficulty in obtaining these measurements. 
Data for plasma concentrations of VEGF ligands were widely available due to studies testing 
their performance as pharmacodynamic markers of VEGF-targeting drugs (Table 4-5). To our 
knowledge, only one study has been published with data for plasma Semaphorin concentrations, 
which found a plasma Sema3A concentration of 74.41 ng/mL in healthy patients [136]. Here, we 
used this order of magnitude (104 pg/mL) for each of the seven class 3 Semaphorins (Table 4-5). 
Variation due to gene expression. Gene expression data was used to vary the protein production 
rates in tumor cells only. The log2-transformed gene expression data was first median-centered 
and then added to the log2-transformed nominal production rates found in the previous section. 
The actual production rate was then found by exponentiation with base 2. Thus the median gene 
expression corresponds to the nominal secretion rate found in the previous section. For VEGFA, 
PGF, VEGFB, and FLT1, two isoforms were represented in the model for each gene. We used 
TCGA data to determine average isoform fractions of total gene expression (Figure 4-2). 
Isoforms from identical genes were typically highly correlated.  
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Figure 4-2: Isoform ratios of genes with alternative splicing. 
Four genes known to have multiple isoforms due to alternative transcript splicing were analyzed 
in the TCGA RNA-Seq dataset. Linear regression models showed a high degree of correlation 
between pairs of isoforms originating from the same gene. From the linear models, we calculated 
the relative fraction of total gene expression accounted for by each isoform (bottom right of each 
plot). These values were used to determine isoform secretion rates in the mathematical model of 
tumor VEGF/Semaphorin receptor binding. 
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The system of coupled nonlinear differential equations describing the amounts of each 
molecule/complex was solved numerically in Fortran using the fifth-order Runge-Kutta method 
with adaptive step-size control. 
4.3 Results 
4.3.1 Primary prostate tumor VEGF/Sema alterations 
To examine why prostate cancer is less susceptible to VEGF inhibition, we first 
compared gene expression between primary prostate tumors and a cancer type that typically does 
respond to VEGF inhibitors, renal cell carcinoma [137]. Using the TCGA RNA-Seq dataset, we 
found that while two key pro-angiogenic ligands, VEGFA and PGF, were up-regulated in renal 
cell carcinoma, they were down-regulated in primary prostate adenocarcinoma (Figure 4-3A 
through 4-3D). This could indicate a lack of VEGF signaling for VEGF inhibitors to target, 
making attempts at targeting the VEGF pathway in prostate cancer futile. This pattern was 
observed for several other VEGF ligands and receptors: these genes were down-regulated or 
unchanged in prostate cancer whereas they were up-regulated in renal cell carcinoma (Figure 4-
3E for prostate cancer; renal cell carcinoma not shown). However, the up- or down-regulation of 
VEGF ligands and receptors in cancer types may not fully explain the response to VEGF 
inhibitors in prostate cancer. Subsets of tumors may have pro-angiogenic gene expression despite 
the anti-angiogenic pattern in the tumors as an overall group. Additionally, other pathways that 
interact with the VEGF pathway may affect signaling. 
We considered an additional set of genes that have been demonstrated to affect VEGF 
signaling: the semaphorins and their plexin receptors, bringing the total number of VEGF/Sema-
related genes under consideration to 39.  We expanded our comparison of normal prostate tissue 
and primary prostate tumors to include multiple microarray datasets in addition to the TCGA 
dataset. For primary tumor versus normal tissue comparisons, we measured differences in gene 
expression using a two-tailed t-test with multiple testing correction using the Benjamini- 
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Figure 4-3: Down-regulation of pro- and anti-angiogenic ligands in primary prostate 
tumors. 
A-B: VEGFA (A) and PGF (B) are expressed at lower levels in prostate tumors than in normal 
prostate tissue in the TCGA dataset, as shown by the density plots (top), box plots (middle), and 
spike plots (bottom). C-D: This contrasts with the TCGA renal cell carcinoma (kidney) dataset, 
where VEGFA (C) and PGF (D) are heavily up-regulated in tumors. E, VEGFA down-regulation 
in primary prostate cancer is observed across TCGA and microarray datasets, as is consistent 
down-regulation of class 3 semaphorins. The number in the boxes indicates the two-tailed t-test 
p-value after multiple testing correction with the Benjamini-Hochberg procedure. Only 
comparisons with corrected p-values less than 0.05 are displayed. The colors of the boxes indicate 
the magnitude of the t-statistic. The blue boxes to the right of the rows indicate that a gene is 
significantly down-regulated in two or more datasets with no significant differences in other 
datasets.  
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Hochberg procedure. We found that in addition to VEGF ligands, many semaphorins were also 
down-regulated in prostate cancer (Figure 4-3E). In particular, class 3 semaphorins, which have 
potential anti-angiogenic effects due to their ability to compete with VEGF for neuropilin 
binding, were down-regulated. Not all gene expression changes were consistent across all 
datasets; ones that were significant (defined as q-value less than 0.05) in two or more datasets 
were marked with blue or red boxes to the right. The subset of genes consistently down-regulated 
in primary tumors included three out of five VEGF ligands (VEGFA, VEGFB, and VEGFC) and 
five out of seven class 3 semaphorins (SEMA3A, SEMA3B, SEMA3C, SEMA3D, and SEMA3E). 
These results made the overall impact on angiogenesis unclear as both pro-angiogenic VEGF 
signals and anti-angiogenic semaphorin signals were reduced in primary tumors. 
4.3.2 A pro-lymphangiogenic gene expression signature is associated with aggressive 
primary tumors 
To assess whether some subsets of primary prostate tumors may have differing potential 
benefits from VEGF signaling inhibitors, we used partial least squares discriminant analysis 
(PLS-DA), a multivariate algorithm that allowed us to simultaneously consider both the pattern of 
VEGF/Sema gene expression and effects on an output variable. As an output, we used a binary 
variable indicating whether biochemical recurrence (BCR) eventually occurred. Data for 
BCR/follow-up times were available in the TCGA and GSE21034 datasets, with 10 and 27 BCR 
events, respectively. Since BCR-negative samples with short follow-up times may eventually 
undergo recurrence, we used only the 10 and 27 BCR-negative samples with the longest follow-
up times in the TCGA and GSE21034 datasets, respectively. These groups of indolent samples 
had follow-up times greater than 3.3 years in the TCGA dataset and greater than 5.2 years in the 
GSE21034 dataset. The TCGA PLS-DA model was effective in differentiating aggressive and 
indolent tumors, with a 95% training accuracy (Figure 4-4A). The GSE21034 PLS-DA model, on 
the other hand, was less effective with only a 68.5% training accuracy (Figure 4-4B). This  
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Figure 4-4: VEGF/Sema expression signatures predicting biochemical recurrence (BCR). 
A-B: PLS-DA scores/loadings plots for the TCGA (A) and GSE21034 (B) datasets. The training 
accuracies and the discriminant line separating the two classes are displayed C-D: Survival 
curves show prognostic significance of VEGF/Sema signatures in the TCGA (C) and GSE21034 
(D) datasets. The p-values are from log rank tests of the Kaplan-Meier survival estimators for 
each group. 
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discrepancy in performance between TCGA and GSE21034 datasets was seen for other 
biomarkers meant to distinguish aggressive from indolent tumors (data not shown). Notably, the 
VEGF/Sema PLS-DA model (and PLS-DA models based on the genes from other biomarkers) 
lost some of its predictive ability when correcting for Gleason score, but still was significantly 
prognostic (Figure 4-5). ROC curves from leave-one-out cross-validation barely deviated from a 
45-degree line (data not shown), indicating that these models would likely be ineffective in 
distinguishing aggressive and indolent tumors in other datasets. Nonetheless, the PLS-DA models 
provided gene expression signatures with potential prognostic significance: when the PLS 
discriminant scores were used as predictive variables in Kaplan-Meier survival analysis, 
aggressive and indolent tumors had significantly different outcomes (Figures 4-4C, 4-4D). 
The PLS-DA models also yielded information regarding patterns of VEGF/Sema 
expression associated with aggressive prostate tumors. The gene-specific loadings vectors 
(arrows in Figures 4-4A, 4-4B) showed that association of VEGF/Sema genes with 
aggressiveness was different between the two datasets. For the TCGA dataset, aggressive tumors 
were associated with high expression of FIGF (VEGFD), NRP2, PLXNA1, PLXNB1, PLXNB3, 
and SEMA5B and low expression of PLXNB2 and SEMA4D. The first two of these genes, FIGF 
(VEGFD) and NRP2, mediate pro-lymphangiogenesis signals. The process of lymphangiogenesis 
may provide tumors with a route by which to escape their tissue of origin into the bloodstream 
[138]. In the GSE21034 model, high expression of VEGFC, KDR, and NRP1 and low expression 
of VEGFA and SEMA4B were associated with aggressive tumors. Although this signature was 
different than the one found in the TCGA dataset, the high expression of VEGFC also suggested a 
potential for lymphangiogenic activity in aggressive primary tumors. 
4.3.3 Metastatic prostate tumors are associated with a pro-angiogenic signature 
While primary tumors are often treated with surgery and radiation, targeted therapeutics 
such as VEGF inhibitors are used more often in metastatic disease. Therefore, we next considered  
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Figure 4-5: Cox proportional hazards modeling of the association between PLS-DA 
biomarkers and biochemical recurrence (BCR).  
This figure expands upon Figure 4-4. A: Hazard ratios for the four biomarkers in all primary 
tumors of the GSE21034 dataset (n=131). Both univariate and Gleason score-corrected models 
are displayed. B: Univariate models of primary tumors with Gleason scores equal to 6 or 7 with a 
primary score of 3 (n=94). The four biomarkers and the VEGF/Sema PLS-DA predictor are 
shown. 
 73 
VEGF/Sema gene expression in metastatic tumors. In contrast to the reduced expression of VEGF 
ligands in primary tumors, metastatic tumors tended to have higher expression of the major pro-
angiogenic ligand, VEGFA (Figures 4-6A, 4-6B). This ligand was up-regulated in metastases 
relative to primary tumors and normal tumors in the GSE6919, GSE35988, and GSE38241 
datasets, but was actually down-regulated in GSE21034 and GSE32269. Notably, metastatic 
samples in the three datasets with up-regulated VEGFA were all obtained from warm autopsy 
programs where samples were processed rapidly upon the death of the patient. Metastatic samples 
in GSE32269 were from bone marrow biopsies of live patients, and no details were given 
regarding how metastatic samples were obtained in the GSE21034 dataset. The class 3 
semaphorins were down-regulated in metastases relative to normal prostate tissue (Figure 4-6B), 
suggesting that the loss of semaphorin expression in primary prostate tumors was maintained 
upon metastasis. SEMA3C was further down-regulated relative to primary tumors as well. Other 
expression alterations recurrent across datasets included up-regulation of NRP1, PLXNA1, and 
PLXNA3 relative to both normal tissue and primary tumors. These three genes participate in class 
3 semaphorin signaling, while only NRP1 participates in VEGF signaling. KDR and NRP2 were 
recurrently down-regulated in metastases relative to normal tissue but not relative to primary 
tumors. 
 We used PLS-DA to show that the VEGF/Sema gene expression alterations present in 
metastatic prostate tumors differed significantly from both normal tissue and primary tumors. 
PLS-DA models comparing metastases with primary tumors in the GSE35988 dataset and with 
normal tissue in the GSE38241 dataset led to large separation between the PLS scores of the two 
classes (Figures 4-6C, 4-6D). The leave-one-out cross-validation accuracy was 100% for both of 
these comparisons.  
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Figure 4-6: Pro-angiogenic VEGF/Sema gene expression in prostate cancer metastasis. 
A-B: A greater number of VEGF/Sema genes have recurrent expression alterations when 
comparing metastases to normal samples (B) than to primary tumor samples (A). The p-values 
are displayed according to the same criteria as in Fig.1, and red and blue boxes on the right hand 
sides of panels A and B indicate recurrent up- and down-regulation, respectively. C-D: PLS-DA 
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scores plots show separation of metastases and primary tumors in GSE35988 (C) and of 
metastases and normal tissues in GSE38241 (D). Each dot represents a sample with colors as 
indicated. Arrows correspond to gene loadings in the PLS-DA models, with the names of the 
genes displayed in the vicinity of the arrowhead. Only the genes with the largest magnitude 
loadings vectors are displayed. Accuracy refers to the accuracy of the LOOCV predictions; AUC 
refers to the area under the curve of the LOOCV ROC curve. In both cases, values of 1 indicate 
perfect prediction.  
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4.3.4 VEGF/Sema alterations are consistent across multiple metastases within individual 
patients 
The metastasis samples in the GSE38241 dataset included three to four metastases per 
patient from five different patients, providing the opportunity to analyze VEGF/Sema gene 
expression in both inter- and intra-patient contexts. We observed a high degree of consistency 
between metastases from the same patient, with VEGFA consistently up-regulated and several 
class 3 semaphorins, KDR, and NRP2 consistently down-regulated (Figure 4-7A). Some genes 
that were not significantly altered when comparing all metastases to normal samples did show 
patient-specific alterations: VEGFC and SEMA6A were up-regulated in some metastases and 
down-regulated in others. SEMA6A was consistent within patients, while VEGFC was not. 
 To assess the overall consistency of metastases from individual patients, we performed 
consensus K-means clustering of the metastatic samples and compared the clusters to the patients 
of origin. Repeating the clustering on random subsets of the data yielded a consensus matrix with 
clear separations of the groups when the number of clusters was five (Figures 4-7B, 4-7C). This 
did not perfectly separate the patients, but there was a significant association between clusters and 
patients (!2 test P=0.001). We also found that if we expanded our set of VEGF/Sema genes to 
include other ligands and receptors important in angiogenesis, we obtained consensus K-means 
clusters that resulted in perfect separation of the patients into clusters (Figures 4-7D, 4-7E). This 
supports the hypothesis that, although signaling pathways that contribute to angiogenesis may 
vary from patient to patient, the multiple metastases that can arise from a single prostate tumor 
would likely all respond (or not respond) to the same or similar therapies.  
 
4.3.5 Computational modeling of the VEGF/Sema pathway stratifies patients 
To further analyze the contributions of gene expression changes to angiogenesis-related 
signaling, we developed a computational model consisting of ordinary differential equations  
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Figure 4-7: Intra-patient variability of metastases is low relative to inter-patient variability. 
A: Many genes have consistent alterations in metastatic samples from the same patient while 
variable expression patterns between patients are more common. Blue box plots indicate the 
range of expression in the 21 normal samples, with the upper and lower ends of the boxes 
corresponding to the third and first quartiles of the data, respectively. The numbers along the x-
axis indicate to which patient the dots above correspond. B: Consensus K-means clustering of 
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GSE38241 metastases according to VEGF/Sema expression shows a consistent co-clustering 
pattern for 5 clusters. Dark blue indicates a high frequency of co-clustering between consensus 
runs, while white indicates no co-clustering. Colors at the top and left indicate the patient from 
which each metastatic sample was taken. C: Heatmap of gene expression across 18 GSE38241 
metastases. The mean expression of each gene in the normal prostate tissue samples is subtracted 
from the expression of each gene in the metastases so that the heatmap shows up/downregulation 
relative to normal. Only the most variable of the VEGF/Sema genes are displayed. Dashed lines 
separate clusters, and colors at the top correspond to patients as in B. D-E: As for B and C, but 
with the set of 85 angiogenesis-related genes. 
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(ODEs) describing the ligand-receptor binding kinetics of the five VEGF ligands and seven class 
3 Semaphorins. A detailed model is essential, given the high inter-individual variability in gene 
expression, and given that predicting the outcome on signaling of simultaneous changes in 
expression of multiple genes encoding competing ligands and receptors becomes difficult. For a 
more detailed description of the model development, see Section 4.1.6. A key component of the 
model is that it incorporates both tumor cells and tumor endothelial cells, and these cells can 
express both the ligands and receptors of the VEGF and Sema pathways. We show some general 
characteristics of this model in Figure 4-8. On both cell types, VEGF RTKs and Plexin receptors 
tend to be present either in a ligated or neuropilin-coupled (or both) state (Figure 4-8A, 4-8B). 
Neuropilins, which outnumber the other receptors (Table 4-6), are present mostly in an 
uncoupled, unligated state. The effect of individually doubling the production rate of each protein 
in the model shows how each protein affects each receptor signaling complex (Figure 4-8C, 4-
8D). 
Instead of using an 'average' model, the tumor cell ligand and receptor production rates 
were varied based on the gene expression data in the GSE35988 dataset, which included normal 
prostate, primary prostate tumors, and metastatic tumors. This enabled us to run many simulations 
– one for each individual – and to predict the amounts of VEGF and Semaphorin signaling 
complexes in a patient-specific manner.  
The results of simulating many individuals with tumors were divided into groups (benign, 
localized, metastatic) and the distribution of predicted signaling outputs across the population are 
calculated. Binding of the two major isoforms of VEGFA (VEGF165 and VEGF121) to VEGFR-2 
and VEGFR-1 on endothelial cells was lowest in primary (localized) tumors, whereas the 
collective binding of the class 3 Semaphorins to endothelial plexins decreased in primary tumors 
relative to normal tissue and decreased further in metastatic tumors (Figure 4-9A). The receptor 
binding trends closely followed ligand expression levels, with VEGFA expression being the  
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Figure 4-8: Receptor occupancy and sensitivity to protein production rates.  
A-B, Most VEGFR and Plexin receptors are present in an unligated, Neuropilin-coupled state on 
both endothelial (A) and tumor (B) cells. Two exceptions are VEGFR-2 and VEGFR-3, which do 
not form ligand-independent complexes with Neuropilin. C-D, The production rate of each of the 
22 proteins was doubled while holding other protein production rates steady. The heatmap shows 
the log2 ratio of the post-doubling steady-state to pre-doubling steady-state level of each receptor 
complex. VA-R1 includes all complexes with both VEGF-A and VEGFR-1 (VEGFA165-R1, 
VEGFA121-R1, and VEGFA121-R1-NRP1), and so on for the rest of the complexes listed along the 
top of the figure. Receptor production rates were doubled on tumor cells only; thus, the effects on 
endothelial (C) and tumor (D) cells varied. 
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Figure 4-9: Simulated VEGF/Sema ligand-receptor binding on endothelial cells. 
A: VEGFR2 (left), VEGFR1 (middle), and Sema3-NRP1 (right) binding in benign prostate 
(n=12), primary tumors (n=49) and metastatic tumors (n=27) in the GSE35988 dataset. B: VEGF 
secretion and total Sema3 secretion most strongly affect their respective ligand-receptor 
complexes although weak competitive effects are observed. Lines represent least squares fits of 
the log-transformed simulated receptor binding data to the gene expression data. R2 values 
represent the proportion of variance explained by the least squares fit. C: Scatter plots of 
simulated VEGFA-VEGFR2 and Sema3-NRP-PlxnA across tissue types show that only fraction 
of the metastatic samples fall into the expected anti-VEGFA responsive region, i.e. high VEGFA-
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VEGFR2 signaling and low Sema3-NRP-PlxnA signaling. Gradients correlate with expected 
favorability for angiogenesis: darker red for higher VEGFA-VEGFR2 and darker blue for lower 
Sema3-NRP-PlxnA. Colors indicate tissue type: Benign (green); Localized (orange); Metastasis 
(gray). 
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predominant factor driving VEGFR-1/2 binding, while the total Sema3 expression accounted for 
most of the variation in Sema3-NRP-PlxnA binding (Figure 4-9B). The receptor binding profiles 
on tumor cells (Figure 4-10) were similar to those on endothelial cells. These results indicated 
that primary tumors are associated with both pro-angiogenic (decreased Sema3-NRP-PlxnA 
binding) and anti-angiogenic (decreased VEGFR-2 binding) alterations, making it difficult to 
predict whether primary tumors would benefit from therapies that inhibit VEGF signaling. On the 
other hand, the alterations in metastatic tumors were all pro-angiogenic: VEGFR-2 binding was 
higher and Sema3-NRP-PlxnA binding was lower. The range of VEGFR-2 binding was highest 
in metastatic samples, going beyond both the low and high ends of the range of normal samples. 
This suggested an important role for patient selection in the use of anti-angiogenic therapies, as 
only the patients with high baseline VEGFR-2 signaling would be expected to respond. 
Aside from anti-angiogenic signaling initiated by Sema3 binding to neuropilins and 
plexins, Sema3s also may inhibit angiogenesis by competitively displacing VEGF from 
neuropilins. In our model, we found only a weak competitive effect: the least squares fits for the 
non binding ligand-receptor pairs (VEGFA effects on Sema3-NRP-PlxnA and Sema3 effects on 
VEGFA-VEGFR-2 in Figure 4-9B) had slight negative slopes, but the least squares models 
explained a very small proportion of the overall variance. This was due to the fact that the amount 
of NRP1 and NRP2 present in ligand-containing signaling complexes was low relative to the total 
amount of neuropilins present on endothelial cells. If the amount of endothelial NRP1 and/or 
NRP2 were lower or the ligand secretion rates were higher, competition would be expected to 
have more impact. Thus, although direct VEGF-Sema competition for neuropilin is included in 
the model, the quantitative impact of the competition is predicted to be small. 
Our simulation results suggest that determining patients with sensitivity to anti-
angiogenic therapies would require biomarkers consisting of multiple predictor variables. Each 
individual tumor has a different predicted level of VEGFA-VEGFR-2 and low Sema3-NRP- 
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Figure 4-10: Simulated VEGF/Sema ligand-receptor binding on tumor cells. 
A, Box plots of binding by tissue type (benign, localized, metastasis). B-C, Scatter plots showing 
the effects of VEGF secretion (B) and total Sema3 secretion (C) on binding. 
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PlxnA activity (Figure 4-9C). The red and blue gradients, and the arrows on the axes, indicate 
direction of increasing pro-angiogenic signaling for VEGFR2 (accelarator 'ON') and PlxnA1 
(brake 'OFF'), respectively. Metastatic samples predominantly have high simulated VEGFA-
VEGFR-2 and low Sema3-NRP-PlxnA (lower right quadrant of Figure 4-9C: accelerator 'ON', 
brake 'OFF'), and would be expected to benefit the most from VEGF-targeting therapies. 
However, this is not true of all metastatic tumors; a minority of patients with high VEGFA-
VEGFR-2 also have high Sema3-NRP-PlxnA, possibly negating any clinical benefit of an anti-
VEGFA agent. That combination is also predicted to be the most common for the benign tumors 
(green symbols in Figure 4-9C). There are also a subset of metastatic tumors predicted to have 
low VEGFA-VEGFR2 signaling. This heterogeneity amonst the metastatic tumors reinforces the 
need to bring an individualized understanding to therapeutic selection. For those with localized 
disease (grey symbols in Figure 4-9C) the characteristic signaling state is low VEGFA-VEGFR2 
and high Sema-Plexin (upper left quadrant of Figure 4-9C: accelerator 'OFF', brake 'ON'), 
correlating with low angiogenesis potential and no metastases. Further analysis of this model and 
availability of both gene expression and clinical anti-VEGF outcome data will allow us to 
develop simulation-based biomarkers. 
4.4 Discussion 
As with many types of cancer, angiogenesis may enable prostate cancer growth and 
progression. Tumor vessels tend to be more irregular than normal prostate vessels [139,140], and 
higher microvessel density is associated with higher tumor stage [141,142]. Some studies have 
reported a reduction in tumor microvessel density relative to normal prostate tissue, but even in 
these studies it is noted that “hotspots” exist i.e. regions with locally high microvessel densities 
[140]. Prostate tumors are known to have intra-tumoral heterogeneity [121,143], raising the 
possibility that these hotspots correspond to regions with a pro-angiogenic genomic signature. 
Multiple molecular regulators of angiogenesis could be responsible for the tumor-associated 
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changes in the microvasculature. The predominant pro-angiogenic factor, VEGFA, is elevated in 
the plasma of patients with metastatic prostate cancer, but not in patients with localized primary 
prostate tumors [144,145,146,147,148]. This does not rule out a role for VEGFA in primary 
tumors, as immunohistochemistry has revealed increased VEGFA in primary tumors relative to 
benign prostate tissue, and in castration-resistant tumors relative to hormone-naïve [149]. Our 
analysis of previously published gene expression data in this study revealed increases in VEGFA 
expression only in metastatic tumor samples; VEGFA expression in primary tumors was actually 
decreased. Despite elevations in VEGFA in metastatic disease, most VEGF inhibitors have failed 
clinical trials in metastatic CRPC [31,150,151,152]. One compound that has shown some promise 
in phase II trials, cabozantinib, also targets the Met receptor [153]. The lack of success of VEGF 
inhibitors suggests that other angiogenesis modulators may be involved. Therefore, we performed 
an analysis of VEGF-related genes and a family of potential modulators, the semaphorins, across 
stages of prostate cancer to gain a system-wide perspective on VEGF activity in this disease. Our 
methodology could be widened in the future to include more relevant RTK families. 
An active area of research in prostate cancer molecular biomarkers is predicting whether 
a primary tumor will eventually become aggressive or if it will remain indolent as indolent 
prostate cancers can often be left untreated and monitored. We found that a multivariate 
VEGF/Sema signature was associated with aggressive tumors. We used PLS-DA for 
distinguishing between aggressive and indolent tumors, as well as different tissue types, as it 
provided both effective classification and information about the correlation structure within the 
gene expression data. This allowed for interpretation of the expected joint effects of expression 
variation on VEGF signaling activity. We expected the performance of this approach to be 
comparable to other multivariate methods used for similar purposes, including linear discriminant 
analysis [154], random forests [155], and decision trees [156]. Our VEGF/Sema PLS-DA 
biomarkers had similar prognostic capabilities to PLS-DA biomarkers based on the genes from 
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other prostate cancer prognostic indicators available and in development for clinical use. We used 
PLS-DA, as opposed to the algorithm actually used in the prognostic indicators, because the 
algorithms and parameters used in these indicators were proprietary. The VEGF/Sema signature 
of aggressiveness that we found contained several genes that promote lymphangiogenesis, 
including FIGF (VEGFD), NRP2, VEGFC, and KDR. This fits with previous research that 
suggests lymphangiogenesis plays a role in allowing primary tumors to escape their tissue of 
origin via the lymphatic vessels [138,157,158]. Inhibiting one or more of these genes could be an 
effective therapeutic mechanism in patients whose tumors are predicted to be aggressive, possibly 
as a neoadjuvant therapy prior to radical prostatectomy.  
Most approaches to targeting VEGF-dependent cancer angiogenesis have relied on 
inhibiting VEGF or VEGFR2. This focus on blocking the accelerator of tumor angiogenesis may 
have overlooked a key aspect of tumor angiogenesis – the endogenous brakes provided by the 
Semaphorins. Analysis of metastatic tumor gene expression suggested several possible reasons 
for the failure of anti-angiogenic therapies in prostate cancer. As noted above, VEGFA expression 
was consistently elevated in metastases relative to normal samples, but treatment of metastatic 
prostate cancer with VEGF inhibitors typically fails. Reductions in class 3 semaphorins were 
observed, which could enhance VEGF signaling by making more NRP1 available; lower Sema3 
levels could also enhance angiogenesis by removing inhibitory signals mediated by plexins (i.e. 
the brakes on tumor angiogenesis are removed). Our simulation data provide mechanistic insight 
that supports this latter case: Sema3s did not appear to alter the availability of NRP1 to VEGF, 
but the formation of anti-angiogenic Sema3-Plexin complexes was decreased in metastases. Thus 
one possible mechanism of resistance to VEGF inhibitors is reduced anti-angiogenic Sema3 
signaling. With the repression of anti-angiogenic Sema signaling, blocking the accelerator may be 
insufficient to halt the runaway tumor vasculature; thus treatment might best be achieved, or 
augmented, by restoring or replacing the endogenous brakes on tumor angiogenesis.  
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We observed high correlation among the various metastases from each individual 
(Figure 4-7). These multiple metastases arising from a single primary tumor may then respond 
similarly to particular therapies. Also, given recent findings of heterogeneity in primary tumors, it 
may suggest that either (a) metastases come from a selected subset of the primary tumor or (b) 
environments receiving and nurturing metastases may cause the metastatic tumor cells to 
converge. The gene expression clustering analysis in this study also presented other possible 
resistance mechanisms that we did not simulate. For example, SEMA6A was up-regulated in 
metastases from two patients and down-regulated in three. It has roles in angiogenesis, potentially 
though an interaction with VEGFR2 [115].  
To move beyond the 'average patient' that is typically simulated by molecularly-detailed 
mechanistic computational models, we have integrated mechanistic simulations with high-
throughput data to create a population of tumor models that can simulate variability in receptor 
activation and response to treatment. Our simulation results suggest that determining patients 
with sensitivity to anti-angiogenic therapies would require biomarkers consisting of multiple 
predictor variables. This is one of the most important considerations for this type of approach. 
Linear approaches such as PLS-DA are ultimately limited to identifying linear combinations of 
effects within the gene expression data. By adding the mechanism-based, quantitative, nonlinear 
protein-interaction network, we can generate latent variables that integrate both gene expression 
and mechanistic information. These predicted mechanistic latent variables may then be more 
predictive of the angiogenesis potential of the tumor and of the outcome of therapeutic inhibition. 
Simulations of the kind presented here can be expanded to incorporate additional proteins 
and multiple tissue compartments to model drug pharmacokinetics and pharmacodynamics. This 
will be useful for developing patient-specific models capable of identifying the most appropriate 
molecular therapies. Therapies could include VEGF-targeting agents such as bevacizumab as well 
as drugs that target neuropilin, either by blocking ligand binding to neuropilin or by blocking the 
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coupling of neuropilin to other receptors. Inclusion of semaphorins in these models allows us to 
analyze whether neuropilin-targeting therapies could inadvertently have a pro-angiogenic effect 
due to reduced semaphorin signaling. Additional semaphorins (classes 4, 5, 6, and 7) could be 
added as data for the kinetics becomes available. Further development of the model could also 
address several of the limitations of the current model. Proteolytic processing is known to alter 
the receptor binding and therefore the activity of VEGFC, VEGFD, and several of the class 3 
Semaphorins. We neglected these effects here due to a lack of data describing the relative 
amounts of processed and unprocessed forms in tumors. Additionally, we have assumed that 
competition of VEGF and class 3 Semaphorins occurs due to the inability of both to occupy 
neuropilin receptors simultaneously. Further validation against published in vitro data may allow 
us to refine this assumption for specific VEGF and Semaphorin ligands; there is evidence that 
certain ligands (and proteolytically processed forms) are more or less able to sterically inhibit the 
binding of other ligands to neuropilin. 
Several limitations of gene expression data may affect the conclusions of this study. 
Prostate tumors are typically multifocal and heterogeneous [159,160], creating the possibility of 
gene expression data for a patient that does not reflect the clone that actually gives rise to 
aggressive disease. This is a possible explanation for the difference between the TCGA and 
GSE21034 datasets in the VEGF/Sema signatures found in this study to distinguish aggressive 
and indolent tumors. Additionally, gene expression levels are not always representative of the 
level of the corresponding protein. Instead of equating gene expression to protein levels, we 
assumed that protein secretion rates were proportional to gene expression in our patient-specific 
simulations. This is a useful first approximation; further analysis could include miRNA data and 
other regulatory factors that would be expected to influence the rate of translation of a transcript 
to a protein. A final limitation is the small size of metastasis datasets. Metastatic samples are of 
particular interest because metastases give prostate cancer its lethality and here we show that they 
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may have increased VEGF signaling activity. A larger rapid autopsy dataset would allow 
expansion of limited analysis performed here.  
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5 Cancer-Specific Differences in Sensitivity to VEGF-
Targeting Therapies: Predictions from Expression-Based 
Personalized Models 
5.1 Summary 
There are currently no predictive biomarkers of VEGF-targeting therapies that can 
accurately distinguish responders from non-responders. A major obstacle in developing 
biomarkers is the difficulty in obtaining measurements of the levels of VEGF signaling 
complexes in tumor patients. Here we develop a computational modeling framework that 
incorporates patient gene expression data in a multiscale compartment model of VEGFA and 
PlGF signaling. The model allows us to simulate the effects of two VEGF-targeting therapies in 
virtual populations of breast, kidney, and prostate cancer patients. We used this simulated dataset 
to define treatment response metrics consisting of aggregates of highly correlated variables that 
were altered substantially by either treatment. The typical pattern observed was a reduction in 
VEGF-receptor binding in the tumor accompanied by elevated VEGF concentrations in the 
plasma and normal tissues. Varying effects on PlGF binding were observed: PlGF1 binding was 
elevated in the tumor in response to anti-VEGF, whereas binding of both isoforms was elevated 
in tumors in response to anti-NRP1. After defining metrics, we analyzed the performance of 
various biomarkers as predictors of these response metrics. The possible biomarkers included 
both gene expression data and simulated baseline data. We found that simulated baseline data 
almost always served as better predictors of treatment response metrics. This suggested that the 
levels of various protein complexes, which may be difficult to measure in vivo, but which may be 
simulated based on other measurable parameters, may be better predictors of treatment response. 
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5.2 Methods 
5.2.1 Compartment modeling 
To examine the effects of gene expression variability and drug interactions, we simulated 
the binding and transport of ligands throughout three compartments of the body: the tumor, the 
blood, and all other normal tissues. Compartment models of this kind have previously been used 
to analyze the distribution of VEGFA isoforms in diseased tissues [44,47]; here, we expand 
previous compartment models to include two isoforms of PlGF. The parameters for all rate 
constants in the reactions between ligands and receptors were as listed in Tables 4-3 and 4-4 
(note that here, only VEGFA and PlGF were present). 
 The ordinary differential equations describing association and dissociation of ligands and 
receptors, as well as coupling between receptor complexes, remain the same as in Section 4. 
Additional terms are included to describe the transport of soluble proteins and protein complexes 
between compartments. Three types of transport reactions are included in the model: vascular 
permeability, lymphatic transport, and clearance from the blood. Equation 5-1 is an example of 
the how these new terms affect the differential equation for VEGFA165 in the blood. 














































 The B, N, and T superscripts in this equation indicate the compartment (blood, normal, or 
tumor). The vascular permeability constants kp,V and the surface area-to-volume ratios S have two 
compartment superscripts or subscripts, indicating that transport occurs across the vascular 
endothelium separating the blood from either the tumor or the normal tissue. The values for these 
constants and the other constants (clearance rate constant cV, compartment volumes U, available 




Table 5-1: Transport and geometric parameters. 
Parameter Symbol Value Units 
Microvessel SAV (tumor compartment) STB 105 cm2/cm3 tissue 
Tumor SAV ST 1416 cm2/cm3 tissue 
Microvessel SAV (normal compartment) SNB 108 cm2/cm3 tissue 
Parenchyma SAV (normal compartment) SP 664 cm2/cm3 tissue 
Interstitial volume fraction (tumor) KAVT 0.611 cm3/cm3 tissue 
Interstitial volume fraction (blood) KAVB 0.567 cm3/cm3 tissue 
Interstitial volume fraction (normal) KAVN 0.0816 cm3/cm3 tissue 
Tumor compartment volume UV 940 cm3 tissue 
Blood compartment volume UB 5,000 cm3 tissue 
Normal compartment volume UN 61,200 cm3 tissue 
Endothelial cell surface area aEC 1!10-5 cm2/cell 
Parenchyma/Tumor cell surface area aTC 1.85!10-5 cm2/cell 
VEGF normal tissue permeability kp,VNB 4!10-8 cm/sec 
VEGF tumor tissue permeability kp,VTB 4!10-7 cm/sec 
sVEGFR1 normal tissue permeability kp,R1NB 1.9!10-8 cm/sec 
sVEGFR1 tumor tissue permeability kp,R1TB 1.9!10-7 cm/sec 
Drug normal tissue permeability kp,DNB 3!10-8 cm/sec 
Drug tumor tissue permeability kp,DTB 3!10-7 cm/sec 
Clearance – VEGF and PlGF cV 1!10-3 sec-1 
Clearance – sR1 & sR1 complexes cR1 5!10-6 sec-1 
Clearance – drug & drug complexes cD 3.2!10-7 sec-1 
Lymphatic drainage – normal tissue kLN 0.033 cm3/sec 
 
5.2.2 Angiogenesis-targeting therapies 
 We tested the effects of two therapies in the model: an antibody that binds to VEGFA and 
an antibody that binds to the co-receptor Neuropilin-1. The anti-VEGF antibody binds to 
VEGFA165 and VEGFA121 and prevents them from binding to receptors. The anti-NRP1 antibody 
binds to NRP1 and prevents it from coupling with other receptors but allows ligand binding. Both 
therapies were infused into the blood over an hour and a half to final doses of 10 mg/kg (all 
patients were equal mass – 70 kg). A duration of three weeks was then simulated to observe the 
effects of the treatments. Equations 5-2 and 5-3 are examples of how these drugs effect the 
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5.2.3 Virtual population 
 To create a virtual population of models, we used gene expression data to vary the 
production rate of proteins by tumor cells. We made the assumption that all variability in gene 
expression was due to tumor cells; thus, the production rates in the model varied in the tumor 
cells while the production rate of receptors on endothelial cells remained constant across the 
population. 
 We varied protein production rates linearly with untransformed gene expression data. We 
set the nominal tumor protein production rates for VEGFA, PlGF, VEGFR-1, VEGFR-2, and 
NRP1 by finding the production rates that corresponded to 2.67 pM total VEGFA, 0.71 pM total 
PlGF, and 120 pM sVEGFR1 in the blood. These values correspond to the median concentrations 
found in cancer patients The production rates that yielded these concentrations were therefore the 
population median production rates. To determine the patient-specific production rates, we 
normalized gene expression data by dividing by the median. We then multiplied this quantity by 
the corresponding median protein production rate to get the individual production rate for each 
gene/protein. Although this is by no means an exact method for converting between gene  
 95 
 
Figure 5-1: Flowchart of VEGF compartment model simulations for TCGA data. 
Gene expression data from three cancer types were used to parameterize production rates of 
VEGFA165, VEGFA121, PlGF1, PlGF2, sVEGFR1, VEGFR1, VEGFR2, and NRP1 in tumor cells. 
These individualized models were first simulated in the absence of drugs to find the untreated 
baseline. Then, either anti-VEGF (bevacizumab) or anti-NRP1 were added via infusion into the 
bloodstream. This resulted in three simulated datasets: the untreated baseline, anti-VEGF-treated, 
and anti-NRP1-treated. Subsequently, biomarkers for predicting the behavior of the two treatment 
datasets were developed based on either the gene expression or the untreated baseline data. 
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expression and protein production, it is an approximation that preserves a linear relationship 
between protein production and gene expression, which does occur in some cases.  
 We used TCGA RNA-Seq datasets to introduce variability to protein production rates. 
We focused on breast adenocarcinoma, renal cell carcinoma, and prostate adenocarcinoma. For 
each cancer type, we generated three simulated datasets: one with no treatments, one with anti-
VEGF (bevacizumab), and one with anti-NRP1 (Figure 5-1). 
5.3 Results 
5.3.1 VEGFA and PGF expression drive VEGF- and PlGF-containing complexes.  
The virtual population, with patient-specific protein production rates, was simulated in 
the absence of treatments until a steady state was reached. This corresponded to the untreated 
baseline present in tumors at diagnosis. For each cancer type, we applied principal component 
analysis to determine patterns of co-variability among the steady-state variables consisting of the 
concentrations of the ligands and receptor complexes throughout the three tissues in the model. 
We found that the principal component loadings associated with the first and second components 
always consisted entirely of VEGF- and PlGF-containing complexes, respectively (Figures 5-2A, 
5-2B, and 5-2C). Some variations in this pattern were observed: the number of VEGF-containing 
complexes with large magnitude first component loadings varied between cancer types, with 
renal cell carcinoma having more complexes with large loadings than breast or prostate cancers.  
The pattern observed in the PCA loadings plots indicated that the variability in the 
steady-state simulated data was primarily driven by the expression of genes encoding the ligands, 
VEGFA and PGF, but not the receptors. Indeed, the Pearson correlations between the log-
transformed gene expression and log-transformed level of signaling complexes on the tumor 
endothelium were greater than 0.9 for both VEGFA and PGF across the tumor types (Figures 5-
2D through 5-2I). 
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Figure 5-2: Steady-state behavior is driven by expression of the two ligands. 
A-C, PCA of the steady-state simulation data for breast (A), kidney (B), and prostate (C) cancers 
reveals a pattern of correlation among VEGFA-containing as well as PlGF-containing complexes. 
The loadings plots show the projections of the 324 simulated variables onto the first two principal 
components. Red points correspond to any ligand or receptor complex that contains either PlGF 
isoform, while the green points correspond to any ligand or receptor complex that contains either 
VEGFA isoform. The size of the point indicates whether the variable is a NRP1-containing 
complex (large) or not (small). The shape of the point indicates if the variable is a complex 
containing VEGFR1 (circle), VEGFR2 (triangle), or neither (square). D-F, VEGFA expression is 
correlated with the aggregate steady-state level of all VEGFA-VEGFR complexes in breast (D), 
kidney (E), and prostate (F) cancers. G-I, Same as D-F, but with PlGF instead of VEGFA. 
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5.3.2 Derivation of treatment response metrics from PCA. 
We simulated the intravenous infusion of two monoclonal antibody drugs in the virtual 
patient populations: anti-VEGF (bevacizumab) and anti-NRP1. To show the variability across 
each cancer population, we used the concentration of free VEGFA (both isoforms – VEGFA165 
and VEGFA121) in the plasma, which is known to increase in many patients after administration 
of anti-VEGF. In all three cancer types, plasma free VEGFA increased on average in response to 
both anti-VEGF and anti-NRP1 (Figure 5-3A through 5-3C and 5-3G through 5-3I). There was 
an initial repression of plasma VEGFA after addition of anti-VEGFA, but this was reversed 
quickly in most of the patients (Figure 5-3D through 5-3F). The range of the plasma VEGFA 
elevation was higher in response to anti-VEGFA than anti-NRP1. The effect of receptor-mediated 
clearance of the anti-NRP1 antibody can be seen by the reduction in plasma VEGFA at later time 
points (Figure 5-3J through 5-3L). 
A difficulty with analyzing the post-treatment simulated data was the large size of the 
dataset: there were 324 variables comprising the soluble and surface-bound molecular complexes 
across cell types and tissues. Each of these variables in turn had simulation data available at 523 
time points spanning the three-week treatment. To facilitate the analysis of this large dataset, we 
used PCA for dimension reduction. This allowed us to combine highly correlated variables 
together so that we could consider fewer variables while still retaining all relevant variability in 
the dataset. 
An example of the PCA-based dimensional reduction follows for the response of the 
virtual populations to bevacizumab (Figure 5-4A through 5-4C). We evaluated the time integral 
of the level of each complex over the three-week treatment duration and then computed the 
relative change in this quantity from the baseline steady-state level, which corresponds to time 
zero. This resulted in a simulated dataset comprising 324 variables for each patient in the three 
virtual populations, which was used as input for PCA. The loadings of the first four components 
were used to find sets of correlated variables. Soluble and receptor-bound VEGFA in the normal  
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Figure 5-3: Plasma free VEGFA varies widely in response to VEGF-targeting therapies. 
A-C, The aggregated steady-state level of plasma VEGFA165 and VEGFA121 is inversely 
associated with the fold change in plasma VEGFA165 and VEGFA121 in response to anti-VEGF in 
breast (A), kidney (B), and prostate (C) cancers. Colored dots correspond to 20 patients, evenly 
spaced when ranking them from highest to lowest baseline plasma VEGFA. Colors progress from 
blue to purple to red, with red corresponding to the highest level of plasma baseline VEGFA. D-
F, Time courses of plasma VEGFA after administration of anti-VEGF in all patients in the breast 
(D), kidney (E), and prostate (F) virtual populations. Line colors are patient-specific as in A-C. 
G-L, As in A-F, but the drug is anti-NRP1.  
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Figure 5-4: Derivation of bevacizumab response metrics.  
A-C, PCA loadings plots show the relationships between simulated variables in response to 
bevacizumab for breast (A), kidney (B), and prostate (C) cancers. Patterns that recur in multiple 
tumor types are enclosed in dashed circles. The numbers correspond to the time course plots in D-
G. D-G, Population time courses of aggregate variables consisting of the correlated simulated 
variables from A-C. Solid lines indicate the population median at each time point, while dashed 
lines correspond to the 5th and 95th percentiles at each time point. All curves are normalized by 
subtracting the sample-specific baseline value and then dividing by the baseline. Only breast 
cancer data is shown here; the kidney and prostate cancer data had very similar behavior. The 
drug response metrics found here correspond to on-target effects – reduced tumor compartment 
VEGF binding (E) – as well as off-target effects – elevated normal compartment VEGF binding 
(D) and tumor PlGF2-VEGFR1 binding (F). The elevation in normal tissue PlGF2-VEGFR1 
binding (G) has only slight variation from the baseline level (<10%) thus it was not included as a 
metric in subsequent analyses. 
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compartment were associated with the first component in breast cancer (enclosed in a dashed 
circle and labeled 1 in Figure 5-4A), while the second component was associated with soluble 
and receptor-bound VEGFA in the tumor compartment (enclosed in a dashed circle and labeled 2 
in Figure 5-4A). Isoform-specific effects were not noted; this was expected as bevacizumab 
binds both VEGFA165 and VEGFA121 with equal affinity. The third and fourth components for 
breast cancer were associated with PlGF-containing variables in an isoform-specific manner. 
Complexes containing PlGF in the tumor compartment were associated with the third component 
(enclosed in a dashed circle and labeled 3 in Figure 5-4A), while soluble and NRP1-bound 
PlGF2 in all compartments was associated with the fourth component (enclosed in a dashed circle 
but not labeled in Figure 5-4A).  
Similar patterns were observed in kidney cancer (Figure 5-4B) and prostate cancer 
(Figure 5-4C). Normal compartment VEGF binding and tumor compartment VEGF binding were 
associated with the first and second principal components, respectively, in all three cancer types. 
A new set of variables was observed with a distinct loading pattern in kidney and prostate 
cancers: normal compartment PlGF2-VEGFR1 complexes (enclosed in a dashed circle and 
labeled 4 in Figure 5-4B and 5-4C).  
To aggregate the collections of variables with labels in Figures 5-4A through 5-4C, we 
added together the simulated level of each variable at each time point, then computed the relative 
change from time zero. This method allowed us to preserve the relative cell surface densities of 
receptor complexes. The time courses of these aggregated relative variables showed the impact of 
bevacizumab on the breast cancer virtual population (Figure 5-4D through 5-4G): VEGFA was 
redistributed from the tumor compartment to the normal compartment, and PlGF binding was 
enhanced, particularly for PlGF2 binding to VEGFR1 in the tumor and normal compartments. 
The range of variability across the population (dashed lines in time course plots in Figure 5-4 
indicate 5th and 95th percentiles, while solid lines indicate median) demonstrated a fairly 
consistent on-target response, namely reduction in tumor compartment VEGF binding (Figure 5-
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4D). The increased level of normal compartment VEGF binding (Figure 5-4E) varied widely 
across the population, with some patients having negligible increases, while others had more than 
200% increases. The elevations in PlGF2-VEGR1 binding in the tumor compartment (Figure 5-
4F) also varied widely. We excluded PlGF2-VEGFR1 binding in the normal compartment 
(Figure 5-4G) from the bevacizumab metrics because it increased by less than 10%. The ranges 
of variation for the four aggregate variables in the other two cancer types (data not shown) was 
similar to the range in breast cancer. 
Applying dimensional reduction to the anti-NRP1 responses yielded patterns with some 
similarities to the anti-VEGF responses. Normal and tumor compartment VEGF complexes each 
were strongly associated with principal components (data not shown). However, other patterns 
were difficult to discern, therefore we considered the metrics shown along the left side of Figure 
5-5. These metrics are made up of some complexes including NRP1 and some that do not include 
NRP1. In breast cancer, addition of the anti-NRP1 antibody always increased the level of the 
complexes without NRP1 (first column of Figure 5-5) and always reduced the level of complexes 
with NRP1 (middle column of Figure 5-5). When we considered the net effect, we found that 
tumor VEGF binding decreased overall (Figure 5-5F) while the other three metrics increased 
(Figure 5-5C, 5-5I, 5-5L). All of these metrics had ranges of variability that exceeded 10%. The 
range of the changes was similar in the kidney and prostate populations as well (data not shown). 
5.3.3 Prediction of drug sensitivity metrics. 
Since clinical data describing patient responses to bevacizumab and anti-NRP1 was 
unavailable in these datasets, we used the drug metrics derived in the previous section. Our goal 
was to fit statistical models to these metrics using gene expression data or simulated baseline data 
as predictor variables. We tested all possible univariate linear regression models. We then found 
the best gene expression predictor for each metric and the best baseline simulation predictor for 
each metric (Figure 5-6). In most cases, the best simulated baseline variable had higher  
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Figure 5-5: Anti-NRP1 response metrics. 
A-C, Time course plots of the relative change in aggregate binding of both VEGFA isoforms to 
VEGFR1 and VEGFR2 in endothelial cells of normal tissues. Solid lines indicate the breast 
cancer population median at each time point, and dashed lines indicate the 5th and 95th percentiles. 
VEGF binding to VEGFR1 and VEGFR2 in the absence of NRP1 increased in response to anti-
NRP1 (A), whereas the level of VEGF-VEGFR complexes including NRP1 decreased (B). The 
net effect, which corresponds to the biological signal of interest, was an elevation in VEGF-
VEGFR binding. D-F, VEGF-VEGFR binding on endothelial cells of the tumor compartment had 
a net negative change in response to anti-NRP1. G-L, Binding of both PlGF isoforms to VEGFR1 
followed a similar pattern in the normal and tumor compartments, but both had net elevations. 
The drug response metrics used in subsequent analyses were the net effects for each complex (C, 
F, I, L). All results here are from the breast cancer virtual population; the kidney and prostate 




Figure 5-6: Performance of gene expression and simulated baseline as biomarkers of drug 
response metrics. 
A-C, The best single predictor for each metric was almost always a simulated baseline variable. 
Bars correspond to the highest squared Pearson correlations for each metric in the breast (A), 
kidney (B), and prostate (C) virtual populations. Grey bars correspond to the best predictor out of 
the five gene expression variables, with the gene whose correlation was highest listed inside the 
bar. Blue bars correspond to the best predictor out of the 324 simulated steady-state variables, 
with the variable listed inside the bar. Simulated variable names ending in “TendoS” indicate that 
a complex is found in the Tumor compartment on the endothelial cell Surface. An “N” in place of 
the “T” indicates the Normal compartment. If “parencS” is present in place of “endoS”, the 
variable is located on the parenchymal cell Surface. Simulated variable names ending in “B” 
indicate the ligand is present in the Blood. 
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correlations than the best gene expression variable. This is expected as the computational model 
incorporates the expression of all the genes; thus even though we used a single simulation 
variable as a predictor, we actually account for variation in all five genes. 
When comparing the best predictors across cancer types, we found that the metrics 
accounting for ligand binding in the normal compartment consistently had high correlations with 
the ligands that were part of those complexes (i.e. VEGFA for normal compartment VEGF 
binding in response to both anti-VEGF and anti-NRP1, and PGF for normal compartment PlGF 
binding in response to anti-NRP1). This was not the case for the complexes in the tumor 
compartments. We also found that plasma ligand concentrations, which are often measured in 
patients, were not typically good predictors, with the exception of the high correlation between 
plasma PlGF2 concentration and normal compartment PlGF binding in response to anti-NRP1 in 
breast and prostate cancers. 
5.4 Discussion 
Here we studied the baseline VEGF signaling and responses to VEGF-targeting therapies 
in a virtual population of cancer patients. The virtual populations were built based on actual 
patient-derived cancer gene expression data and knowledge of the molecular interactions between 
VEGF ligands and their receptors, as well as transport of VEGF ligands and therapeutic agents 
throughout the body. This approach gave us insight into the amounts of receptor binding that are 
currently impossible to measure in vivo in the clinic.   
Although previous studies have analyzed bevacizumab in whole-body compartment 
models of VEGF signaling, this study expands on that work in three ways: first, we added PlGF 
into the model; second, we introduced patient-specific variability in protein production rates 
using gene expression data; and third, we simulated the effects of an anti-NRP1 antibody. PlGF 
binding to VEGFR1 increased in response to both therapies, thus the inclusion of PlGF may 
allow us to account for intrinsic resistance mechanisms due to up-regulated PlGF signaling. The 
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effects of PlGF signaling have not been studied as extensively as VEGF, but there is some 
evidence that it promotes angiogenesis [161]; thus, enhancement of PlGF-VEGFR1 signaling is a 
potentially deleterious off-target effect.  
 Parameterizing protein production rates based on gene expression data allowed us to 
create virtual population models. This allowed us to computationally compare drug response 
profiles in multiple cancer types. Although the range of variation in the drug response metrics 
tended to be similar in different tumor types, the different gene expression covariance matrices 
between populations resulted in differing dependencies of drug response metrics on gene 
expression variables. For example, the best gene expression predictor of bevacizumab-induced 
reduction in tumor VEGF binding in breast cancer was KDR, the gene encoding VEGFR2, 
whereas in kidney and prostate cancer VEGFA was the best predictor. In clinical trials, 
prospective biomarkers for bevacizumab can succeed in some trials while failing to separate 
patients in other trials. Our results suggest that differences in gene expression co-variation may be 
responsible for differing performance of biomarkers between cancer types. 
 Previous studies involving computational modeling of anti-NRP1 antibodies involved 
single compartment models [113]; here, our use of multi-compartment models allowed drug 
pharmacokinetics to be taken into account. We found that the anti-NRP1 antibody had similar 
effects to bevacizumab: VEGF was redistributed from the tumor compartment to the normal 
compartment, while some up-regulation of PlGF-VEGFR1 binding occurred. However, there 
were slight differences, including the reduced range of plasma VEGF up-regulation in the anti-
NRP1-treated population. An anti-NRP1 antibody has been tested in the clinic [162]; our results 
could be useful in suggesting biomarkers that may be able to separate responsive patients from 
non-responders. 
One limitation of this approach is that the only data available for validation at present are 
plasma measurements of ligand concentrations. Additional measurements will allow for better 
validation. Gene expression data paired with clinical outcomes for VEGF-targeting drugs will 
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also be needed to fully validate this approach. However, our results do demonstrate the potential 
of integrating models describing the kinetics of molecular interactions with patient-specific data. 
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6 Effect of Cell Heterogeneity on Anti-VEGF Drug Response 
6.1 Summary 
VEGF-targeting therapies inhibit tumor angiogenesis by preventing VEGF-induced 
sprouting of new blood vessels from existing vasculature. A difficulty in using gene expression 
data as a biomarker of the effectiveness of VEGF-targeting therapies is that it is unknown which 
cells in a tumor contribute to measured gene expression variability. While cancerous tumor cells 
often comprise the majority of the cells in a tumor, stromal cells such as endothelial cells, 
fibroblasts, and immune cells may be present in significant quantities as well. Here, we 
investigated the consequences of assuming that a significant amount of the variability in 
expression of the genes encoding VEGFR-1, VEGFR-2, and NRP1 arises due to varying 
production by endothelial cells instead of tumor cells. We use a computational framework 
previously developed for assessing patient variability in tumor cell expression and adapt it so that 
production rates by endothelial cells vary linearly with gene expression. We found that drug 
response metrics maintained the same pattern of association with ligand gene expression, but the 
receptor expression often had opposite effects when expression variability was on endothelial 
cells. 
6.2 Methods 
The computational models used in this chapter were described in Chapter 5. In Chapter 5, all 
simulations were configured so that variability in the expression of genes encoding receptors led 
to variability in tumor cell receptors. In this section we test the effect of attributing gene 
expression variability to the endothelial cells of the tumor compartment instead of the tumor cells. 
When endothelial cell receptor production rates varied with gene expression, the tumor cell 
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receptor production rates were held constant at their median values. We considered only the 
breast cancer dataset in this chapter. 
6.3 Results 
We first compared how receptor variation on endothelial cells changed the steady-state 
relationships between gene expression and three key model outputs, relative to the case where 
receptor variation was primarily on tumor cells. VEGFA expression had the strongest association 
with free VEGF, endothelial VEGF binding, and parenchymal VEGF binding, regardless of 
compartment and which cell type had receptor variation (Figure 6-1). Receptor variation only 
had a strong correlation in the tumor compartment (Figure 6-1A). The correlation of receptor 
expression with free VEGF in the tumor compartment was negative regardless of which cell type 
had receptor variation (top panel). However, the sign of the correlation switched for endothelial 
and parenchymal (tumor) cell variation (middle and bottom panels, respectively). Receptor gene 
expression had positive correlations with VEGF binding on the cell type on which receptor 
variation occurred, and negative correlations on the cell type for which receptor levels were fixed 
to the median. We examined the correlations of gene expression with each steady-state untreated 
simulated variable individually as well (Figure 6-2). This demonstrated that the trends noted in 
Figure 6-1 held across individual variables. Outside of the VEGF complexes on tumor and 
endothelial cells in the tumor compartment (labeled in Figure 6-2), there was little difference in 
Pearson correlation in the population where variation occurred on endothelial cells.  
To assess how endothelial cell receptor variation affects drug response, we simulated the 
addition of an anti-VEGF antibody (bevacizumab) and an anti-NRP1 antibody. We examined the 
range of variation in tumor endothelial cell VEGF binding and found that whereas the 
bevacizumab response profile had only a slight increase in the range in variation across the 
population, the anti-NRP1 response had wider variation (top panels of Figure 6-3). When we 
compared the time-averaged responses in a patient-specific manner, we found a strong correlation 
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Figure 6-1:  Effects of receptor variation cell type on compartment VEGF binding profiles. 
A-C, Gene expression versus free VEGF165+VEGF121 (top), endothelial VEGF binding (middle), 
and parenchymal VEGF binding (bottom) in the tumor (A), blood (B), and normal (C) 
compartments. In each rectangle of 10 plots, the top five correspond to simulations where tumor 
cell receptor levels vary, while the bottom five correspond to simulations where the endothelial 
cell receptor levels vary. The x-axes always correspond to the five gene expression variables.  
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Figure 6-2: Expression-baseline correlation dependence on cell type of receptor variation. 
The heatmaps compare the Pearson correlation between gene expression and individual simulated 
variables, with each row corresponding to the labeled gene and each column corresponding to a 
different simulation variable. Compartments are noted along the top. The blood compartment has 
fewer variables than the other two compartments because only soluble complexes are present. 
The normal compartment has fewer variables than the tumor compartment because some of the 
normal compartment variables have variances of zero. These are omitted because Pearson 
correlation coefficients cannot be calculated for these variables. The labeled variables are the 
ones of interest that display differing patterns depending on the cell type with receptor variability. 
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Figure 6-3: Drug response dependence on receptor cell type variation. 
The range of variation when receptor levels varied on endothelial cells was higher in response to 
anti-NRP1 (top right panel) but not in response to anti-VEGF (top left panel). The fold-change 
from baseline of tumor endothelial VEGF binding was calculated by dividing each time point by 
the initial untreated level. Blue and green shaded regions indicate the range of population 
variability when receptor expression varies on tumor and endothelial cells, respectively. The time 
average of the fold-change from baseline of tumor endothelial binding in response to anti-VEGF 
is similar when regardless of which cell type has receptor variation; the response to anti-NRP1 
does not have this property. 
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between the populations with receptor variation on endothelial cells and on tumor cells (bottom 
left panel of Figure 6-3). In other words, if patients were ranked from most responsive to least 
responsive, the order would not change significantly regardless of which cell type contributed cell 
type receptor variation. This was not the case for the average anti-NRP1 response (bottom right 
panel of Figure 6-3): here, the ranking of patients in the population with varying tumor cell 
receptor levels would be drastically different than that of the patients in the population with 
varying endothelial cell receptor levels. 
Pearson correlations between gene expression and time-averaged post-bevacizumab 
simulated variables did not change with differing receptor variation cell types (Figure 6-4). Gene 
expression of the three receptors was highly correlated with the average change in VEGF 
complexes on both cell types, regardless of which cell type had varying receptor expression. The 
pattern of correlations between gene expression and time-averaged post-anti-NRP1 simulated 
variables was less distinct (Figure 6-5). Expression of NRP1 had higher correlations with VEGF 
complexes on endothelial cells in the tumor compartment when receptors varied on endothelial 
cells compared to when receptors varied on tumor cells. Overall these results suggested that while 
gene expression-based predictors of bevacizumab response may not be sensitive to assumptions 
about which cells have varying receptor levels, predictors of anti-NRP1 response are.  
6.4 Discussion 
A major assumption in building population-based computational models of VEGF signaling 
involves assigning VEGFR1, VEGFR2, and NRP1 gene expression variability to specific cell 
types within the tumor compartment. Here we tested how this assumption affects both the 
untreated baseline levels of VEGF signaling complexes, as well as the drug response profiles. The 
effects on baseline signaling were somewhat expected: receptor gene expression was strongly 
correlated with the levels of VEGF complexes on whichever cell type had varying receptor levels. 
Notably, VEGFA expression was strongly correlated with levels of baseline VEGF complexes in  
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Figure 6-4: Effect of receptor variation cell type on expression-bevacizumab response 
correlation.  
Analogous to Figure 6-2, but the simulated variables along the columns are now the time-
averaged fold-change in post-bevacizumab values. The color bar on the right displays the scale, 




Figure 6-5: Effect of receptor variation cell type on expression-anti-NRP1 response 
correlation. 
Analogous to Figure 6-2, but the simulated variables along the columns are now the time-
averaged fold-change in post-anti-NRP1 values. The color bar on the right displays the scale, with 
red indicating strong positive Pearson correlations and blue indicating strong negative Pearson 
correlations. 
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both populations. This suggests that simulated predictions of the effect of VEGFA expression on 
VEGF signaling are insensitive to the assumption of which cell types contribute gene expression 
variability. 
When considering the impact of the receptor variability cell type on drug response, 
bevacizumab response did not depend on the cell type, but anti-NRP1 response did. This implies 
that developing biomarkers for response to bevacizumab based on this approach may not require 
further knowledge as to which cell types in a tumor contribute gene expression variability. 
However, cell-type specific measurements of receptor gene expression would be helpful for 
developing anti-NRP1 biomarkers. This discrepancy could be due to the fact that bevacizumab 
binds to a ligand while anti-NRP1 binds to a receptor. This could have implications for other 
VEGF receptor-targeting therapies, such as the anti-VEGFR2 antibody ramucirumab. 
Here, we tested two extremes: receptors either varied solely on tumor cells or solely on 
endothelial cells. A more realistic simulation would include variation on both cell types. 
Measurements of cell-specific receptor gene expression will be useful in further fine-tuning the 
expression-based computational models of patient populations. Pairing these measurements with 
relative frequencies of cell types in a patient’s tumor would allow us to simulate varying levels of 
receptors on both cell types.  
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7 Personalized Computational Models of EGFR/ErbB Family 
Signaling Reveal Mechanisms of Intrinsic Resistance in 
Patient Subgroups 
7.1 Summary 
A major obstacle in oncology drug development is the variability among patients of 
effectiveness of therapies, due to the heterogeneity of tumors across populations. Molecular 
biomarkers such as the expression levels of genes or proteins have proven useful, particularly in 
the epidermal growth factor (EGF) family, but these kinds of markers are still unable to 
accurately predict all responsive patients. These biomarkers are typically univariate and linear, 
whereas multivariate, nonlinear biomarkers are needed to adequately describe the network of 
molecular interactions targeted by a drug. Here, we present a method for building multivariate 
biomarkers that incorporates BOTH patient-specific transcriptomic/proteomic data AND detailed 
mechanistic models of the nonlinear interactions between ligands and receptors. We applied the 
method to the EGFR/ErbB family and showed that the personalized models accurately captured 
variability in receptor phosphorylation. Before the addition of drugs, the models behaved in a 
relatively monotonic fashion, with signaling outputs following closely the expression of the key 
ligands. However, the response to the addition of drugs was much more complex. We simulated 
the addition of three antibody drugs that each target one of EGFR, HER2, and HER3 and applied 
principal component analysis to characterize the post-therapy time course response. We derived 
metrics that accounted for both target-specific and off-target effects. We then used multivariate 
supervised learning methods to develop predictive biomarkers. We found that biomarkers derived 
from gene expression data were outperformed by biomarkers derived from simulated baseline 
tumor behavior (i.e. that combined quantitative mechanistic information with gene expression 
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data). This suggested that linear transformations of transcriptomic and proteomic data may not be 
adequate for predicting drug response; instead, the nonlinear transformation central to the 
computational model is needed. With paired transcriptome/proteome and clinical drug response 
data, the method proposed here could yield improvements in predictive biomarker development. 
7.2 Introduction 
Drugs that target epidermal growth factor (EGF) family signaling have shown success as 
cancer treatments. Several of these target the receptors for the EGF family – the 
EGFR/ErbB/HER family of receptors (Figure 7-1B). The EGFR-targeting antibody cetuximab 
[163] and the HER2/ErbB2-targeting antibodies trastuzumab [56] and pertuzumab [57] are 
approved for use in certain cancer types. A HER3/ErbB3-targeting antibody, MM-121, has shown 
promise in preclinical models [164] and early-stage clinical trials. Tyrosine kinase inhibitors that 
repress receptor phosphorylation, such as erlotinib [165] and lapatinib [166], have also been 
approved. A major problem with these and other cancer therapies is that the tumors of many 
individuals have intrinsic resistance and do not respond. This is likely due to the tumor-to-tumor 
variation in expression not only of the targets but also of the other proteins in the protein 
interaction network of the target. Predictive biomarkers are needed that can distinguish between 
responders and non-responders so that these costly therapies can be selectively administered to 
patients who will benefit.  
Predictive biomarkers already exist for some therapies, with one of the best known 
examples being HER2 amplification predicting response to trastuzumab, a HER2 antibody. 
Testing for HER2 overexpression/amplification by immunohistochemistry and in situ 
hybridization can separate patients into two to four groups, with increasing rates of pathologic 
complete response in groups with higher HER2 amplification [167]. However, even among 
patients with the highest levels of HER2, the drug is not completely effective: at a median of 3.9 
years of follow-up in two large clinical trials, 85.8% of treated patients were disease-free 
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compared to 75.8% of controls [168]. Thus, 14.2% of HER2-positive patients relapse despite 
treatment. In colorectal cancer, expression of two EGFR ligands is predictive of cetuximab 
response, as is mutation status of the downstream signaling protein K-ras [169]. Studies of 
mechanisms of resistance in cell line and xenograft models can be useful in the development of 
predictive biomarkers for the clinic. For example, ErbB2 amplification and overexpression of the 
ErbB3 ligand heregulin (HRG) were demonstrated to promote cetuximab resistance in cell lines 
[170]. HRG expression was demonstrated to be necessary for responsiveness to MM-121 in cell 
lines and xenografts [164]. HER2 amplification by itself may not always be sufficient to predict 
response to trastuzumab: the oligomeric state of HER2 is also important for prediction of 
response in cell lines, with high levels of homodimers promoting sensitivity and high levels of 
ligand-induced heterodimers promoting resistance [171].  
Here, we present an approach for integrating genomic data from patient tumor samples into 
computational models of interactions between ligands and receptors in the EGF family. We build 
upon work previously published by other groups: we start with the model of Shankaran et al. 
[172], which was used to determine patterns of receptor dimerization that lead to 
phosphorylation. To this model, we add an additional ligand and adapt the geometry so that it 
represents a human breast tumor. We also add three EGF family-targeting drugs, cetuximab, 
pertuzumab, and MM-121, based on the kinetics and interaction topology previously published by 
Schoeberl et al. [173]. We calibrate a "mean" model based on published ligand concentrations in 
cancer patients, and then parameterize the protein production rates using individualized data. 
Thus, we generate a population of models, each parameterized to a different individual.  This 
allows us to simulate the drug responses of the virtual patient population (Figure 7-1A). From 
this data, we use several machine learning approaches to develop predictive biomarkers for drug 
response, and show that these biomarkers, mechanism-based nonlinear latent variables that could 
not be obtained from expression data alone, perform better than biomarkers derived only from 
gene expression data.  
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7.3 Methods 
7.3.1 Mathematical model of the EGFR family 
To predict the EGF family ligand-receptor binding based on patient gene expression data, 
we used the mathematical model developed and published by Shankaran et al. [172]. This model 
was comprised of the binding and trafficking reactions involving EGF, HRG, EGFR, 
HER2/ErbB2, and HER3/ErbB3 (Figure 7-1B) in cultured cells. We omitted the late endosome 
compartment because molecular species in the late endosome did not contribute to the dynamics 
of other species and did not contribute to the phosphorylation measurements. This meant that 
molecules exiting the early endosome were either recycled or degraded as opposed to entering the 
late endosome for subsequent degradation. 
We adapted the model so that it represented a tumor while retaining the binding and 
trafficking kinetics that had previously been validated; this required making changes to the 
geometry of the model but not to the molecular interactions. Shankaran et al. modeled cells with a 
media volume of 5x10-10 liters/cell and endosome volume of 3x10-14 liters/cell. We modeled 
tumor tissue consisting of tumor cells and interstitial space. The interstitial volume fraction was 
0.58 cm3/cm3 tissue, while the tumor surface area-to-volume ratio was 1534 cm2/cm3 tissue. 
Assuming a surface area of 1000 um2/cell, this equates to 1.534x108 cells/cm3 tissue. We use this 
cell density to convert the endosome volume to a tissue volume basis, yielding an endosome 
volume fraction of 0.0046 cm3/cm3 tissue. We assumed that the surface area of endosome was 
equivalent to the surface area of the cell membrane, giving the endosome the same surface area-
to-volume ratio of 1534 cm2/cm3 tissue. We simulated the addition of 10 ng/mL EGF and 40 
ng/mL HRG into the interstitial space to confirm that our model yielded similar results to those of 
Figure 3 in Shankaran et al. (Figure 7-2). 
To generate patient-specific models of EGF family signaling, we used a unique set of 




Figure 7-1: Overview of computational approach for identifying predictive biomarkers. 
A, Gene expression data for six EGF family genes were used to simulate the ligand-receptor 
interactions in a population of patients. Time course data describing the response of the simulated 
population to three therapies was analyzed to find potential response metrics. These metrics were 
then modeled using supervised learning to compare the performance of transcriptomic/proteomic 
data with simulated baseline predictions. B, The molecules in the computational model include 
the ligands EGF, TGF", and HRG, the receptors EGFR, ErbB2, and ErbB3, and the therapeutic 
monoclonal antibodies cetuximab, pertuzumab, and MM-121. All free receptors and ligand-
receptor complexes can be found at the surface of the cell as well as in the endosome. 
122 
Figure 7-2: Comparison of simulation results to Shankaran et al.  
Our implementation of the model returned identical results to those in Figure 3 of Shankaran et 
al., which shows the response of the D20 clone of mammary epithelial cells (85,896 EGFR/cell, 
643,777 ErbB2/cell, and 28,770 ErbB3/cell) to 12 ng/mL EGF alone, 40 ng/mL HRG alone, and 
EGF and HRG combined for two hours. 
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rates that yielded protein levels comparable to the median protein level measurements from 
populations of cancer patients. We then varied these median production rates in each patient 
based on expression data from the Cancer Genome Atlas (TCGA).  
We also added three therapies into the model based on the work of Schoberl et al. [173]: 
cetuximab, pertuzumab, and MM-121. These drugs target EGFR, ErbB2, and ErbB3, 
respectively. Each antibody binds to its target receptor and prevents ligand binding (for EGFR 
and ErbB3) and receptor dimerization (for all three receptors). The antibodies are able to bind two 
receptors, so ternary complexes consisting of an antibody and two receptors are included in the 
model. Internalization of antibody-bound receptors does not occur except in the case of MM-121; 
here, the ternary complex consisting of MM-121 and two ErbB3 receptors can enter the early 
endosome, where it is recycled or degraded. We included pertuzumab as an anti-ErbB2 antibody 
instead of trastuzumab because the mechanism of action of trastuzumab is less clear and may 
involve antibody-dependent cell-mediated cytotoxicity, whereas pertuzumab acts by blocking 
dimerization [174]. 
The mathematical models of the EGF family interactions were coded in Fortran and 
integrated using a fourth-order Rosenbrock step [175], implemented using the Intel ifort compiler.  
7.3.2 Gene and protein expression datasets 
We used TCGA data (cancergenome.nih.gov) to determine protein production rates in the 
model. We used RNA-Seq measurements of EGF, TGFA, and NRG1 expression to determine the 
EGF, TGF", and HRG production, respectively. We used reverse phase protein array (RPPA) 
measurements of EGFR, ErbB2, and ErbB3 levels to estimate the steady-state levels of these 
proteins, and from this their production rates. We also used RPPA measurements of receptor 
phosphorylation for comparison with steady-state model predictions. In total, there were 400 
patients with both RNA-Seq and RPPA data.  
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7.3.3 Outputs of the model 
We simulated the population several times: once to determine the steady-state baseline 
levels of the molecular complexes in all 400 individuals across the population, and once for each 
of the three drugs at multiple concentrations. For each of the three drugs, each individual in the 
population started from the corresponding steady-state baseline for that individual. The 
observation time was 48 hours following treatment. The dose of each drug was chosen by 
performing dose response simulations across the population and choosing the minimum dose that 
was at least moderately effective in most patients. The individual simulated baseline molecular 
complex levels were subsequently used as predictor variables in the supervised learning models, 
while drug response time course-derived variables were used as outcome metrics (see Supervised 
Learning of Multivariate Predictive Biomarkers below). 
7.3.4 Principal component analysis 
We performed PCA using the prcomp function in the stats package in R. We selected the 
number of components to include in the PCA model so that subsequent addition of components 
did not significantly increase the total variance explained. We performed rotation of the loadings 
for these components using the varimax function in the stats package in R. 
7.3.5 Supervised learning of multivariate predictive biomarkers 
We used two supervised learning algorithms to create statistical models of the PCA-
derived metrics from two sets of predictor variables: the gene/protein expression data and the 
simulated steady-state model results. For partial least squares (PLS) regression, we used the plsr 
function in the pls package in R. The number of components was chosen by cross-validation. For 
support vector machine (SVM) regression, we used the svm function in the e1071 package in R. 
We used the default kernel, a radial basis function, with the default value of #. 
We chose parameter values as needed in the supervised learning models by performing 
leave-one-out cross-validation (LOOCV). Each sample was withheld once. Output values were 
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predicted for the held out sample using a model trained with all remaining samples. The model 
goodness of fit was then assessed by finding the R2 value between the values predicted for the 
held out samples and the actual data. 
7.4 Results 
7.4.1 Model expansion and calibration 
As a first step toward building patient-specific computational models of EGF family 
signaling, we began with a previously-published model. Extensive work has been done modeling 
the interactions of EGF family proteins and downstream signaling [173,176,177]; we selected the 
recently published model of Shankaran et al. [172] as it focused on the relative signaling potency 
of the various receptor homo- and hetero-dimers. Transforming growth factor-" (TGF") is an 
EGFR ligand with potential importance in breast cancer due to its up-regulation in the triple-
negative subtype (Figure 7-3), but to our knowledge no detailed mathematical models have 
included TGF". We therefore expanded the Shankaran et al. model to include TGF" based on 
published data describing the affinities and trafficking of multiple EGFR ligands [178]. The 
TGF"-EGFR affinity was similar to that of EGF-EGFR, whereas the rate of recycling of TGF"-
EGFR complexes was higher than for EGF-EGFR complexes. We therefore modeled TGF" as 
having the same binding kinetics as EGF and the same recycling rate constant as HRG-ErbB3 
complexes, which recycle faster than EGF-EGFR complexes.  
The Shankaran et al. model was developed for application to cells in culture; to adapt this 
model so that it represented a tumor, we added production terms for the three ligands and 
adjusted the geometric parameters, as described in the Methods. We set the receptor production 
rates to values that yielded densities of 120,000 EGFR/cell, 200,000 ErbB2/cell, and 20,000 
ErbB3/cell in the absence of ligands; these values fall in the middle of the range of measured cell 
densities across cell lines in [172]. We then adjusted the production rates of EGF, TGF", and 
HRG to target extracellular concentrations of 158 pM [179], 29 pM [180], and 216 pM [170],  
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Figure 7-3: Comparison of EGF familiy proteins between triple-negative breast cancer 
(TNBC) and other breast cancers.  
A, Most ligands were significantly altered in TNBC. The ligands included in the computational 
model in this study are enclosed in the box. B, All 4 EGF family receptors were significantly 
altered in TNBC. C, The three receptors with RPPA data were significantly altered. The pattern 
of receptor alterations agreed between the RNA-Seq and RPPA measurements. P-values were 
calculated using the Mann-Whitney U-test. 
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respectively. These six production rates served as population median values in the patient-specific 
models. For a given protein in a particular patient, the protein production rate was determined by 
dividing the measured expression of that protein by the median expression across the population. 
This normalized value was then multiplied by the median production rate to yield the individual 
production rate. This resulted in patient-specific models of EGF family signaling. 
7.4.2 Predictions of baseline pre-drug tumor state correlate strongly with gene expression 
and breast cancer subtypes 
The steady-state levels of each of the molecular complexes in the model, simulated for 
each individual in the population of 400 breast cancer patients, were predicted; these correspond 
to the baseline, untreated levels for these complexes in tumors. Analysis of the steady-state 
predictions across the 400 patients revealed extensive correlations among the 50 distinct 
molecular entities in the model. We used principal component analysis to investigate the 
correlation structure in depth. We found that the first six principal components contained 97.6% 
of the overall variance. After rotating the first six component loadings using the varimax 
procedure, we found that the first four components were significantly associated with the 
production rate of four of the proteins (Figure 7-4A and 7-4B, components are labeled with the 
“SS” subscript to differentiate these principal components from later applications of PCA). 
Specifically, only EGF-containing complexes had high magnitude PC1SS loadings. The same 
pattern was observed for HRG-containing complexes and PC2SS, TGF"-containing complexes 
and PC3SS, and ErbB2-containing complexes and PC4SS. The two molecules with high magnitude 
PC1SS and PC2SS loadings were the surface and endosome EGF-HRG-EGFR-ErbB3 complexes, 
and the two molecules with high magnitude PC3SS and PC4SS loadings were the surface and 
endosome TGF"-EGFR-ErbB2 complexes. Thus nearly all of the variation in predicted baseline 
EGF family signaling could be described by four reduced variables: EGF binding, HRG binding, 
TGF" binding, and ErbB2 dimerization.  
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Figure 7-4: Simulated ligand binding profiles are predictive of receptor phosphorylation. 
A-B, The rotated principal component loadings for the first 6 PCs (97.6% of the total variance) 
show ligand-driven patterns for the first three PCs (EGF, HRG, and TGF-"-containing complexes 
shown in green, red, and blue, respectively), and a receptor-driven pattern for PC4SS (ErbB2-
containing complexes shown in yellow). C, TN status and PAM50 subtypes (top block), reduced 
simulated variables (third block), and phosphorylation measurements (bottom block) were 
associated with gene expression (second block). Samples were ordered according to K-means 
clustering of the samples based on the expression of the six input genes, with the cluster 
membership labeled at the bottom of the heatmap. Expression, simulated variables, and 
phosphorylation measurements were all log-transformed if needed, and scaled to have zero mean 
and unit variance so that the same color scale could be applied to all three data types. 
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We compared the four reduced simulated variables to previously defined breast cancer 
subtypes, sometimes referred to as the PAM50 subtypes. When grouping the samples into five 
gene expression-based K-means clusters, we noted that the four PAM50 subtypes aligned well 
with these clusters, suggesting that EGF family signaling varies in a subtype-specific manner 
(Figure 7-4C, the fifth K-means cluster was very small and cannot be seen here). Specifically, the 
luminal A subtype was strongly associated with overexpression of NRG1 (HRG) and ERBB3 
(cluster 1), the basal/triple-negative subtype was associated with TGFA over-expression (cluster 
3), and the HER2-enriched subtype was associated with ERBB2 over-expression (cluster 4). The 
luminal B subtype had no over-expression of any of these genes; the only distinctions noted were 
reduced expression of TGFA, NRG1, and EGFR (cluster 2). Note that while the subtypes tended 
to cluster together there were some tumors in each subtype that were more similar to those in 
other clusters (data not shown).  
The phosphorylation measurements of these receptors in the TCGA dataset were 
consistent with model predictions (Figure 7-4C, bottom block). Phosphorylation of HER2 at 
Y1248 was associated with high ERBB2 expression/predicted ErbB2 dimerization (Pearson 
correlation r = 0.82 for expression, r = 0.44 for predicted dimerization – see Table 7-1), and 
phosphorylation of HER3 at Y1289 was associated with NRG1 expression/predicted HRG 
binding (r = 0.19 for expression, r = 0.15 for simulated binding). None of the phosphorylation 
measurements were associated with the basal/triple-negative subtype, where TGF" binding was 
predicted to be high. The association of EGFR phosphorylation at two sites, Y1068 and Y1173, 
appeared to be associated with HER2 and HER3 phosphorylation, respectively (EGFR pY1068-
HER2 pY1248 r = 0.63 and EGFR pY1173-HER3 pY1289 r = 0.42).  
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Table 7-1: Correlations between gene expression, simulation steady-state, and RPPA phosphorylation measurements. 
 Gene Expression Measurements Simulated Variables RPPA Phosphorylation 













EGF              
TGFA -0.12             
NRG1 0.12 0.12            
EGFR -0.07 0.22 0.11           
HER2 0.05 -0.07 -0.03 -0.13          
HER3 0.03 -0.10 0.07 0.05 -0.03         
Bound EGF 0.99 -0.15 0.14 -0.07 0.13 0.03        
Bound HRG 0.22 0.10 0.96 0.04 0.02 0.11 0.23       
Bound TGFA -0.46 0.89 0.09 0.22 0.03 -0.11 -0.44 0.03      
Dimerized ErbB2 0.31 0.53 0.05 0.04 0.55 -0.06 0.32 0.11 0.38     
EGFR pY1068 0.03 0.07 0.03 0.38 0.38 -0.07 0.06 0.03 0.11 0.23    
EGFR pY1173 0.06 -0.02 0.08 0.57 -0.21 0.28 0.06 0.05 -0.05 -0.15 0.18   
HER2 pY1248 0.02 0.00 0.04 0.03 0.82 -0.03 0.09 0.08 0.09 0.44 0.63 -0.03  
HER3 pY1289 0.04 -0.07 0.19 0.21 0.23 0.17 0.08 0.15 -0.04 0.06 0.34 0.42 0.43 
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7.4.3 PCA of dynamic responses reveals potential mechanisms of resistance 
Based on the steady-state model analysis, we expected that groups of patients sensitive to 
EGF family-targeting drugs would overlap with PAM50 subtypes (i.e. basal/triple-negative 
patients would respond to the EGFR-targeting drug cetuximab since TGF! binding is elevated in 
that group). To assess the effects of therapies, we simulated the addition of three monoclonal 
antibody drugs: cetuximab (anti-EGFR), pertuzumab (anti-ErbB2), and MM-121 (anti-ErbB3). 
We selected doses by simulating a range of doses in the virtual population and then selecting the 
dose that yielded a significant amount of population variability (Figure 7-5A through 7-5D). As 
expected, across the population of patients, cetuximab lowered EGF and TGF-! binding across 
the patients (Figure 7-5A), pertuzumab lowered ErbB2 dimerization (Figure 7-5C), and MM-
121 lowered HRG binding (Figure 7-5D). At high enough doses, targeted binding and 
dimerization were completely inhibited. Off-target effects were also noted. These were largest for 
cetuximab, which up-regulated HRG binding (Figure 7-5B). Small off-target effects were noted 
for pertuzumab, in the form of slight down-regulation of EGF, TGF!, and HRG binding. MM-
121 appeared to be a drug with high specificity: no off-target effects were observed across the 
range of doses (data not shown).  
At drug doses that yielded a wide range of population variability, we analyzed the time 
course behavior. There was significant inter-individual variability across the population in terms 
of the time-course of response to the three drugs (Figures 7-6, 7-7, and 7-8 for cetuximab, 
pertuzumab, and MM-121, respectively). The drug effects did not always persist for the duration 
of the treatment: on-target effects for all three drugs were repressed the most at early time points, 
followed by a gradual rise throughout the 48-hour treatment (Figure 7-5E, F, G). In some 
patients, cetuximab-induced EGF binding and MM-121-induced HRG binding were actually 
higher than the baseline level at later time points. Off-target effects, when present, tended to last 
for the entire treatment duration (Figure 7-5H, I, J). 
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Figure 7-5: Therapeutic targeting of receptors inhibits receptor binding with some up-
regulation of off-target complexes. 
A-D, Dose response curves show that therapies are effective in reducing target binding – 
cetuximab inhibits EGF binding to EGFR (A), pertuzumab inhibits ErbB2 dimerization (C), MM-
121 inhibits HRG binding to ErbB3 (D) – with some off-target effects, including the cetuximab-
induced up-regulation of HRG binding to ErbB3 (B). Each line corresponds to one patient. 
Values on the y-axis correspond to the time integral of the specified complex at each dose divided 
by the time integral when the dose is zero. Each plot has 20 lines with non-gray colors, ranging 
from blue to purple to red. These samples are determined by ordering the samples according to 
the steady-state level of the specified complex and then choosing 20 evenly spaced samples from 
this list. Vertical dashed lines are located at the dose chosen for further simulations. E-J, Time 
courses at the doses selected in A-D show the varying levels of target inhibition found across the 
population for cetuximab (E), pertuzumab (F), and MM-121 (G), as well as off-target effects (H, 
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Figure 7-6: Individual cetuximab time courses. 
All 400 individual time course cetuximab responses for the four reduced steady-state-derived 
variables. Absolute (#/cell) is shown on the top row, fractional change from baseline is shown on 
the bottom row. 
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Figure 7-7: Individual pertuzumab time courses.  
All 400 individual time course pertuzumab responses for the four reduced steady-state-derived 
variables. Absolute (#/cell) is shown on the top row, fractional change from baseline is shown on 




Figure 7-8: Individual MM-121 time courses.  
All 400 individual time course MM-121 responses for the four reduced steady-state-derived 
variables. Absolute (#/cell) is shown on the top row, fractional change from baseline is shown on 
the bottom row. 
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To better assess the impact of treatments, we sought metrics that account for both on-
target and off-target effects. In addition to the obvious requirement for strong on-target effects, it 
is also important to consider off-target effects since an unintended increase in signaling through 
an off-target receptor could render a therapy ineffective. To find metrics from time course drug 
response data in an unbiased manner, we again turned to PCA. We normalized the data by 
subtracting the steady-state level of each molecular complex from the time course data, and then 
divided by the steady-state levels. Thus the time course data was transformed so that each time 
point represented the fractional change from the initial steady-state level for that individual. To 
capture the variation in time while not including every data point (50 variables x 193 time points 
= 9,650 data points per sample), we averaged each variable in two time windows: 0 to 6 hours 
and 24 to 30 hours. This represented both the early and late responses while only requiring 100 
data points per sample.  
We applied PCA to each of the drug response time courses and analyzed the component 
loadings after varimax rotation. Although there was some evidence of gene-based clustering of 
variable loadings, in general the input genes did not have as strong an effect on loadings as they 
did in the steady-state PCA (Figure 7-9A for PC1Cetux-PC2Cetux as an example; note the absence 
of color-clustering). Instead, we built aggregate variables out of collections of variables that had 
similar loadings and examined their time courses across the 400 patients (shown in Figure 7-9B 
for PC1Cetux-PC2Cetux).  
For the cetuximab response, three of the principal components resulted in aggregate 
variables that varied significantly across the patients: PC1Cetux was associated with endosome 
EGFR complexes that were repressed for almost the entire 48-hour duration, PC2Cetux was 
associated with temporarily repressed surface EGFR complexes, and PC4Cetux was associated with 
both ErbB3 complexes and ErbB2 monomer and homodimer levels (Figure 7-9C). The 
distinction between PC1Cetux and PC2Cetux was possible because of the inclusion of both early and 
late time points. We used the scores for these three principal components as response metrics for  
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Figure 7-9: Variation in the dynamics of response to treatments is captured by PCA. 
A, Projection of the PCA loadings onto the PC1Cetux-PC2Cetux subspace reveals that gene 
expression does not linearly affect drug response time courses as it did for the steady-state 
simulated variables. B, The PCA-based aggregate variables are better able to capture the 
variability in cetuximab response. C, The four cetuximab aggregate variables with significant 
fractional changes from baseline include on-target reductions (endosome and late time-point 
surface EGFR complexes, top two panels) and off-target up-regulation (ErbB3 and ErbB2 
complexes, bottom two panels). The solid line corresponds to the median across the population at 
each time point, while the dashed lines correspond to 5th and 95th percentiles. D, The two 
aggregate variables derived from PC4Cetux are anti-correlated. The point colors indicate the value 
of the PC4Cetux score for a given sample. E, The two aggregate variables derived from PC2Pertuz 
are also anti-correlated. The point colors indicate the value of the PC2Pertuz score for a given 
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sample. F, PLS and SVM models based on simulated variables yielded better fits than the gene 
expression-based models for the majority of the response metrics. Bars indicate the R2 value 
obtained when comparing predictions from LOOCV to the simulated data. 
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cetuximab: the PC1Cetux and PC2Cetux scores captured on-target effects whereas the PC4Cetux score 
captured two off-target effects. The opposing signs of the loadings of the ErbB3 complex 
formation and ErbB2 monomer/dimer variables indicated that these two metrics were anti-
correlated. Indeed, the PC4Cetux score could be divided based on these two aggregate variables 
(Figure 7-9D). For this metric, intermediate values are likely ideal, whereas extreme positive or 
negative values indicate drug resistance due to off-target effects. 
For the pertuzumab response PCA, we found that PC1Pertuz and PC2Pertuz resulted in 
aggregate variables with significant variation from the baseline (data not shown). PC1Pertuz was 
associated with ErbB2 homo- and hetero-dimers, the target for this drug. The variables included 
in the PC2Pertuz-based aggregate were free EGF and EGFR complexes present in the endosome, 
thus this represented an off-target resistance metric. The two aggregate variables with opposite 
loadings derived from this component displayed anti-correlation, with large increases in EGFR 
complexes associated with large decreases in free EGF concentration (Figure 7-9E). This has 
potential clinical utility, as the change in circulating free EGF after pertuzumab administration 
could be indicative of the extent of off-target up-regulation in EGFR signaling in the endosome.  
For the MM121 response PCA, the only principal component that yielded aggregate 
variables with significant variability was PC1MM121, which corresponded to the reduction in 
ErbB3 complexes (data not shown). This collection of variables was also represented in 
PC4MM121, but we excluded this from further analysis due to its similarity to the first component. 
7.4.4 Simulated data yields effective multivariate predictive biomarkers 
We used two supervised machine learning methods, partial least squares (PLS) and 
support vector machines (SVM), to build regression models of the six metrics identified from the 
drug response PCA. We compared the performance of two types of predictor variables: gene 
expression data and simulated steady-state variables. To assess biomarker performance, we used a 
leave-one-out cross-validation (LOOCV) approach where model fitting occurred 400 times, with 
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one of the 400 samples withheld each time. The metric for the withheld sample was predicted, 
allowing us to compute the coefficient of determination (R2) across the 400 samples.  
We determined the number of components to use in the PLS regression models by 
finding the LOOCV R2 for each metric at a range of component numbers. For all metrics, the PLS 
models with gene expression data as predictors did not improve as the number of components 
increased. The PLS models with simulated variables as predictors, however, did improve as the 
component number increased to 8 in five out of six cases (data not shown). For SVM, we used 
epsilon regression with a radial basis kernel with the default value for ".  
We compared the performance of the two types of predictors across both PLS and SVM 
models, with optimized component numbers for PLS. In almost all cases, the simulated variables 
outperformed the expression data as predictors (Figure 7-9F). In the few cases where the 
expression data outperformed the simulated variables, it was by only a very small margin. In 
general, the PLS models performed similarly to the SVM models, with very high LOOCV R2 
values especially for the three cetuximab metrics and for PC1Pertuz.  
7.4.5 Ranking of patients based on response metrics predicts similar drug response rates 
across breast cancer subtypes 
We examined the response metrics across individuals in the four major PAM50 subtypes 
(basal-like/triple-negative, HER2-enriched, luminal A, and luminal B) to determine whether any 
of these subtypes were more susceptible to the drugs being tested. Ordering the samples within 
each subtype by the on-target metric produced no patterns in the off-target metrics, indicating a 
lack of correlation between the on-target and off-target responses. There were also no subtype-
specific patterns in either the on- or off-target responses (Figure 7-10); each of the subtypes were 
comprised of both likely responders and likely non-responders. This suggests that identification  
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Figure 7-10: Treatment response metrics further subdivide PAM50 subtypes into treatment 
sensitive and resistant groups. 
A, Average fractional changes from steady-state (top panel) in each individual of endosome 
EGFR binding (negative axis) and the three cetuximab resistance mechanisms, namely up-
regulation of surface EGFR binding (blue), surface ErbB3 binding (red), and ErbB2 dimerization 
(does not appear due to low magnitude). Patients are split into the four major PAM50 subtypes 
and are ordered by the magnitude of down-regulation of endosome EGFR binding. The heatmap 
(bottom panel) shows scaled fractional changes in the cetuximab response data. Individuals are 
ordered as in the top panel, but now the scaling allows each of the four metrics to be represented 
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on the same color scale. Darker blue indicates a more favorable outcome, either more reduction in 
endosome EGFR binding or smaller increases in the other three metrics. B, As for A, but with the 
pertuzumab response data. Individuals are now ordered by the magnitude of reduction in ErbB2 
dimerization. The other metric included is endosome EGFR complexes (red; always increased in 
response to pertuzumab). 
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of subtype, which is itself highly correlated with gene expression clustering and pre-treatment 
signaling levels (Figure 7-4C), is insufficient for predicting response to drugs. The nonlinear 
nature of the protein interaction networks being targeted by these drugs results in nonlinear 
effects of the drugs that run across the subtypes. Incorporation of mechanistic, quantitative 
interaction information gives hope that better predictions of drug effects can be made. 
7.5 Discussion 
Here we showed that combining tumor measurements of EGF family gene expression 
with computational kinetic models (based on quantitative mechanistic knowledge) can enhance 
the prediction of drug response. In addition to predictive biomarkers for EGF family-targeting 
drugs, our approach also yields potential insight into mechanisms of resistance to these treatments 
and shows that the traditional basal/luminal distinction of breast tumors may not be sufficient in 
making treatment decisions regarding EGF family-targeting drugs. One limitation of this 
approach is that gene and protein expression measurements are expected to be noisy and may not 
always correlate with actual in vivo protein production rates. Another limitation is that the use of 
pre-treatment gene expression in the model can account for intrinsic resistance to therapies but 
not adaptive resistance, which includes longer-term changes arising due to adjustment of protein 
production rates or activation of entirely different pathways. Nonetheless, the approach described 
here could yield biomarkers with clinical utility in treatment selection, and can be adapted to 
obtain a fuller picture of the therapeutic dynamics, by incorporating post-treatment measurements 
of expression over time. 
Complex biomarkers involving as many as 100 genes have been developed, however 
these linear combinations do not take advantage of the hard-won molecular-mechanism 
information available for the drug targets and their interacting proteins. By using our knowledge 
of molecular mechanisms of interaction, as well as the individualized gene and protein expression 
levels of multiple ligands and receptors, we can predict mechanism-based nonlinear latent 
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variables that could not be obtained from expression data alone, and which may be more effective 
biomarkers. 
We found evidence in literature for several of the mechanisms of resistance described in 
this study. In colorectal cancer patients treated with cetuximab, both of the resistance mechanisms 
associated with the PC4Cetux metric have been observed: patients with ErbB2 amplification or high 
plasma levels of HRG have lower overall survival after cetuximab treatment [170]. We were 
unable to find clinical data implicating EGFR and ErbB3 ligands in pertuzumab resistance, but 
one study found that trastuzumab-resistant breast cancer xenografts expressed higher levels of 
TGF!, HBEGF, and HRG than sensitive xenografts [181]. 
Our finding that transcriptomic and proteomic data had strong linear relationships with 
baseline pre-treatment EGF family signaling, but weaker relationships with post-treatment 
response, suggests a possible reason why gene expression-based subtypes often have overall 
prognostic significance but fail to predict treatment response. Based on our analysis, gene 
expression measurements can describe the baseline signaling activity; however, when a treatment 
is added, the complex molecular interactions make it difficult to predict the response of the 
pathway without the help of a computational model. This discrepancy in the predictive capability 
of baseline and stimulated signaling has been suggested previously: one study found that data 
describing the response of breast cancer cells to HRG provided better prediction of drug response 
to phosphoinositide 3-kinase (PI3K) inhibitors than baseline receptor phosphorylation levels 
[182]. 
The approach described here to explore drug response metrics can be extended to other 
drugs and growth factor families, and could also include simulating alternate dose scheduling, 
routes of administration and drug release profiles. To validate the approach, paired genomic and 
clinical outcome data is needed; the samples included in this study did not have information 
regarding clinical outcomes. An ideal dataset would consist of gene expression data from biopsy 
samples paired with the clinical response to a drug (e.g. complete or partial response versus stable 
 146 
disease or progression), and would be further enhanced by the obtaining of multiple samples over 
time to improve simulation of the response. 
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8 Conclusions and Future Directions 
8.1 Mechanism-Based Gene Selection for Biomarkers 
We used multivariate statistical methods to identify groups of patients with altered 
expression of VEGF- and Semaphorin-related genes. In breast cancer, a signature consisting of 
high VEGFA expression and low class 3 Semaphorin expression was associated with the 
aggressive triple-negative subtype, suggesting a role for angiogenesis due to elevated VEGF and 
reduced anti-angiogenic Semaphorins. Analysis of the survival times in different VEGF/Sema 
clusters revealed that the high VEGFA/low class 3 Sema pattern, although associated with 
TNBCs, also had significant prognostic effects in non-TNBCs. Thus, it identified a group of 
patients who were not triple-negative but had poor outcomes similar to triple-negative patients. 
Similarly, within the HER2-enriched PAM50 subtype, the high VEGFA/low class 3 Sema pattern 
was associated with poor prognosis, whereas HER2-enriched patients not enriched for this pattern 
had good prognoses. Clustering the VEGF/Sema gene expression of 2,656 breast cancer samples 
revealed strong overlap between the VEGF/Sema clusters and the PAM50 subtypes. Clustering 
only the triple-negative breast cancers resulted in five distinct clusters. One of these clusters was 
associated with one of the six previously-defined TNBC subtypes [81], the mesenchymal stem-
like subtype, which is enriched with expression of epithelial-to-mesenchymal transition genes. 
The pattern of VEGF-related gene expression found in this subtype was elevated VEGFC, KDR, 
and NRP1.  
TCGA gene expression datasets for other cancer types did not display the high VEGFA/low 
class 3 Semaphorin expression pattern, but the elevated VEGFC, KDR, and NRP1 pattern was 
found in several subtypes of cancers, notably the MSI/CIMP subtype of colon cancer and the 
mesenchymal subtype of glioblastoma. The VEGF/Sema cluster with this pattern in glioblastoma 
had significantly worse survival times than other clusters, suggesting a role in disease 
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progression. Notably, out of the seven TCGA primary tumor datasets analyzed, only prostate 
cancer failed to yield distinct VEGF/Sema clusters. Thus, we explored prostate cancer further. 
 In several prostate cancer microarray and RNA-Seq datasets, we found that both VEGFA 
and class 3 semaphorins were down-regulated in primary prostate tumors compared to normal 
prostate tissue. The reduced class 3 Semaphorin expression suggests removal of inhibitory signals 
for angiogenesis, while the reduced VEGFA expression suggests a lack of responsiveness to anti-
VEGF therapies. We then examined gene expression datasets for metastatic prostate cancer and 
found that VEGFA was up-regulated, along with down-regulation of class 3 semaphorins. Thus, 
although VEGF-based subtypes of primary prostate cancers are difficult to detect, metastatic 
prostate cancer may be responsive to VEGF-targeting therapies. Simulations of VEGF signaling 
with protein production rates proportional to gene expression will provide further information 
regarding the role of elevated VEGFA and reduced class 3 Semaphorins. 
8.2 Personalized Computational Models for Biomarker Testing 
We used computational modeling to predict growth factor signaling and drug response for 
genes that encode proteins whose interactions and kinetics were known. We applied this in 
multiple settings. 
 First, we considered a single compartment model where the compartment corresponded 
to normal prostate tissue, a primary prostate tumor, or a metastasis originating from a prostate 
tumor. This model showed that VEGF-Semaphorin competition for Neuropilin co-receptors likely 
has little impact on either VEGF signaling or Semaphorin signaling. Thus, class 3 Semaphorin-
mediated anti-angiogenic activity likely occurs due to signals transduced by plexin receptors after 
interacting with Sema3-NRP complexes. We found that some metastases had down-regulated 
class 3 Semaphorin signaling, others had up-regulated VEGF signaling, and others had both. This 
demonstrates the need for considering multiple pathways when targeting angiogenesis. 
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We then analyzed VEGF signaling in whole-body multi-compartment models based on 
gene expression from three TCGA datasets: breast, kidney, and prostate cancers. We found that 
expression of genes encoding soluble ligands were highly correlated with the untreated baseline 
level of the corresponding ligand-receptor complexes. This was not the case when comparing 
gene expression to the changes in ligand-receptor complexes after treatment with either 
bevacizumab (anti-VEGF) or anti-NRP1. When considering gene expression variables as 
predictors of treatment response, we found that different genes served as the best predictors in 
different types of cancer. This demonstrates that differing covariances between genes in different 
cancer types can lead to changes in how predictive of response a particular biomarker is. This is 
seen in clinical trials of bevacizumab, where plasma VEGFA concentration is only predictive of 
response for some cancers [39]. The cell type that exhibits the most variability in receptor levels 
(tumor versus endothelial) can also affect biomarker performance. Across the virtual populations, 
simulated baseline variables tended to outperform gene expression variables as predictive 
biomarkers, suggesting that the incorporation of mechanistic information does yield improved 
biomarkers.  
We also applied our method to the well-studied EGFR/ErbB family of growth factor 
receptors. Using a previously published model of ligand-receptor interactions, with some key 
additions, we tested the effects of cetuximab (anti-EGFR), pertuzumab (anti-ErbB2), and MM-
121 (anti-ErbB3) in a virtual population derived from the TCGA breast cancer RNA-Seq dataset. 
We predicted that cetuximab would have off-target effects (increased HRG-ErbB3 binding and in 
some cases, increased EGFR binding at the cell surface) that could lead to treatment resistance. 
We also predicted that pertuzumab may lead to elevated EGFR signaling in the endosome, but we 
found no evidence of MM-121 off-target effects. Biomarkers for treatment response metrics 
typically had better performance when they were built with simulated baseline data instead of 
gene expression data. This was consistent with our results for the VEGF signaling compartment 
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models. Together, this suggests that biomarkers from computational models can improve drug 
response prediction. 
8.3 Future Directions 
One potential future direction for this work is to incorporate additional data. Measurements 
of cytokine protein levels, either in the plasma or within tumors, would be useful in further 
constraining the model to ensure that the parameter values are accurate and yield robust 
performance. In the gene expression-based virtual populations, clinical outcome data in response 
to the drugs of interest would be helpful. Of particular interest would be post-treatment clinical 
outcome data paired with a transcriptomic dataset taken from the tumor. This would allow us to 
assess whether the on-target and off-target drug response metrics that we derived are truly 
associated with patient responses. 
The framework we have developed also lends itself to application to other growth factor 
families with roles in angiogenesis. Many protein families other than VEGF and Semaphorin 
contribute to angiogenesis. We considered the platelet-derived growth factor (PDGF), insulin-like 
growth factor (IGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), and 
angiopoietin families in Chapter 4. These and other families may be able to support angiogenesis 
independently of the VEGF family. Ultimately, once more measurements and mechanistic 
information become available for these pathways, large comprehensive models such as the one 
developed here may enable a comprehensive analysis of the multiple families that affect tumor 
angiogenesis. 
The compartment model can also be extended to include additional compartments 
corresponding to a primary tumor and multiple metastases, which is often the setting in which 
anti-VEGF therapeutics are administered. Measurements describing the geometric characteristics 
and permeability of the metastases would be needed. This would make the models more realistic 
and allow for improved prediction of drug response. 
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